10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________________

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2017

or

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from            to            

Commission File Number: 001-35568 (Healthcare Trust of America, Inc.)

Commission File Number: 333-190916 (Healthcare Trust of America Holdings, LP)

_________________________ 

HEALTHCARE TRUST OF AMERICA, INC.

HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

(Exact name of registrant as specified in its charter)

Maryland (Healthcare Trust of America, Inc.)	20-4738467
Delaware (Healthcare Trust of America Holdings, LP)	20-4738347
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

16435 N. Scottsdale Road, Suite 320

Scottsdale, Arizona 85254

(Address of principal executive offices)

(480) 998-3478

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Sections 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    

Healthcare Trust of America, Inc.	x Yes	¨ No
Healthcare Trust of America Holdings, LP	x Yes	¨ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    

Healthcare Trust of America, Inc.	x Yes	¨ No
Healthcare Trust of America Holdings, LP	x Yes	¨ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Healthcare Trust of America, Inc.	Large-accelerated filer x	Accelerated filer ¨	Non-accelerated filer ¨	Smaller reporting company ¨	Emerging growth company ¨
			(Do not check if a smaller reporting company)
Healthcare Trust of America Holdings, LP	Large-accelerated filer ¨	Accelerated filer ¨	Non-accelerated filer x	Smaller reporting company ¨	Emerging growth company ¨
			(Do not check if a smaller reporting company)

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Healthcare Trust of America, Inc.	¨
Healthcare Trust of America Holdings, LP	¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   

Healthcare Trust of America, Inc.	¨ Yes	x No
Healthcare Trust of America Holdings, LP	¨ Yes	x No

As of April 24, 2017, there were 143,841,711 shares of Class A common stock of Healthcare Trust of America, Inc. outstanding.

Explanatory Note

This Quarterly Report combines the Quarterly Reports on Form 10-Q (“Quarterly Report”) for the quarter ended March 31, 2017 of Healthcare Trust of America, Inc. (“HTA”), a Maryland corporation, and Healthcare Trust of America Holdings, LP (“HTALP”), a Delaware limited partnership. Unless otherwise indicated or unless the context requires otherwise, all references in this Quarterly Report to “we,” “us,” “our,” “the Company” or “our Company” refer to HTA and HTALP, collectively, and all references to “common stock” shall refer to the Class A common stock of HTA.

HTA operates as a real estate investment trust (“REIT”) and is the general partner of HTALP. As of March 31, 2017, HTA owned a 97.0% partnership interest in HTALP, and other limited partners, including some of HTA’s directors, executive officers and their affiliates, owned the remaining partnership interest (including the long-term incentive plan (“LTIP” Units) in HTALP. As the sole general partner of HTALP, HTA has the full, exclusive and complete responsibility for HTALP’s day-to-day management and control, including its compliance with the Securities and Exchange Commission (“SEC”) filing requirements.

We believe it is important to understand the few differences between HTA and HTALP in the context of how we operate as an integrated consolidated company. HTA operates in an umbrella partnership REIT structure in which HTALP and its subsidiaries hold substantially all of the assets. HTA’s only material asset is its ownership of partnership interests of HTALP. As a result, HTA does not conduct business itself, other than acting as the sole general partner of HTALP, issuing public equity from time to time and guaranteeing certain debts of HTALP. HTALP conducts the operations of the business and issues publicly-traded debt, but has no publicly-traded equity. Except for net proceeds from public equity issuances by HTA, which are generally contributed to HTALP in exchange for partnership units of HTALP, HTALP generates the capital required for the business through its operations and by direct or indirect incurrence of indebtedness or through the issuance of its partnership units.

Noncontrolling interests, stockholders’ equity and partners’ capital are the primary areas of difference between the condensed consolidated financial statements of HTA and HTALP. Limited partnership units in HTALP are accounted for as partners’ capital in HTALP’s condensed consolidated balance sheets and as noncontrolling interest reflected within equity in HTA’s condensed consolidated balance sheets. The differences between HTA’s stockholders’ equity and HTALP’s partners’ capital are due to the differences in the equity issued by HTA and HTALP, respectively.

The Company believes combining the Quarterly Reports of HTA and HTALP, including the notes to the condensed consolidated financial statements, into this single Quarterly Report results in the following benefits:

• enhances stockholders’ understanding of HTA and HTALP by enabling stockholders to view the business as a whole in the same manner that management views and operates the business;

• eliminates duplicative disclosure and provides a more streamlined and readable presentation since a substantial portion of the disclosure in this Quarterly Report applies to both HTA and HTALP; and

• creates time and cost efficiencies through the preparation of a single combined Quarterly Report instead of two separate Quarterly Reports.

In order to highlight the material differences between HTA and HTALP, this Quarterly Report includes sections that separately present and discuss areas that are materially different between HTA and HTALP, including:

• the condensed consolidated financial statements;

• certain accompanying notes to the condensed consolidated financial statements, including Note 7 - Debt, Note 10 - Stockholders’ Equity and Partners’ Capital, Note 12 - Per Share Data of HTA and Note 13 - Per Unit Data of HTALP;

• the Funds From Operations (“FFO”) and Normalized FFO in Part 1, Item 2 of this Quarterly Report;

• the Controls and Procedures in Part 1, Item 4 of this Quarterly Report; and

• the Certifications of the Chief Executive Officer and the Chief Financial Officer included as Exhibits 31 and 32 to this Quarterly Report.

In the sections of this Quarterly Report that combine disclosure for HTA and HTALP, this Quarterly Report refers to actions or holdings as being actions or holdings of the Company. Although HTALP (directly or indirectly through one of its subsidiaries) is generally the entity that enters into contracts, holds assets and issues or incurs debt, management believes this presentation is appropriate for the reasons set forth above and because the business of the Company is a single integrated enterprise operated through HTALP.

2

HEALTHCARE TRUST OF AMERICA, INC. AND

HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

TABLE OF CONTENTS

		Page
PART I - FINANCIAL INFORMATION
Item 1.	Financial Statements (Unaudited)	4
Healthcare Trust of America, Inc.
	Condensed Consolidated Balance Sheets as of March 31, 2017 and December 31, 2016	4
	Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2017 and 2016	5
	Condensed Consolidated Statements of Comprehensive Income (Loss) for the Three Months Ended March 31, 2017 and 2016	6
	Condensed Consolidated Statements of Equity for the Three Months Ended March 31, 2017 and 2016	7
	Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2017 and 2016	8
Healthcare Trust of America Holdings, LP
	Condensed Consolidated Balance Sheets as of March 31, 2017 and December 31, 2016	9
	Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2017 and 2016	10
	Condensed Consolidated Statements of Comprehensive Income (Loss) for the Three Months Ended March 31, 2017 and 2016	11
	Condensed Consolidated Statements of Changes in Partners’ Capital for the Three Months Ended March 31, 2017 and 2016	12
	Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2017 and 2016	13
Notes for Healthcare Trust of America, Inc. and Healthcare Trust of America Holdings, LP
	Notes to Unaudited Condensed Consolidated Financial Statements	14
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	28
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	38
Item 4.	Controls and Procedures	39
PART II - OTHER INFORMATION
Item 1.	Legal Proceedings	40
Item 1A.	Risk Factors	40
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	40
Item 6.	Exhibits	40
Signatures		41

3

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements (Unaudited)

HEALTHCARE TRUST OF AMERICA, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share data)

(Unaudited)

	March 31, 2017			December 31, 2016
ASSETS
Real estate investments:
Land	$	392,714		$	386,526
Building and improvements	3,500,633			3,466,516
Lease intangibles	467,559			467,571
	4,360,906			4,320,613
Accumulated depreciation and amortization	(856,986		)	(817,593		)
Real estate investments, net	3,503,920			3,503,020
Cash and cash equivalents	16,034			11,231
Restricted cash and escrow deposits	8,043			13,814
Receivables and other assets, net	179,719			173,461
Other intangibles, net	45,301			46,318
Total assets	$	3,753,017		$	3,747,844
LIABILITIES AND EQUITY
Liabilities:
Debt	$	1,811,208		$	1,768,905
Accounts payable and accrued liabilities	98,222			105,034
Derivative financial instruments - interest rate swaps	1,653			1,920
Security deposits, prepaid rent and other liabilities	51,409			49,859
Intangible liabilities, net	36,009			37,056
Total liabilities	1,998,501			1,962,774
Commitments and contingencies
Redeemable noncontrolling interests	4,661			4,653
Equity:
Preferred stock, $0.01 par value; 200,000,000 shares authorized; none issued and outstanding	—			—
Class A common stock, $0.01 par value; 1,000,000,000 shares authorized; 141,825,110 and 141,719,134 shares issued and outstanding as of March 31, 2017 and December 31, 2016, respectively	1,418			1,417
Additional paid-in capital	2,754,229			2,754,818
Accumulated other comprehensive loss	(85		)	—
Cumulative dividends in excess of earnings	(1,098,561		)	(1,068,961		)
Total stockholders’ equity	1,657,001			1,687,274
Noncontrolling interests	92,854			93,143
Total equity	1,749,855			1,780,417
Total liabilities and equity	$	3,753,017		$	3,747,844

The accompanying notes are an integral part of these condensed consolidated financial statements.

4

HEALTHCARE TRUST OF AMERICA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

(Unaudited)

	Three Months Ended March 31,
	2017			2016
Revenues:
Rental income	$	123,993		$	107,250
Interest and other operating income	354			65
Total revenues	124,347			107,315
Expenses:
Rental	39,020			33,353
General and administrative	8,423			6,773
Transaction	284			1,813
Depreciation and amortization	47,056			37,828
Total expenses	94,783			79,767
Income before other income (expense)	29,564			27,548
Interest expense:
Interest related to derivative financial instruments	(324		)	(645		)
Gain (loss) on change in fair value of derivative financial instruments, net	839			(2,792		)
Total interest related to derivative financial instruments, including net change in fair value of derivative financial instruments	515			(3,437		)
Interest related to debt	(16,058		)	(14,128		)
Gain on sale of real estate, net	3			—
Loss on extinguishment of debt, net	(32		)	—
Other income	8			53
Net income	$	14,000		$	10,036
Net income attributable to noncontrolling interests (1)	(455		)	(176		)
Net income attributable to common stockholders	$	13,545		$	9,860
Earnings per common share - basic:
Net income attributable to common stockholders	$	0.10		$	0.08
Earnings per common share - diluted:
Net income attributable to common stockholders	$	0.09		$	0.08
Weighted average common shares outstanding:
Basic	141,780			129,336
Diluted	146,117			131,240
Dividends declared per common share	$	0.300		$	0.295
(1) Includes amounts attributable to redeemable noncontrolling interests.

The accompanying notes are an integral part of these condensed consolidated financial statements.

5

HEALTHCARE TRUST OF AMERICA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(In thousands)

(Unaudited)

	Three Months Ended March 31,
	2017			2016
Net income	$	14,000		$	10,036
Other comprehensive loss
Change in unrealized losses on cash flow hedges	(88		)	—
Total other comprehensive loss	(88		)	—
Total comprehensive income	13,912			10,036
Comprehensive income attributable to noncontrolling interests	(422		)	(145		)
Total comprehensive income attributable to common stockholders	$	13,490		$	9,891

The accompanying notes are an integral part of these condensed consolidated financial statements.

6

HEALTHCARE TRUST OF AMERICA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY

(In thousands)

(Unaudited)

	Class A Common Stock					Additional Paid-In Capital			Accumulated Other Comprehensive Loss			Cumulative Dividends in Excess of Earnings			Total Stockholders’ Equity			Noncontrolling Interests			Total Equity
	Shares		Amount
Balance as of December 31, 2015	127,027		$	1,270		$	2,328,806		$	—		$	(950,652	)	$	1,379,424		$	27,534		$	1,406,958
Issuance of common stock	3,418		34			91,235			—			—			91,269			—			91,269
Share-based award transactions, net	191		2			1,801			—			—			1,803			—			1,803
Repurchase and cancellation of common stock	(70	)	—			(1,901		)	—			—			(1,901		)	—			(1,901		)
Redemption of noncontrolling interest and other	96		1			2,197			—			—			2,198			(2,198		)	—
Dividends declared	—		—			—			—			(38,540		)	(38,540		)	(543		)	(39,083		)
Net income	—		—			—			—			9,860			9,860			145			10,005
Balance as of March 31, 2016	130,662		$	1,307		$	2,422,138		$	—		$	(979,332	)	$	1,444,113		$	24,938		$	1,469,051
Balance as of December 31, 2016	141,719		$	1,417		$	2,754,818		$	—		$	(1,068,961	)	$	1,687,274		$	93,143		$	1,780,417
Issuance of operating partnership units in connection with an acquisition	—		—			—			—			—			—			610			610
Share-based award transactions, net	213		2			2,528			—			—			2,530			—			2,530
Repurchase and cancellation of common stock	(107	)	(1		)	(3,117		)	—			—			(3,118		)	—			(3,118		)
Dividends declared	—		—			—			—			(43,145		)	(43,145		)	(1,321		)	(44,466		)
Net income	—		—			—			—			13,545			13,545			425			13,970
Other comprehensive loss	—		—			—			(85		)	—			(85		)	(3		)	(88		)
Balance as of March 31, 2017	141,825		$	1,418		$	2,754,229		$	(85	)	$	(1,098,561	)	$	1,657,001		$	92,854		$	1,749,855

The accompanying notes are an integral part of these condensed consolidated financial statements.

7

HEALTHCARE TRUST OF AMERICA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

	Three Months Ended March 31,
	2017			2016
Cash flows from operating activities:
Net income	$	14,000		$	10,036
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation, amortization and other	46,213			37,091
Share-based compensation expense	2,530			1,803
Bad debt expense	103			92
Gain on sale of real estate, net	(3		)	—
Loss on extinguishment of debt, net	32			—
Change in fair value of derivative financial instruments	(839		)	2,792
Changes in operating assets and liabilities:
Receivables and other assets, net	(7,771		)	(1,438		)
Accounts payable and accrued liabilities	(7,934		)	(10,370		)
Security deposits, prepaid rent and other liabilities	682			446
Net cash provided by operating activities	47,013			40,452
Cash flows from investing activities:
Investments in real estate	(34,706		)	(158,686		)
Proceeds from the sale of real estate	4,746			—
Capital expenditures	(12,894		)	(8,824		)
Restricted cash, escrow deposits and other assets	5,771			(799		)
Net cash used in investing activities	(37,083		)	(168,309		)
Cash flows from financing activities:
Borrowings on unsecured revolving credit facility	92,000			166,000
Payments on unsecured revolving credit facility	(10,000		)	(88,000		)
Payments on secured mortgage loans	(40,155		)	(1,761		)
Security deposits	14			729
Proceeds from issuance of common stock	—			91,757
Repurchase and cancellation of common stock	(3,118		)	(1,901		)
Dividends paid	(42,536		)	(37,473		)
Distributions paid to noncontrolling interest of limited partners	(1,332		)	(737		)
Net cash (used in) provided by financing activities	(5,127		)	128,614
Net change in cash and cash equivalents	4,803			757
Cash and cash equivalents - beginning of period	11,231			13,070
Cash and cash equivalents - end of period	$	16,034		$	13,827

The accompanying notes are an integral part of these condensed consolidated financial statements.

8

HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except unit data)

(Unaudited)

	March 31, 2017			December 31, 2016
ASSETS
Real estate investments:
Land	$	392,714		$	386,526
Building and improvements	3,500,633			3,466,516
Lease intangibles	467,559			467,571
	4,360,906			4,320,613
Accumulated depreciation and amortization	(856,986		)	(817,593		)
Real estate investments, net	3,503,920			3,503,020
Cash and cash equivalents	16,034			11,231
Restricted cash and escrow deposits	8,043			13,814
Receivables and other assets, net	179,719			173,461
Other intangibles, net	45,301			46,318
Total assets	$	3,753,017		$	3,747,844
LIABILITIES AND PARTNERS’ CAPITAL
Liabilities:
Debt	$	1,811,208		$	1,768,905
Accounts payable and accrued liabilities	98,222			105,034
Derivative financial instruments - interest rate swaps	1,653			1,920
Security deposits, prepaid rent and other liabilities	51,409			49,859
Intangible liabilities, net	36,009			37,056
Total liabilities	1,998,501			1,962,774
Commitments and contingencies
Redeemable noncontrolling interests	4,661			4,653
Partners’ Capital:
Limited partners’ capital, 4,343,782 and 4,323,095 units issued and outstanding as of March 31, 2017 and December 31, 2016, respectively	92,584			92,873
General partner’s capital, 141,825,110 and 141,719,134 units issued and outstanding as of March 31, 2017 and December 31, 2016, respectively	1,657,271			1,687,544
Total partners’ capital	1,749,855			1,780,417
Total liabilities and partners’ capital	$	3,753,017		$	3,747,844

The accompanying notes are an integral part of these condensed consolidated financial statements.

9

HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per unit data)

(Unaudited)

	Three Months Ended March 31,
	2017			2016
Revenues:
Rental income	$	123,993		$	107,250
Interest and other operating income	354			65
Total revenues	124,347			107,315
Expenses:
Rental	39,020			33,353
General and administrative	8,423			6,773
Transaction	284			1,813
Depreciation and amortization	47,056			37,828
Total expenses	94,783			79,767
Income before other income (expense)	29,564			27,548
Interest expense:
Interest related to derivative financial instruments	(324		)	(645		)
Gain (loss) on change in fair value of derivative financial instruments, net	839			(2,792		)
Total interest related to derivative financial instruments, including net change in fair value of derivative financial instruments	515			(3,437		)
Interest related to debt	(16,058		)	(14,128		)
Gain on sale of real estate, net	3			—
Loss on extinguishment of debt, net	(32		)	—
Other income	8			53
Net income	$	14,000		$	10,036
Net income attributable to noncontrolling interests	(30		)	(31		)
Net income attributable to common unitholders	$	13,970		$	10,005
Earnings per common unit - basic:
Net income attributable to common unitholders	$	0.10		$	0.08
Earnings per common unit - diluted:
Net income attributable to common unitholders	$	0.10		$	0.08
Weighted average common units outstanding:
Basic	146,117			131,242
Diluted	146,117			131,242
Dividends declared per common unit	$	0.300		$	0.295

The accompanying notes are an integral part of these condensed consolidated financial statements.

10

HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(In thousands)

(Unaudited)

	Three Months Ended March 31,
	2017			2016
Net income	$	14,000		$	10,036
Other comprehensive loss
Change in unrealized losses on cash flow hedges	(88		)	—
Total other comprehensive loss	(88		)	—
Total comprehensive income	13,912			10,036
Comprehensive income attributable to noncontrolling interests	(30		)	(31		)
Total comprehensive income attributable to common unitholders	$	13,882		$	10,005

The accompanying notes are an integral part of these condensed consolidated financial statements.

11

HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN PARTNERS’ CAPITAL

(In thousands)

(Unaudited)

	General Partner’s Capital					Limited Partners’ Capital					Total Partners’ Capital
	Units		Amount			Units		Amount
Balance as of December 31, 2015	127,027		$	1,379,694		1,930		$	27,264		$	1,406,958
Issuance of general partner units	3,418		91,269			—		—			91,269
Share-based award transactions, net	191		1,803			—		—			1,803
Redemption and cancellation of general partner units	(70	)	(1,901		)	—		—			(1,901		)
Redemption of limited partner units and other	96		2,198			(96	)	(2,198		)	—
Distributions declared	—		(38,540		)	—		(543		)	(39,083		)
Net income	—		9,860			—		145			10,005
Balance as of March 31, 2016	130,662		$	1,444,383		1,834		$	24,668		$	1,469,051
Balance as of December 31, 2016	141,719		$	1,687,544		4,323		$	92,873		$	1,780,417
Issuance of limited partner units in connection with an acquisition	—		—			21		610			610
Share-based award transactions, net	213		2,530			—		—			2,530
Redemption and cancellation of general partner units	(107	)	(3,118		)	—		—			(3,118		)
Distributions declared	—		(43,145		)	—		(1,321		)	(44,466		)
Net income	—		13,545			—		425			13,970
Other comprehensive loss	—		(85		)	—		(3		)	(88		)
Balance as of March 31, 2017	141,825		$	1,657,271		4,344		$	92,584		$	1,749,855

The accompanying notes are an integral part of these condensed consolidated financial statements.

12

HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

	Three Months Ended March 31,
	2017			2016
Cash flows from operating activities:
Net income	$	14,000		$	10,036
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation, amortization and other	46,213			37,091
Share-based compensation expense	2,530			1,803
Bad debt expense	103			92
Gain on sale of real estate, net	(3		)	—
Loss on extinguishment of debt, net	32			—
Change in fair value of derivative financial instruments	(839		)	2,792
Changes in operating assets and liabilities:
Receivables and other assets, net	(7,771		)	(1,438		)
Accounts payable and accrued liabilities	(7,934		)	(10,370		)
Security deposits, prepaid rent and other liabilities	682			446
Net cash provided by operating activities	47,013			40,452
Cash flows from investing activities:
Investments in real estate	(34,706		)	(158,686		)
Proceeds from the sale of real estate	4,746			—
Capital expenditures	(12,894		)	(8,824		)
Restricted cash, escrow deposits and other assets	5,771			(799		)
Net cash used in investing activities	(37,083		)	(168,309		)
Cash flows from financing activities:
Borrowings on unsecured revolving credit facility	92,000			166,000
Payments on unsecured revolving credit facility	(10,000		)	(88,000		)
Payments on secured mortgage loans	(40,155		)	(1,761		)
Security deposits	14			729
Proceeds from issuance of general partner units	—			91,757
Repurchase and cancellation of general partner units	(3,118		)	(1,901		)
Distributions paid to general partner	(42,536		)	(37,473		)
Distributions paid to limited partners and redeemable noncontrolling interests	(1,332		)	(737		)
Net cash (used in) provided by financing activities	(5,127		)	128,614
Net change in cash and cash equivalents	4,803			757
Cash and cash equivalents - beginning of period	11,231			13,070
Cash and cash equivalents - end of period	$	16,034		$	13,827

The accompanying notes are an integral part of these condensed consolidated financial statements.

13

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Unless otherwise indicated or unless the context requires otherwise the use of the words “we,” “us” or “our” refers to Healthcare Trust of America, Inc. and Healthcare Trust of America Holdings, LP, collectively.

1. Organization and Description of Business

HTA, a Maryland corporation, and HTALP, a Delaware limited partnership, were incorporated or formed, as applicable, on April 20, 2006. HTA operates as a REIT and is the general partner of HTALP, which is the operating partnership. As of March 31, 2017, HTA owned a 97.0% partnership interest and other limited partners, including some of HTA’s directors, executive officers and their affiliates, owned the remaining partnership interest (including the LTIP Units) in HTALP. As the sole general partner of HTALP, HTA has the full, exclusive and complete responsibility for HTALP’s day-to-day management and control. HTA operates in an umbrella partnership REIT structure in which HTALP and its subsidiaries hold substantially all of the assets. HTA’s only material asset is its ownership of partnership interests of HTALP. As a result, HTA does not conduct business itself, other than acting as the sole general partner of HTALP, issuing public equity from time to time and guaranteeing certain debts of HTALP. HTALP conducts the operations of the business and issues publicly-traded debt, but has no publicly-traded equity.

HTA is one of the largest publicly-traded REITs focused on medical office buildings (“MOBs”) in the U.S. as measured by the gross leasable area (“GLA”) of its MOBs. HTA conducts substantially all of its operations through HTALP. We invest in MOBs that we believe will serve the future of healthcare delivery, and MOBs that are primarily located on health system campuses, near university medical centers, or in core community outpatient locations. We also focus on our key markets that have certain demographic and macro-economic trends and where we can utilize our institutional property management and leasing platform to generate strong tenant relationships and operating cost efficiencies. Our primary objective is to maximize stockholder value with disciplined growth through strategic investments that provide an attractive risk-adjusted return for our stockholders by consistently increasing our cash flow. In pursuing this objective, we: (i) seek internal growth through proactive asset management, leasing and property management oversight; (ii) target accretive acquisitions of MOBs in markets with attractive demographics that complement our existing portfolio; and (iii) actively manage our balance sheet to maintain flexibility with conservative leverage.  Additionally, from time to time we consider, on an opportunistic basis, significant portfolio acquisitions that we believe fit our core business and could enhance our existing portfolio. HTA has qualified to be taxed as a REIT for federal income tax purposes and intends to continue to be taxed as a REIT.

Since 2006, we have invested $4.3 billion to create a portfolio of MOBs and other healthcare assets consisting of approximately 17.8 million square feet of GLA throughout the U.S. As of March 31, 2017, approximately 96% of our portfolio, based on GLA, was located on the campuses of, or aligned with, nationally or regionally recognized healthcare systems. Our portfolio is diversified geographically across 31 states, with no state having more than 13% of our total GLA as of March 31, 2017. We are concentrated in 15 to 20 key markets that are experiencing higher economic and demographic trends than other markets, on average, that we expect will drive demand for MOBs. Approximately 92% of our portfolio, based on GLA, is located in the top 75 metropolitan statistical areas (“MSAs”) with Boston, Hartford/New Haven, Dallas, Houston, Phoenix and Orange County/Los Angeles being our largest markets by investment.

Our principal executive office is located at 16435 North Scottsdale Road, Suite 320, Scottsdale, Arizona, 85254.

2. Summary of Significant Accounting Policies

The summary of significant accounting policies presented below is designed to assist in understanding our condensed consolidated financial statements. Such condensed consolidated financial statements and the accompanying notes are the representations of our management, who are responsible for their integrity and objectivity. These accounting policies conform to U.S. generally accepted accounting principles (“GAAP”) in all material respects and have been consistently applied in preparing our accompanying condensed consolidated financial statements.

Basis of Presentation

Our accompanying condensed consolidated financial statements include our accounts and those of our subsidiaries and any consolidated variable interest entities (“VIEs”). All inter-company balances and transactions have been eliminated in the accompanying condensed consolidated financial statements.

14

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Interim Unaudited Financial Data

Our accompanying condensed consolidated financial statements have been prepared by us in accordance with GAAP in conjunction with the rules and regulations of the SEC. Certain information and footnote disclosures required for annual financial statements have been condensed or excluded pursuant to SEC rules and regulations. Accordingly, our accompanying condensed consolidated financial statements do not include all information and footnotes required by GAAP for complete financial statements. Our accompanying condensed consolidated financial statements reflect all adjustments, which are, in our opinion, of a normal recurring nature and necessary for a fair presentation of our financial position, results of operations and cash flows for the interim periods. Interim results of operations are not necessarily indicative of the results to be expected for the full year; such results may be less favorable for the full year. Our accompanying condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and the notes thereto included in our 2016 Annual Report on Form 10-K.

Principles of Consolidation

The consolidated financial statements include our accounts of those of our subsidiaries and consolidated joint venture arrangements. The portions of the operating partnership not owned by us are presented as non-controlling interests in our consolidated balance sheets and statements of operations, consolidated statements of equity, and consolidated statements of changes in partners’ capital. The portions of other joint venture arrangements not owned by us are presented as redeemable non-controlling interests in our consolidated balance sheets. In addition, as described in Note 1 - Organization and Description of Business, certain third parties have been issued limited partner units in HTALP (“OP Units”). Holders of OP Units are considered to be non-controlling interest holders in HTALP and their ownership interests are reflected as equity in the consolidated balance sheets. Further, a portion of the earnings and losses of HTALP are allocated to non-controlling interest holders based on their respective ownership percentages. Upon conversion of OP Units to common stock, any difference between the fair value of common shares issued and the carrying value of the OP Units converted is recorded as a component of equity. As of March 31, 2017 and December 31, 2016, there were approximately 4.3 million of OP Units issued and outstanding.

VIEs are entities where investors lack sufficient equity at risk for the entity to finance its activities without additional subordinated financial support or where equity investors, as a group, lack one of the following: (i) the power to direct the activities that most significantly impact the entity’s economic performance; (ii) the obligation to absorb the expected losses of the entity; and (iii) the right to receive the expected returns of the entity. We consolidate our investment in VIEs when we determine that we are the primary beneficiary. A primary beneficiary is one that has both: (i) the power to direct the activities of the VIE that most significantly impacts the entity’s economic performance; and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could be significant to the entity. Our operating partnership (HTALP) and other joint venture arrangements are VIEs, because the limited partners in those partnerships, although entitled to vote on certain matters, do not possess kick-out rights or substantive participating rights. Additionally, we determined that we are the primary beneficiary of our VIEs. Accordingly, we consolidate our interests in the HTALP operating partnership and other joint venture arrangements. However, because we hold what is deemed a majority voting interest in the operating partnership and other joint venture arrangements, it qualifies for the exemption from providing certain disclosure requirements associated with investments in VIEs. We will evaluate on an ongoing basis the need to consolidate entities based on the standards set forth in GAAP as described above.

Investments in Real Estate

Depreciation expense of buildings and improvements for the three months ended March 31, 2017 and 2016 was $32.7 million and $25.7 million, respectively.

15

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Recently Issued or Adopted Accounting Pronouncements

The following table provides a brief description of recently adopted accounting pronouncements:

Accounting Pronouncement	Description	Effective Date	Effect on financial statements
ASU 2017-01 Business Combinations: Clarifying the Definition of a Business (Issued January 2017)	ASU 2017-01 clarifies the definition of a business by adding guidance to assist entities evaluate whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The definition of a business affects many areas of accounting, including, but not limited to, acquisitions, disposals, goodwill and consolidation.	ASU 2017-01 is effective for fiscal years beginning after December 15, 2017 with early adoption permitted.	We adopted ASU 2017-01 as of January 1, 2017 on a prospective basis. We expect that the majority of our future investments in real estate will be accounted for as asset acquisitions under ASU 2017-01. The adoption of ASU 2017-01 will impact how we account for acquisition-related expenses and contingent consideration which may result in lower acquisition-related expenses and eliminate fair value adjustments related to future contingent consideration arrangements.

The following table provides a brief description of recently issued accounting pronouncements:

Accounting Pronouncement	Description	Effective Date	Effect on financial statements
ASU 2014-09 Revenue from Contracts with Customers (Issued May 2014)	ASU 2014-09 is a comprehensive new revenue recognition model requiring a company to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration (i.e., payment) to which the company expects to be entitled in exchange for those goods or services. In adopting ASU 2014-09, companies may use either a full retrospective or a modified retrospective approach.	In July 2015, the FASB deferred the effective date of ASU 2014-09 to the first interim period within annual reporting periods beginning after December 15, 2017 along with the right of early adoption as of the original effective date.	We have identified our revenue streams and are in the process of evaluating the impact on our consolidated financial statements and internal accounting processes; however, the majority of our revenues are derived from real estate lease contracts, as discussed in relation to ASU 2016-02 below. We will adopt ASU 2014-09 effective January 1, 2018 using the retrospective approach and the adoption is not expected to have a material impact on our consolidated financial statements.
ASU 2016-02 Leases (Issued February 2016)	ASU 2016-02 will supersede the existing guidance for lease accounting and states that companies will be required to recognize lease assets and lease liabilities on the balance sheet and disclose key information about leasing arrangements. ASU 2016-02 requires qualitative and quantitative disclosures to supplement the amounts recorded in the financial statements so that users can understand the nature of the entity’s leasing activities, including significant judgments and changes in judgments. Within ASU 2016-02 lessor accounting remained fairly unchanged. In adopting ASU 2016-02, companies will be required to use a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements.	ASU 2016-02 is effective for the fiscal years beginning after December 15, 2018 with early adoption permitted.	We will adopt ASU 2016-02 as of January 1, 2019 using the modified retrospective approach.  We are currently evaluating the full impact of ASU 2016-02 will have on our consolidated financial statements and disclosures, however, we anticipate there to be a significant increase in our assets and liabilities on our consolidated balance sheets due to the recognition of our current ground leases which represented rental expense of $7.6 million and have an average remaining term of 48.2 years for the year ended December 31, 2016.  In addition, we anticipate there to be a material impact on our consolidated balance sheets and statements of operations as certain leasing costs will no longer qualify for capitalization over the life of the lease, but instead will be required to be expensed as incurred.
ASU 2016-13 Financial Instruments Credit Losses: Measurement of Credit Losses on Financial Instruments (Issued June 2016)	ASU 2016-13 is intended to improve financial reporting by requiring more timely recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. ASU 2016-13 requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected through an allowance for credit losses that is deducted from the amortized cost basis.	ASU 2016-13 is effective for fiscal years beginning after December 15, 2019 with early adoption permitted.	We do not anticipate early adoption or for there to be a material impact, however, we are evaluating the impact of adopting ASU 2016-13 on our consolidated financial statements.
ASU 2016-15 Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments (Issued August 2016)	ASU 2016-15 includes multiple provisions intended to clarify various aspects of cash flow presentation by making eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows.	ASU 2016-15 is effective for fiscal years beginning after December 15, 2017 with early adoption permitted.	We will adopt ASU 2016-15 as of the year ended December 31, 2017. We do not anticipate there to be a material impact, however, we are still evaluating the impact ASU 2016-15 will have on our consolidated financial statements.

16

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Accounting Pronouncement	Description	Effective Date	Effect on financial statements
ASU 2016-18 Statement of Cash Flows: Restricted Cash (Issued November 2016)	ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows.	ASU 2016-18 is effective for fiscal years beginning after December 15, 2017 with early adoption permitted.	We will adopt ASU 2016-18 as of the year ended December 31, 2017. We do not anticipate there to be a material impact on our consolidated financial statements, however, we are still evaluating the impact ASU 2016-18 will have on our consolidated financial statements.
ASU 2017-05 Other Income: Clarifying the Scope of Asset Derecognition Guidance and Accounting for Partial Sales of Nonfinancial Assets (Issued February 2017)	ASU 2017-05 defines an in-substance nonfinancial asset, unifies guidance related to partial sales of nonfinancial assets, eliminates rules specifically addressing the sales of real estate, removes exception to the financial asset derecognition model and clarifies the accounting for contributions of nonfinancial assets to joint ventures.	ASU 2017-05 is effective for fiscal years beginning after December 15, 2017 with early adoption permitted.	We do not anticipate early adoption, however, we are evaluating the impact of adopting ASU 2017-05 on our consolidated financial statements.

3. Investments in Real Estate

For the three months ended March 31, 2017, our investments had an aggregate purchase price of $39.0 million. We incurred $0.3 million of costs attributable to these investments, which were capitalized in accordance with the adoption of ASU 2017-01 during the three months ended March 31, 2017. As part of one of our acquisitions, we issued 20,687 OP Units with a market value at the time of issuance of $0.6 million.

The following investments were determined to be individually not significant, but significant on a collective basis. The allocations for these investments are set forth below in the aggregate for the three months ended March 31, 2017 and 2016, respectively (in thousands):

	Three Months Ended March 31,
	2017			2016
Land	$	4,934		$	17,315
Building and improvements	29,762			128,945
In place leases	3,185			15,919
Below market leases	(65		)	(5,382		)
Above market leases	—			840
Below market leasehold interests	—			1,099
Above market leasehold interests	—			(50		)
Net assets acquired	37,816			158,686
Other, net	1,230			3,321
Aggregate purchase price	$	39,046		$	162,007

The acquired intangible assets and liabilities referenced above had weighted average lives of the following for the three months ended March 31, 2017 and 2016, respectively (in years):

	Three Months Ended March 31,
	2017	2016
Acquired intangible assets	11.3	10.5
Acquired intangible liabilities	10.2	8.9

Subsequent to March 31, 2017, we executed a purchase and sale agreement with a purchase price of $150.0 million consisting of approximately 592,000 square feet of GLA located within certain of our 15 to 20 key markets.

4. Dispositions

During the three months ended March 31, 2017, we completed the disposition of an MOB located in Texas for a gross sales price of $5.0 million, representing approximately 48,000 square feet of GLA.

17

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

5. Intangible Assets and Liabilities

Intangible assets and liabilities consisted of the following as of March 31, 2017 and December 31, 2016, respectively (in thousands, except weighted average remaining amortization):

	March 31, 2017				December 31, 2016
	Balance			Weighted Average Remaining Amortization in Years	Balance			Weighted Average Remaining Amortization in Years
Assets:
In place leases	$	296,018		9.9	$	294,597		9.7
Tenant relationships	171,541			10.6	172,974			10.6
Above market leases	28,149			6.3	28,401			6.3
Below market leasehold interests	38,136			60.3	38,136			60.4
	533,844				534,108
Accumulated amortization	(266,758		)		(256,305		)
Total	$	267,086		16.4	$	277,803		16.1
Liabilities:
Below market leases	$	34,081		19.0	$	34,370		18.6
Above market leasehold interests	11,632			52.8	11,632			53.0
	45,713				46,002
Accumulated amortization	(9,704		)		(8,946		)
Total	$	36,009		29.0	$	37,056		28.5

The following is a summary of the net intangible amortization for the three months ended March 31, 2017 and 2016, respectively (in thousands):

	Three Months Ended March 31,
	2017			2016
Amortization recorded against rental income related to above and (below) market leases	$	(223	)	$	337
Rental expense related to above and (below) market leasehold interests	129			96
Amortization expense related to in place leases and tenant relationships	12,730			10,767

6. Receivables and Other Assets

Receivables and other assets consisted of the following as of March 31, 2017 and December 31, 2016, respectively (in thousands):

	March 31, 2017		December 31, 2016
Tenant receivables, net	$	8,750	$	8,722
Other receivables, net	8,949		9,233
Deferred financing costs, net	3,867		4,198
Deferred leasing costs, net	21,906		20,811
Straight-line rent receivables, net	76,287		74,052
Prepaid expenses, deposits, equipment and other, net	58,926		55,904
Derivative financial instruments - interest rate swaps	1,034		541
Total	$	179,719	$	173,461

18

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

The following is a summary of the amortization of deferred leasing costs and financing costs for the three months ended March 31, 2017 and 2016, respectively (in thousands):

	Three Months Ended March 31,
	2017		2016
Amortization expense related to deferred leasing costs	$	1,262	$	1,052
Interest expense related to deferred financing costs	331		331

7. Debt

Debt consisted of the following as of March 31, 2017 and December 31, 2016, respectively (in thousands):

	March 31, 2017			December 31, 2016
Unsecured revolving credit facility	$	170,000		$	88,000
Unsecured term loans	500,000			500,000
Unsecured senior notes	950,000			950,000
Fixed rate mortgages loans	164,646			204,562
Variable rate mortgages loans	38,666			38,904
	1,823,312			1,781,466
Deferred financing costs, net	(9,042		)	(9,527		)
Discount, net	(3,062		)	(3,034		)
Total	$	1,811,208		$	1,768,905

Unsecured Credit Agreement

Unsecured Revolving Credit Facility

In 2015, we entered into an $850.0 million Unsecured Credit Agreement. The actual amount of credit available to us is a function of certain loan-to-value and debt service coverage ratios set forth in the unsecured revolving credit facility. The maximum principal amount of the unsecured revolving credit facility may be increased, subject to additional financing being provided by our existing lenders or new lenders being added to the unsecured revolving credit facility. The unsecured revolving credit facility matures on January 31, 2020 and is guaranteed by HTA.

Borrowings under the unsecured revolving credit facility accrue interest at a rate equal to adjusted LIBOR, plus a margin ranging from 0.88% to 1.55% per annum based on our credit rating. We also pay a facility fee ranging from 0.13% to 0.30% per annum on the aggregate commitments under the unsecured revolving credit facility. As of March 31, 2017, the margin associated with our borrowings was 1.05% per annum and the facility fee was 0.20% per annum.

Unsecured Term Loan

As of March 31, 2017, we had a $300.0 million unsecured term loan outstanding that was guaranteed by HTA. Borrowings accrue interest equal to adjusted LIBOR, plus a margin ranging from 0.90% to 1.80% per annum based on our credit rating. The margin associated with our borrowings as of March 31, 2017 was 1.15% per annum. Including the impact of the interest rate swaps associated with our unsecured term loan, the interest rate was 2.15% per annum, based on our current credit rating. The unsecured term loan matures on January 31, 2019, and includes a one-year extension exercisable at the option of the borrower, subject to certain conditions.

$200.0 Million Unsecured Term Loan

As of March 31, 2017, HTALP had a $200.0 million unsecured term loan outstanding maturing on September 26, 2023. Borrowings under the unsecured term loan accrue interest at a rate equal to LIBOR, plus a margin ranging from 1.50% to 2.45% per annum based on our credit rating. The margin associated with our borrowings as of March 31, 2017 was 1.65% per annum. HTALP had interest rate swaps in place that fix the interest rate at 2.87% per annum, based on our current credit rating.

$300.0 Million Unsecured Senior Notes due 2021

As of March 31, 2017, HTALP had $300.0 million unsecured senior notes outstanding that are guaranteed by HTA and that mature on July 15, 2021. The unsecured senior notes are registered under the Securities Act of 1933, as amended (the “Securities Act”), bear interest at 3.38% per annum and are payable semi-annually. The unsecured senior notes were offered at 99.21% of the principal amount thereof, with an effective yield to maturity of 3.50% per annum.

19

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

$300.0 Million Unsecured Senior Notes due 2023

As of March 31, 2017, HTALP had $300.0 million of unsecured senior notes outstanding that are guaranteed by HTA and that mature on April 15, 2023. The unsecured senior notes are registered under the Securities Act, bear interest at 3.70% per annum and are payable semi-annually. The unsecured senior notes were offered at 99.19% of the principal amount thereof, with an effective yield to maturity of 3.80% per annum.

$350.0 Million Unsecured Senior Notes due 2026

As of March 31, 2017, HTALP had $350.0 million of unsecured senior notes outstanding that are guaranteed by HTA and that mature on August 1, 2026. The unsecured senior notes are registered under the Securities Act, bear interest at 3.50% per annum and are payable semi-annually. The unsecured senior notes were offered at 99.72% of the principal amount thereof, with an effective yield to maturity of 3.53% per annum.

Fixed and Variable Rate Mortgages

As of March 31, 2017, HTALP and its subsidiaries had fixed and variable rate mortgages loans with interest rates ranging from 2.45% to 6.39% per annum and a weighted average interest rate of 5.01% per annum. Including the impact of the interest rate swap associated with our variable rate mortgages, the weighted average interest rate was 5.41% per annum.

Future Debt Maturities

The following table summarizes the debt maturities and scheduled principal repayments of our indebtedness as of March 31, 2017 (in thousands):

Year	Amount
2017	$	36,428
2018	4,721
2019	310,839
2020	219,795
2021	303,842
Thereafter	947,687
Total	$	1,823,312

The above scheduled debt maturities do not include the extension available to us under the Unsecured Credit Agreement as discussed above.

Deferred Financing Costs

As of March 31, 2017, the future amortization of deferred financing costs is as follows (in thousands):

Year	Amount
2017	$	1,362
2018	1,775
2019	1,780
2020	1,338
2021	1,060
Thereafter	1,727
Total	$	9,042

We are required by the terms of our applicable debt agreements to meet various affirmative and negative covenants that we believe are customary for these types of facilities, such as limitations on the incurrence of debt by us and our subsidiaries that own unencumbered assets, limitations on the nature of HTALP’s business, and limitations on distributions by HTALP and its subsidiaries that own unencumbered assets. Our debt agreements also impose various financial covenants on us, such as a maximum ratio of total indebtedness to total asset value, a minimum ratio of EBITDA to fixed charges, a minimum tangible net worth covenant, a maximum ratio of unsecured indebtedness to unencumbered asset value, rent coverage ratios and a minimum ratio of unencumbered net operating income to unsecured interest expense. As of March 31, 2017, we believe that we were in compliance with all such financial covenants and reporting requirements. In addition, certain of our debt agreements include events of default provisions that we believe are customary for these types of facilities, including restricting HTA from making dividend distributions to its stockholders in the event HTA is in default thereunder, except to the extent necessary for HTA to maintain its REIT status.

20

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

8. Derivative Financial Instruments and Hedging Activities

Risk Management Objective of Using Derivative Financial Instruments

We may use derivative financial instruments, including interest rate swaps, caps, options, floors and other interest rate derivative contracts, to hedge all or a portion of the interest rate risk associated with our borrowings. The principal objective of such arrangements is to minimize the risks and/or costs associated with our operating and financial structure as well as to hedge specific anticipated transactions. We do not intend to utilize derivatives for speculative or other purposes other than interest rate risk management. The use of derivative financial instruments carries certain risks, including the risk that the counterparties to these contractual arrangements are not able to perform under the agreements. To mitigate this risk, we only enter into derivative financial instruments with counterparties with high credit ratings and with major financial institutions with which we and our affiliates may also have other financial relationships. We do not anticipate that any of the counterparties will fail to meet their obligations. We record counterparty credit risk valuation adjustments on interest rate swap derivative assets in order to properly reflect the credit quality of the counterparty. In addition, our fair value of interest rate swap derivative liabilities is adjusted to reflect the impact of our credit quality. As of March 31, 2017, there have been no termination events or events of default related to our interest rate swaps.

Cash Flow Hedges of Interest Rate Risk

Our objectives in using interest rate derivatives are to add stability to interest expense and to manage our exposure to interest rate movements. To accomplish this objective, we primarily use interest rate swaps as part of our interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable rate amounts from a counterparty in exchange for us making fixed rate payments over the life of the agreements without exchange of the underlying notional amount.

The effective portion of changes in the fair value of derivatives designated and that qualify as cash flow hedges is recorded in accumulated other comprehensive income in the accompanying condensed consolidated balance sheets and is subsequently reclassified into earnings in the period that the hedged forecasted transaction affects earnings. During the three months ended March 31, 2017, such derivatives were used to hedge the variable cash flows associated with variable rate debt. The ineffective portion of the change in fair value of the derivatives is recognized directly in earnings. During the three months ended March 31, 2017, we recorded approximately $6,000 of hedge ineffectiveness in earnings. We designated our derivative financial instruments as cash flow hedges in March 2017.

Amounts reported in accumulated other comprehensive income in the accompanying condensed consolidated balance sheets related to derivatives will be reclassified to interest expense as interest payments are made on our variable rate debt. During the next twelve months, we estimate that an additional $0.7 million will be reclassified from other comprehensive income in the accompanying condensed consolidated balance sheets as an increase to interest related to derivative financial instruments in the accompanying condensed consolidated statements of operations.

As of March 31, 2017, we had the following outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk (in thousands, except number of instruments):

Interest Rate Swaps	March 31, 2017
Number of instruments	5
Notional amount	$	190,396

The table below presents the fair value of our derivative financial instruments designated as a hedge as well as our classification in the accompanying condensed consolidated balance sheets as of March 31, 2017 (in thousands). In March 2017, we designated our derivative financial instruments as cash flow hedges. As such, prior to March 2017 we did not have derivatives designated as hedging instruments.

	Asset Derivatives					Liability Derivatives
		Fair Value at:					Fair Value at:
Derivatives Designated as Hedging Instruments:	Balance Sheet Location	March 31, 2017		December 31, 2016		Balance Sheet Location	March 31, 2017		December 31, 2016
Interest rate swaps	Receivables and other assets	$	1,034	$	—	Derivative financial instruments	$	1,653	$	—

21

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

The table below presents the gain or loss recognized on our derivative financial instruments designated as hedges as well as our classification in the accompanying condensed consolidated statements of operations for the three months ended March 31, 2017 (in thousands). In March 2017, we designated our derivative financial instruments as cash flow hedges. As such, prior to March 2017 we did not have derivatives designated as hedging instruments.

	Gain (Loss) Recognized in OCI on Derivative (Effective Portion):						Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion):						Gain (Loss) Recognized in Income on Derivative (Ineffective Portion and Amount Excluded from Effectiveness Testing):
	Three Months Ended March 31,						Three Months Ended March 31,						Three Months Ended March 31,
Derivatives Cash Flow Hedging Relationships:	2017			2016		Statement of Operations Location	2017			2016		Statement of Operations Location	2017			2016
Interest rate swaps	$	(164	)	$	—	Interest related to derivative financial instruments	$	(76	)	$	—	Interest related to derivative financial instruments	$	(6	)	$	—

Non-Designated Hedges

Derivatives not designated as hedges are not speculative and are used to manage our exposure to interest rate movements and other identified risks, but do not meet the strict hedge accounting requirements of ASC 815 - Derivatives and Hedging. Changes in the fair value of derivatives not designated in hedging relationships are recorded directly in earnings. Changes in the fair value of derivatives not designated in hedging relationships are recorded directly to gain or loss on change in fair value of derivative financial instruments in the accompanying condensed consolidated statements of operations. As of March 31, 2017, we recorded a gain on change in fair value of derivative financial instruments of $0.8 million.

The table below presents the fair value of our derivative financial instruments not designated as hedges as well as our classification in the accompanying condensed consolidated balance sheets as of December 31, 2016 (in thousands). In March 2017, we designated our derivative financial instruments as cash flow hedges. As such, as of March 2017 we did not have derivatives not designated as hedging instruments.

	Asset Derivatives					Liability Derivatives
		Fair Value at:					Fair Value at:
Derivatives NOT Designated as Hedging Instruments:	Balance Sheet Location	March 31, 2017		December 31, 2016		Balance Sheet Location	March 31, 2017		December 31, 2016
Interest rate swaps	Receivables and other assets	$	—	$	541	Derivative financial instruments	$	—	$	1,920

Tabular Disclosure of Offsetting Derivatives

The table below details a gross presentation, the effects of offsetting and net presentation of our derivatives as of March 31, 2017 and December 31, 2016, respectively (in thousands). The net amounts of derivative assets or liabilities can be reconciled to the tabular disclosure of fair value. The tabular disclosure of fair value provides the location that derivative assets or liabilities are presented in the consolidated balance sheets.

	Offsetting of Derivative Assets
	Gross Amounts of Recognized Assets		Gross Amounts in the Consolidated Balance Sheets		Net Amounts of Assets Presented in the Consolidated Balance Sheets		Financial Instruments		Cash Collateral Received		Net Amount
March 31, 2017	$	1,034	$	—	$	1,034	$	—	$	—	$	1,034
December 31, 2016	541		—		541		—		—		541

22

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

	Offsetting of Derivative Liabilities
	Gross Amounts of Recognized Liabilities		Gross Amounts in the Consolidated Balance Sheets		Net Amounts of Liabilities Presented in the Consolidated Balance Sheets		Financial Instruments		Cash Collateral Received		Net Amount
March 31, 2017	$	1,653	$	—	$	1,653	$	—	$	—	$	1,653
December 31, 2016	1,920		—		1,920		—		—		1,920

Credit Risk Related Contingent Features

We have agreements with each of our derivative counterparties that contain a provision where if we default on any of our indebtedness, including default where repayment of the indebtedness has not been accelerated by the lender, then we could also be declared in default on our derivative obligations.

We also have agreements with each of our derivative counterparties that incorporate provisions from our indebtedness with a lender affiliate of the derivative counterparty requiring it to maintain certain minimum financial covenant ratios on our indebtedness. Failure to comply with the covenant provisions would result in us being in default on any derivative instrument obligations covered by the agreement.

As of March 31, 2017, the fair value of derivatives in a net liability position including accrued interest but excluding any adjustment for nonperformance risk related to these agreements was $1.8 million. As of March 31, 2017, we have not posted any collateral related to these agreements and were not in breach of any agreement provisions. If we had breached any of these provisions, we could have been required to settle our obligations under the agreements at an aggregate termination value of $1.8 million at March 31, 2017.

9. Commitments and Contingencies

Litigation

We engage in litigation from time to time with various parties as a routine part of our business, including tenant defaults. However, we are not presently subject to any material litigation nor, to our knowledge, is any material litigation threatened against us, which if determined unfavorably to us, would have a material effect on our condensed consolidated financial position, results of operations or cash flows.

Environmental Matters

We follow the policy of monitoring our properties for the presence of hazardous or toxic substances. While there can be no assurance that a material environmental liability does not exist at our properties, we are not currently aware of any environmental liability with respect to our properties that would have a material effect on our condensed consolidated financial position, results of operations or cash flows. Further, we are not aware of any material environmental liability or any unasserted claim or assessment with respect to an environmental liability at our properties that we believe would require additional disclosure or the recording of a loss contingency.

Other

Our other commitments and contingencies include the usual obligations of real estate owners and operators in the normal course of business. In our opinion, these matters are not expected to have a material effect on our condensed consolidated financial position, results of operations or cash flows.

10. Stockholders’ Equity and Partners’ Capital

HTALP’s partnership agreement provides that it will distribute cash flow from operations and net sale proceeds to its partners in accordance with their overall ownership interests at such times and in such amounts as the general partner determines. Dividend distributions are made such that a holder of one partnership unit in HTALP will receive distributions from HTALP in an amount equal to the dividend distributions paid to the holder of one share of HTA’s common stock. In addition, for each share of common stock issued or redeemed by HTA, HTALP issues or redeems a corresponding number of partnership units.

23

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Common Stock Offerings

In January 2016, HTA entered into a new equity distribution agreement with respect to its at-the-market (“ATM”) offering program of common stock with an aggregate sales amount of up to $300.0 million. As of March 31, 2017, $177.1 million remained available for issuance under the ATM.

Subsequent to March 31, 2017, HTA issued and sold 1,998,000 shares of its common stock for $62.3 million at an average price of $31.20 per share.

Common Unit Offerings

During the three months ended March 31, 2017, HTA issued 20,687 OP Units in HTALP for approximately $0.6 million in connection with an acquisition transaction.

Common Stock Dividends

See our accompanying condensed consolidated statements of operations for the dividends declared during the three months ended March 31, 2017 and 2016. On April 26, 2017, HTA declared a quarterly cash dividend of $0.30 per share to be paid on July 11, 2017 to stockholders of record of its common stock on July 5, 2017.

Incentive Plan

HTA’s Amended and Restated 2006 Incentive Plan (the “Plan”) permits the grant of incentive awards to our employees, officers, non-employee directors and consultants as selected by our Board of Directors. The Plan authorizes the granting of awards in any of the following forms: options; stock appreciation rights; restricted stock; restricted or deferred stock units; performance awards; dividend equivalents; other stock-based awards, including units in HTALP; and cash-based awards. Subject to adjustment as provided in the Plan, the aggregate number of awards reserved and available for issuance under the Plan is 5,000,000. As of March 31, 2017, there were 1,710,501 awards available for grant under the Plan.

LTIP Units

Awards under the LTIP consist of Series C units inHTALPand were subject to the achievement of certain performance and market conditions in order to vest. Once vested, the Series C units were converted into common units of HTALP, which may be converted into shares of HTA’s common stock. The LTIP awards were fully expensed or forfeited in 2015.

Restricted Common Stock

For the three months ended March 31, 2017 and 2016, we recognized compensation expense of $2.5 million and $1.8 million, respectively, which was recorded in general and administrative expenses in the accompanying condensed consolidated statements of operations.

As of March 31, 2017, there was $11.1 million of unrecognized compensation expense, net of estimated forfeitures, which will be recognized over a remaining weighted average period of 2.1 years.

The following is a summary of our restricted common stock activity as of March 31, 2017 and 2016, respectively:

	March 31, 2017				March 31, 2016
	Restricted Common Stock		Weighted Average Grant Date Fair Value		Restricted Common Stock		Weighted Average Grant Date Fair Value
Beginning balance	640,870		$	27.36	487,850		$	23.13
Granted	215,333		29.31		194,151		27.17
Vested	(229,621	)	24.88		(162,140	)	22.65
Forfeited	(2,524	)	29.96		(3,244	)	24.23
Ending balance	624,058		$	28.94	516,617		$	24.79

24

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

11. Fair Value of Financial Instruments

Financial Instruments Reported at Fair Value - Recurring

The table below presents our assets and liabilities measured at fair value on a recurring basis as of March 31, 2017, aggregated by the applicable level in the fair value hierarchy (in thousands):

	Level 1		Level 2		Level 3		Total
Assets:
Derivative financial instruments	$	—	$	1,034	$	—	$	1,034
Liabilities:
Derivative financial instruments	$	—	$	1,653	$	—	$	1,653

The table below presents our assets and liabilities measured at fair value on a recurring basis as of December 31, 2016, aggregated by the applicable level in the fair value hierarchy (in thousands):

	Level 1		Level 2		Level 3		Total
Assets:
Derivative financial instruments	$	—	$	541	$	—	$	541
Liabilities:
Derivative financial instruments	$	—	$	1,920	$	—	$	1,920

Financial Instruments Reported at Fair Value - Non-Recurring

As of March 31, 2017, there were noassets measured at fair value on a non-recurring basis. The table below presents our assets measured at fair value on a non-recurring basis as of December 31, 2016, aggregated by the applicable level in the fair value hierarchy (in thousands):

	Level 1		Level 2		Level 3		Total
Assets:
MOB (1)	$	—	$	8,191	$	—	$	8,191
(1) During the year ended December 31, 2016, we recognized impairment charges of $1.3 million and $1.8 million to the carrying value of two MOBs. The estimated fair value as of December 31, 2016 for these MOBs was based upon a pending sales agreement and real estate market comparables.

There have been no transfers of assets or liabilities between levels. We will record any such transfers at the end of the reporting period in which a change of event occurs that results in a transfer. Although we have determined that the majority of the inputs used to value our interest rate swap derivatives fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with these instruments utilize Level 3 inputs, such as estimates of current credit spreads to evaluate the likelihood of default by us and our counterparties. However, we have assessed the significance of the impact of the credit valuation adjustments on the overall valuation of our interest rate swap derivative positions and have determined that the credit valuation adjustments are not significant to their overall valuation. As a result, we have determined that our interest rate swap derivative valuations in their entirety are classified in Level 2 of the fair value hierarchy.

Financial Instruments Disclosed at Fair Value

We consider the carrying values of cash and cash equivalents, tenant and other receivables, restricted cash and escrow deposits and accounts payable, and accrued liabilities, to approximate fair value for these financial instruments because of the short period of time between origination of the instruments and their expected realization. All of these financial instruments are considered Level 2.

The fair value of debt is estimated using borrowing rates available to us with similar terms and maturities, which is considered a Level 2 input. As of March 31, 2017, the fair value of the debt was $1,831.7 million compared to the carrying value of $1,811.2 million. As of December 31, 2016, the fair value of the debt was $1,784.0 million compared to the carrying value of $1,768.9 million.

25

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

12. Per Share Data of HTA

HTA includes unvested share-based payment awards that contain non-forfeitable rights to dividends or dividend equivalents as “participating securities” pursuant to the two-class method. The resulting classes are our common stock and restricted stock. For the three months ended March 31, 2017 and 2016, all of HTA’s earnings were distributed and the calculated earnings per share amount would be the same for all classes.

The following is the reconciliation of the numerator and denominator used in basic and diluted earnings per share of HTA for the three months ended March 31, 2017 and 2016, respectively (in thousands, except per share data):

	Three Months Ended March 31,
	2017			2016
Numerator:
Net income	$	14,000		$	10,036
Net income attributable to noncontrolling interests	(455		)	(176		)
Net income attributable to common stockholders	$	13,545		$	9,860
Denominator:
Weighted average shares outstanding - basic	141,780			129,336
Dilutive shares	4,337			1,904
Weighted average shares outstanding - diluted	146,117			131,240
Earnings per common share - basic
Net income attributable to common stockholders	$	0.10		$	0.08
Earnings per common share - diluted
Net income attributable to common stockholders	$	0.09		$	0.08

13. Per Unit Data of HTALP

The following is the reconciliation of the numerator and denominator used in basic and diluted earnings per unit of HTALP for the three months ended March 31, 2017 and 2016, respectively (in thousands, except per unit data):

	Three Months Ended March 31,
	2017			2016
Numerator:
Net income	$	14,000		$	10,036
Net income attributable to noncontrolling interests	(30		)	(31		)
Net income attributable to common unitholders	$	13,970		$	10,005
Denominator:
Weighted average units outstanding - basic	146,117			131,242
Dilutive units	—			—
Weighted average units outstanding - diluted	146,117			131,242
Earnings per common unit - basic:
Net income attributable to common unitholders	$	0.10		$	0.08
Earnings per common unit - diluted:
Net income attributable to common unitholders	$	0.10		$	0.08

26

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

14. Supplemental Cash Flow Information

The following is the supplemental cash flow information for the three months ended March 31, 2017 and 2016, respectively (in thousands):

	Three Months Ended March 31,
	2017		2016
Supplemental Disclosure of Cash Flow Information:
Interest paid	$	19,186	$	13,062
Income taxes paid	60		88
Supplemental Disclosure of Noncash Investing and Financing Activities:
Accrued capital expenditures	$	5,696	$	5,688
Dividend distributions declared, but not paid	44,489		38,784
Issuance of operating partnership units in connection with an acquisition	610		—
Note receivable retired in connection with an acquisition	2,494		—

27

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The use of the words “we,” “us” or “our” refers to HTA and HTALP, collectively.

The following discussion should be read in conjunction with our condensed consolidated financial statements and notes appearing elsewhere in this Quarterly Report, as well as with the audited consolidated financial statements, accompanying notes and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our 2016 Annual Report on Form 10-K. Such condensed consolidated financial statements and information have been prepared to reflect HTA’s and HTALP’s financial position as of March 31, 2017 and December 31, 2016, together with results of operations and cash flows for the three months ended March 31, 2017 and 2016.

The information set forth below is intended to provide readers with an understanding of our financial condition, changes in financial condition and results of operations.

• Forward-Looking Statements;

• Executive Summary;

• Company Highlights;

• Critical Accounting Policies;

• Recently Issued or Adopted Accounting Pronouncements;

• Factors Which May Influence Results of Operations;

• Results of Operations;

• Non-GAAP Financial Measures;

• Liquidity and Capital Resources;

• Commitments and Contingencies;

• Debt Service Requirements;

• Off-Balance Sheet Arrangements; and

• Inflation.

Forward-Looking Statements

Certain statements contained in this Quarterly Report constitute forward-looking statements within the meaning of the safe harbor from civil liability provided for such statements by the Private Securities Litigation Reform Act of 1995 (set forth in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”)). Such statements include, in particular, statements about our plans, strategies, prospects and estimates regarding future MOB market performance. Additionally, such statements are subject to certain risks and uncertainties, as well as known and unknown risks, which could cause actual results to differ materially and in adverse ways from those projected or anticipated. Therefore, such statements are not intended to be a guarantee of our performance in future periods. Forward-looking statements are generally identifiable by the use of such terms as “expect,” “project,” “may,” “should,” “could,” “would,” “intend,” “plan,” “anticipate,” “estimate,” “believe,” “continue,” “opinion,” “predict,” “potential,” “pro forma” or the negative of such terms and other comparable terminology. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this Quarterly Report is filed with the SEC. We cannot guarantee the accuracy of any such forward-looking statements contained in this Quarterly Report, and we do not intend to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Any such forward-looking statements reflect our current views about future events, are subject to unknown risks, uncertainties, and other factors, and are based on a number of assumptions involving judgments with respect to, among other things, future economic, competitive and market conditions, all of which are difficult or impossible to predict accurately. To the extent that our assumptions differ from actual results, our ability to meet such forward-looking statements, including our ability to generate positive cash flow from operations, provide dividends to stockholders and maintain the value of our real estate properties, may be significantly hindered. Factors that might impair our ability to meet such forward-looking statements include, without limitation, those discussed in Part I, Item 1A - Risk Factors in our 2016 Annual Report on Form 10-K, which is incorporated herein.

28

Forward-looking statements express expectations of future events. All forward-looking statements are inherently uncertain as they are based on various expectations and assumptions concerning future events and they are subject to numerous known and unknown risks and uncertainties that could cause actual events or results to differ materially from those projected. Due to these inherent uncertainties, our stockholders are urged not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date made. In addition, we undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to projections over time, except as required by law.

These risks and uncertainties should be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements. Additional information concerning us and our business, including additional factors that could materially affect our financial results, is included herein and in our other filings with the SEC.

Executive Summary

HTA is one of the largest publicly-traded REITs focused on MOBs in the U.S. as measured by the GLA of its MOBs. HTA conducts substantially all of its operations through HTALP. We invest in MOBs that we believe will serve the future of healthcare delivery and MOBs that are primarily located on health system campuses, near university medical centers, or in core community outpatient locations. We also focus on our key markets that have certain demographic and macro-economic trends and where we can utilize our institutional property management and leasing platform to generate strong tenant relationships and operating cost efficiencies. Our primary objective is to maximize stockholder value with disciplined growth through strategic investments that provide an attractive risk-adjusted return for our stockholders by consistently increasing our cash flow. In pursuing this objective, we: (i) seek internal growth through proactive asset management, leasing and property management oversight; (ii) target accretive acquisitions of MOBs in markets with attractive demographics that complement our existing portfolio; and (iii) actively manage our balance sheet to maintain flexibility with conservative leverage.  Additionally, from time to time we consider, on an opportunistic basis, significant portfolio acquisitions that we believe fit our core business and could enhance our existing portfolio.

Since 2006, we have invested $4.3 billion to create a portfolio of MOBs and other healthcare assets consisting of approximately 17.8 million square feet of GLA throughout the U.S. As of March 31, 2017, approximately 96% of our portfolio, based on GLA, was located on the campuses of, or aligned with, nationally or regionally recognized healthcare systems. Our portfolio is diversified geographically across 31 states, with no state having more than 13% of our total GLA as of March 31, 2017. We are concentrated in 15 to 20 key markets that are experiencing higher economic and demographic trends than other markets, on average, that we expect will drive demand for MOBs. Approximately 92% of our portfolio, based on GLA, is located in the top 75 MSAs with Boston, Hartford/New Haven, Dallas, Houston, Phoenix and Orange County/Los Angeles being our largest markets by investment.

Company Highlights

Portfolio Operating Performance

• For the three months ended March 31, 2017, our total revenue increased15.9%, or $17.0 million, to $124.3 million, compared to the three months ended March 31, 2016.

• For the three months ended March 31, 2017, net income attributable to common stockholders was $0.09 per diluted share, or $13.5 million, compared to $0.08 per diluted share, or $9.9 million, for the three months ended March 31, 2016.

• For the three months ended March 31, 2017, HTA’s FFO was $0.41 per diluted share, or $60.2 million, an increase of $0.05 per diluted share, or 13.9%, compared to the three months ended March 31, 2016. For the three months ended March 31, 2017, HTALP’s FFO was $0.42 per diluted share, or $60.7 million, an increase of $0.06 per diluted share, or 16.7%, compared to the three months ended March 31, 2016.

• For the three months ended March 31, 2017, HTA’s and HTALP’s Normalized FFO was $0.41 per diluted share, or $60.1 million, an increase of $0.01 per diluted share, or 2.5%, compared to the three months ended March 31, 2016.

• For additional information on FFO and Normalized FFO, see “FFO and Normalized FFO” below, which includes a reconciliation to net income attributable to common stockholders/unitholders and an explanation of why we present this non-GAAP financial measure.

• For the three months ended March 31, 2017, our Net Operating Income (“NOI”) increased15.4%, or $11.4 million, to $85.3 million, compared to the three months ended March 31, 2016.

• For the three months ended March 31, 2017, our Same-Property Cash NOI increased3.2%, or $2.2 million, to $70.5 million, compared to the three months ended March 31, 2016.

29

• For additional information on NOI and Same-Property Cash NOI, see “NOI, Cash NOI and Same-Property Cash NOI” below, which includes a reconciliation from net income and an explanation of why we present these non-GAAP financial measures.

Internal Growth through Proactive Asset Management Leasing and Property Management

• As of March 31, 2017, our leased rate (includes leases which have been executed, but which have not yet commenced) was 91.8% by GLA and our occupancy rate was 91.0% by GLA.

• We entered into new and renewal leases on approximately 776,000 square feet of GLA, or 4.4% of our portfolio, during the three months ended March 31, 2017.

• Tenant retention for the Same-Property portfolio was 80%, which included approximately 462,000 square feet of GLA of expiring leases, for the quarter, which we believe is indicative of our commitment to maintaining buildings in desirable locations and fostering strong tenant relationships. Tenant retention is defined as the sum of the total leased GLA of tenants that renewed a lease during the period over the total GLA of leases that renewed or expired during the period.

• As of March 31, 2017, our in-house property management and leasing platform operated approximately 16.2 million square feet of GLA, or 91%, of our total portfolio.

Key Market Focused Strategy and Investments

We believe we have been one of the most active investors in the medical office sector over the last ten years and have developed a presence across 15 to 20 key markets. In each of these markets we have established a strong asset management and leasing platform that has allowed us to develop valuable relationships with health systems, physician practices, universities, and regional development firms that have led to investment and leasing opportunities. Our local platforms have also enabled us to focus on generating cost efficiencies as we gain scale across individual markets and regions.

• As of March 31, 2017, we had an average 800,000 square feet of GLA in each of our top ten markets. We expect to establish this scale across 15 to 20 key markets as our portfolio expands.

• Our key markets represent top MSAs with strong growth metrics in jobs, household income and population; as well as low unemployment and mature healthcare infrastructures. Many are also supported by strong university systems.

• Our investment strategy includes alignment with key healthcare systems, hospitals and leading academic medical universities.

• Over the last several years, our investments have been focused in our key markets, with the majority of our investments also being located either on the campuses of, or aligned with, nationally and regionally recognized healthcare systems.

• During the three months ended March 31, 2017, we acquired investments totaling $35.0 million located in our key market of Tampa, Florida, and strategically expanded our presence in College Station, Texas.

In addition, we invested in $4.1 million to expand our New Haven, Connecticut campus.

• During the three months ended March 31, 2017, we completed the disposition of an MOB located in Texas for a gross sales price of $5.0 million.

Financial Strategy and Balance Sheet Flexibility

• As of March 31, 2017, we had total leverage, measured by debt to market capitalization, of 28.3%. Total liquidity was $690.5 million, including cash and cash equivalents of $16.0 million and $674.5 million available on our unsecured revolving credit facility (includes the impact of $5.5 million of outstanding letters of credit) as of March 31, 2017.

• During the three months ended March 31, 2017, as part of one of our acquisitions, we issued $0.6 million of OP Units.

Critical Accounting Policies

The complete list of our critical accounting policies was disclosed in our 2016 Annual Report on Form 10-K. There have been no material changes to our critical accounting policies as disclosed herein.

Recently Issued or Adopted Accounting Pronouncements

See Note 2 - Summary of Significant Accounting Policies to our accompanying condensed consolidated financial statements for a discussion of recently issued or adopted accounting pronouncements.

30

Factors Which May Influence Results of Operations

We are not aware of any material trends or uncertainties, other than national economic conditions affecting real estate generally and the risk factors previously listed in Part I, Item 1A - Risk Factors, in our 2016 Annual Report on Form 10-K that may reasonably be expected to have a material impact, favorable or unfavorable, on revenues or income from the investment, management and operation of our properties.

Rental Income

The amount of rental income generated by our properties depends principally on our ability to maintain the occupancy rates of currently leased space and to lease currently available space and space that will become available from unscheduled lease terminations at the then applicable rental rates. Negative trends in one or more of these factors could adversely affect our rental income in future periods.

Investment Activity

During the three months ended March 31, 2017, we had investments with an aggregate gross purchase price of $39.0 million and a disposition with a gross sales price of $5.0 million. During the three months ended March 31, 2016, we had investments with an aggregate gross purchase price of $162.0 million and no dispositions. The amount of any future acquisitions or dispositions could have a significant impact on our results of operations in future periods.

Results of Operations

Comparison of the Three Months Ended March 31, 2017 and 2016

As of March 31, 2017 and 2016, we owned and operated approximately 17.8 million and 16.2 million square feet of GLA, respectively, with a leased rate of 91.8% and 92.1%, respectively (includes leases which have been executed, but which have not yet commenced), and an occupancy rate of 91.0% and 91.4%, respectively. All explanations are applicable to both HTA and HTALP unless otherwise noted.

Rental Income

For the three months ended March 31, 2017 and 2016, respectively, rental income was comprised of the following (in thousands):

	Three Months Ended March 31,
	2017		2016
Contractual rental income	$	119,897	$	103,812
Straight-line rent and amortization of above and (below) market leases	2,472		2,073
Other operating revenue	1,624		1,365
Total	$	123,993	$	107,250

Contractual rental income, which includes expense reimbursements, increased$16.1 million for the three months ended March 31, 2017, compared to the three months ended March 31, 2016. This increase was primarily due to $14.2 million of additional contractual rental income from our 2016 and 2017 acquisitions (including properties owned in both periods) and contractual rent increases, partially offset by a decrease in contractual rent as a result of buildings we sold during 2016 and 2017.

Average starting and ending annual base rents and square feet entered into for new and renewal leases consisted of the following for the three months ended March 31, 2017 and 2016, respectively (in square feet and per square foot of GLA):

	Three Months Ended March 31,
	2017		2016
New and renewal leases:
Average starting annual base rents	$	22.63	$	22.37
Average ending annual base rents	23.07		22.06
Square feet of GLA	776,000		254,000

Lease rates can vary across markets, and lease rates that are considered above or below current market rent may change over time. Leases that expired in 2017 had rents that we believed were at market rates. Generally, leasing concessions vary depending on lease type and term.

31

Tenant improvements, leasing commissions and tenant concessions for new and renewal leases consisted of the following for the three months ended March 31, 2017 and 2016, respectively (in per square foot of GLA):

	Three Months Ended March 31,
	2017		2016
New leases:
Tenant improvements	$	18.04	$	27.38
Leasing commissions	2.29		4.34
Tenant concessions	3.04		5.05
Renewal leases:
Tenant improvements	$	7.16	$	6.00
Leasing commissions	1.24		1.09
Tenant concessions	1.70		1.07

The average term for new and renewal leases executed consisted of the following for three months ended March 31, 2017 and 2016, respectively (in years):

	Three Months Ended March 31,
	2017	2016
New leases	5.5	5.8
Renewal leases	4.9	3.7

Rental Expenses

For the three months ended March 31, 2017 and 2016, rental expenses attributable to our properties were $39.0 million and $33.4 million, respectively. The increase in rental expenses was primarily due to $5.8 million of additional rental expenses associated with our 2016 and 2017 acquisitions, partially offset by improved operating efficiencies and a decrease in rental expenses as a result of the buildings we sold during 2016 and 2017.

General and Administrative Expenses

For the three months ended March 31, 2017 and 2016, general and administrative expenses were $8.4 million and $6.8 million, respectively. The increase in general and administrative expenses was primarily due to the increase in non-cash compensation expense. General and administrative expenses include such costs as salaries, corporate overhead and professional fees, among other items.

Transaction Expenses

For the three months ended March 31, 2017 and 2016, transaction expenses were $0.3 million and $1.8 million, respectively. The decrease in transaction expenses was due to the adoption of ASU 2017-01 as of January 1, 2017. As a result of the adoption thereof a significant portion of these expenses are now capitalized as part of our investment allocations.

Depreciation and Amortization Expense

For the three months ended March 31, 2017 and 2016, depreciation and amortization expense was $47.1 million and $37.8 million, respectively. The increase in depreciation and amortization expense was primarily due to the increase in the size of our portfolio.

Interest Expense and Net Change in Fair Value of Derivative Financial Instruments

Interest expense excluding the impact of the net change in fair value of derivative financial instruments increased by $1.6 million during the three months ended March 31, 2017, compared to the three months ended March 31, 2016. This increase was primarily the result of higher average debt outstanding during the three months ended March 31, 2017, as a result of partially funding our investments over the last 12 months with debt and a change in the composition of debt, driven by an increase in long-term senior unsecured notes, including the $350.0 million 10-year senior unsecured notes issued in July 2016 at a coupon rate of 3.50%, offset by a reduction in the aggregate variable unsecured revolving credit facility borrowings and mortgage loans outstanding. During the three months ended March 31, 2017, the fair market value of our derivatives increased $0.8 million, compared to a net decrease of $2.8 million during the three months ended March 31, 2016.

To achieve our objectives, we borrow at both fixed and variable rates. We also enter into derivative financial instruments, such as interest rate swaps, in order to mitigate our interest rate risk on a related financial instrument. We do not enter into derivative or interest rate transactions for speculative purposes. Derivatives not designated as hedges are not speculative and are used to manage our exposure to interest rate movements.

32

NOI and Same-Property Cash NOI

NOI increased$11.4 million to $85.3 million for the three months ended March 31, 2017, compared to the three months ended March 31, 2016. This increase was primarily due to $9.5 million of additional NOI from our 2016 and 2017 acquisitions, partially offset by a decrease in NOI as a result of the buildings we sold during 2016 and 2017, and a reduction in straight-line rent from properties we owned more than a year.

Same-Property Cash NOI increased$2.2 million to $70.5 million for the three months ended March 31, 2017, compared to the three months ended March 31, 2016. This increase was primarily the result of rent escalations, an increase in average occupancy and improved operating efficiencies.

Non-GAAP Financial Measures

FFO and Normalized FFO

We compute FFO in accordance with the current standards established by the National Association of Real Estate Investment Trusts (“NAREIT”). NAREIT defines FFO as net income or loss attributable to common stockholders/unitholders (computed in accordance with GAAP), excluding gains or losses from sales of real estate property and impairment write-downs of depreciable assets, plus depreciation and amortization related to investments in real estate, and after adjustments for unconsolidated partnerships and joint ventures. We present this non-GAAP financial measure because we consider it an important supplemental measure of our operating performance and believe it is frequently used by securities analysts, investors and other interested parties in the evaluation of REITs. Historical cost accounting assumes that the value of real estate assets diminishes ratably over time. Since real estate values have historically risen or fallen based on market conditions, many industry investors have considered the presentation of operating results for real estate companies that use historical cost accounting to be insufficient by themselves. Because FFO excludes depreciation and amortization unique to real estate, among other items, it provides a perspective not immediately apparent from net income or loss attributable to common stockholders/unitholders.

We also compute Normalized FFO, which excludes from FFO: (i) transaction expenses; (ii) gain or loss on change in fair value of derivative financial instruments; (iii) gain or loss on extinguishment of debt; (iv) noncontrolling income or loss from partnership units included in diluted shares (only applicable to HTA); and (v) other normalizing items, which include items that are unusual and infrequent in nature. We present this non-GAAP financial measure because it allows for the comparison of our operating performance to other REITs and between periods on a consistent basis. Our methodology for calculating Normalized FFO may be different from the methods utilized by other REITs and, accordingly, may not be comparable to other REITs. Normalized FFO should not be considered as an alternative to net income or loss attributable to common stockholders/unitholders (computed in accordance with GAAP) as an indicator of our financial performance, nor is it indicative of cash available to fund cash needs. Normalized FFO should be reviewed in connection with other GAAP measurements.

The amounts included in the calculation of FFO and Normalized FFO are generally the same for HTALP and HTA, except for net income or loss attributable to common stockholders/unitholders, noncontrolling income or loss from partnership units included in diluted shares (only applicable to HTA) and the weighted average shares of HTA common stock or HTALP partnership units outstanding.

33

The following is the reconciliation of HTA’s FFO and Normalized FFO to net income attributable to common stockholders for the three months ended March 31, 2017 and 2016, respectively (in thousands, except per share data):

	Three Months Ended March 31,
	2017			2016
Net income attributable to common stockholders	$	13,545		$	9,860
Depreciation and amortization expense related to investments in real estate	46,689			37,521
Gain on sale of real estate, net	(3		)	—
FFO attributable to common stockholders	$	60,231		$	47,381
Transaction expenses (1)	284			1,813
(Gain) loss on change in fair value of derivative financial instruments, net	(839		)	2,792
Loss on extinguishment of debt, net	32			—
Noncontrolling income from partnership units included in diluted shares	425			145
Other normalizing items, net (2)	—			(16		)
Normalized FFO attributable to common stockholders	$	60,133		$	52,115
Net income attributable to common stockholders per diluted share	$	0.09		$	0.08
FFO adjustments per diluted share, net	0.32			0.28
FFO attributable to common stockholders per diluted share	$	0.41		$	0.36
Normalized FFO adjustments per diluted share, net	0.00			0.04
Normalized FFO attributable to common stockholders per diluted share	$	0.41		$	0.40
Weighted average diluted common shares outstanding	146,117			131,240
(1) For the three months ended March 31, 2017, amounts have been adjusted to reflect the prospective presentation of the early adoption of ASU 2017-01 as of January 1, 2017.
(2) For the three months ended March 31, 2017, other normalizing items excludes lease termination fees as they are deemed to be generated in the ordinary course of business.

The following is the reconciliation of HTALP’s FFO and Normalized FFO to net income attributable to common unitholders for the three months ended March 31, 2017 and 2016, respectively (in thousands, except per unit data):

	Three Months Ended March 31,
	2017			2016
Net income attributable to common unitholders	$	13,970		$	10,005
Depreciation and amortization expense related to investments in real estate	46,689			37,521
Gain on sale of real estate, net	(3		)	—
FFO attributable to common unitholders	$	60,656		$	47,526
Transaction expenses (1)	284			1,813
(Gain) loss on change in fair value of derivative financial instruments, net	(839		)	2,792
Loss on extinguishment of debt, net	32			—
Other normalizing items, net (2)	—			(16		)
Normalized FFO attributable to common unitholders	$	60,133		$	52,115
Net income attributable to common unitholders per diluted unit	$	0.10		$	0.08
FFO adjustments per diluted unit, net	0.32			0.28
FFO attributable to common unitholders per diluted unit	$	0.42		$	0.36
Normalized FFO adjustments per diluted unit, net	(0.01		)	0.04
Normalized FFO attributable to common unitholders per diluted unit	$	0.41		$	0.40
Weighted average diluted common units outstanding	146,117			131,242
(1) For the three months ended March 31, 2017, amounts have been adjusted to reflect the prospective presentation of the early adoption of ASU 2017-01 as of January 1, 2017.
(2) For the three months ended March 31, 2017, other normalizing items excludes lease termination fees as they are deemed to be generated in the ordinary course of business.

34

NOI, Cash NOI and Same-Property Cash NOI

NOI is a non-GAAP financial measure that is defined as net income or loss (computed in accordance with GAAP) before: (i) general and administrative expenses; (ii) transaction expenses; (iii) depreciation and amortization expense; (iv) interest expense and net change in fair value of derivative financial instruments; (v) gain or loss on sales of real estate; (vi) gain or loss on extinguishment of debt; and (vii) other income or expense. We believe that NOI provides an accurate measure of the operating performance of our operating assets because NOI excludes certain items that are not associated with the management of our properties. Additionally, we believe that NOI is a widely accepted measure of comparative operating performance of REITs. However, our use of the term NOI may not be comparable to that of other REITs as they may have different methodologies for computing this amount. NOI should not be considered as an alternative to net income or loss (computed in accordance with GAAP) as an indicator of our financial performance. NOI should be reviewed in connection with other GAAP measurements.

Cash NOI is a non-GAAP financial measure which excludes from NOI: (i) straight-line rent adjustments; and (ii) amortization of below and above market leases/leasehold interests. Contractual base rent, contractual rent increases, contractual rent concessions and changes in occupancy or lease rates upon commencement and expiration of leases are a primary driver of our revenue performance. We believe that Cash NOI, which removes the impact of straight-line rent adjustments, provides another measurement of the operating performance of our operating assets. Additionally, we believe that Cash NOI is a widely accepted measure of comparative operating performance of REITs. However, our use of the term Cash NOI may not be comparable to that of other REITs as they may have different methodologies for computing this amount. Cash NOI should not be considered as an alternative to net income or loss (computed in accordance with GAAP) as an indicator of our financial performance. Cash NOI should be reviewed in connection with other GAAP measurements.

To facilitate the comparison of Cash NOI between periods, we calculate comparable amounts for a subset of our owned properties referred to as “Same-Property”. Same-Property Cash NOI excludes properties which have not been owned and operated by us during the entire span of all periods presented, excluding properties intended for disposition in the near term, notes receivable interest income and certain non-routine items. Same-Property Cash NOI should not be considered as an alternative to net income or loss (computed in accordance with GAAP) as an indicator of our financial performance. Same-Property Cash NOI should be reviewed in connection with other GAAP measurements.

The following is the reconciliation of HTA’s and HTALP’s NOI, Cash NOI and Same-Property Cash NOI to net income for the three months ended March 31, 2017 and 2016, respectively (in thousands):

	Three Months Ended March 31,
	2017			2016
Net income	$	14,000		$	10,036
General and administrative expenses	8,423			6,773
Transaction expenses (1)	284			1,813
Depreciation and amortization expense	47,056			37,828
Interest expense and net change in fair value of derivative financial instruments	15,543			17,565
Gain on sale of real estate, net	(3		)	—
Loss on extinguishment of debt, net	32			—
Other income	(8		)	(53		)
NOI	$	85,327		$	73,962
Straight-line rent adjustments, net	(1,209		)	(1,451		)
Amortization of (below) and above market leases/leasehold interests, net and lease termination fees	(94		)	417
Cash NOI	$	84,024		$	72,928
Notes receivable interest income	(292		)	—
Non Same-Property Cash NOI	(13,237		)	(4,596		)
Same-Property Cash NOI (2)	$	70,495		$	68,332
(1) For the three months ended March 31, 2017, amounts have been adjusted to reflect the prospective presentation of the early adoption of ASU 2017-01 as of January 1, 2017.
(2) Same-Property includes 286 buildings for the three months ended March 31, 2017 and 2016.

35

Liquidity and Capital Resources

Our primary sources of cash include: (i) cash flow from operations; (ii) borrowings under our unsecured revolving credit facility; (iii) net proceeds from the issuances of debt and equity securities; and (iv) proceeds from our dispositions. During the next 12 months our primary uses of cash are expected to include: (a) the funding of acquisitions of MOBs and other facilities that serve the healthcare industry; (b) capital expenditures; (c) the payment of operating expenses; (d) debt service payments, including principal payments; and (e) the payment of dividends to our stockholders. We anticipate cash flow from operations, restricted cash and reserve accounts and our unsecured revolving credit facility, if needed, will be sufficient to fund our operating expenses, capital expenditures and dividends to stockholders. Investments and maturing indebtedness may require funds from the issuance of debt and/or equity securities or proceeds from sales of real estate.

As of March 31, 2017, we had liquidity of $690.5 million, including $674.5 million available under our unsecured revolving credit facility (includes the impact of $5.5 million of outstanding letters of credit) and $16.0 million of cash and cash equivalents.

As of March 31, 2017, $177.1 million was available for issuance under our $300.0 million ATM program. In addition, we had unencumbered properties with a gross book value of $3.2 billion. The unencumbered properties may be used as collateral to secure additional financings in future periods or refinance our current debt as it becomes due. Our ability to raise funds from future debt and equity issuances is dependent on our investment grade credit ratings, general economic and market conditions and our operating performance.

When we acquire a property, we prepare a capital plan that contemplates the estimated capital needs of that investment. In addition to operating expenses, capital needs may also include costs of refurbishment, tenant improvements or other major capital expenditures. The capital plan for each investment will be adjusted through ongoing, regular reviews of our portfolio or as necessary to respond to unanticipated additional capital needs. As of March 31, 2017, we estimate that our expenditures for capital improvements for the remainder of 2017 will range from $20.0 million to $25.0 million depending on leasing activity. As of March 31, 2017, we had $3.8 million of restricted cash and reserve accounts for such capital expenditures. We cannot provide assurance, however, that we will not exceed these estimated expenditure levels.

If we experience lower occupancy levels, reduced rental rates, reduced revenues as a result of asset sales, or increased capital expenditures and leasing costs compared to historical levels due to competitive market conditions for new and renewal leases, the effect would be a reduction of net cash provided by operating activities. If such a reduction of net cash provided by operating activities is realized, we may have a cash flow deficit in subsequent periods. Our estimate of net cash available is based on various assumptions which are difficult to predict, including the levels of our leasing activity and related leasing costs. Any changes in these assumptions could impact our financial results and our ability to fund working capital and unanticipated cash needs.

Cash Flows

The following is a summary of our cash flows for the three months ended March 31, 2017 and 2016, respectively (in thousands):

	Three Months Ended March 31,
	2017			2016			Change
Cash and cash equivalents - beginning of period	$	11,231		$	13,070		$	(1,839	)
Net cash provided by operating activities	47,013			40,452			6,561
Net cash used in investing activities	(37,083		)	(168,309		)	131,226
Net cash (used in) provided by financing activities	(5,127		)	128,614			(133,741		)
Cash and cash equivalents - end of period	$	16,034		$	13,827		$	2,207

Net cash provided by operating activities increased in 2017 primarily due to the impact of our 2016 and 2017 acquisitions, contractual rent increasesand improved operating efficiencies, partially offset by our 2016 and 2017 dispositions. We anticipate cash flows from operating activities to increaseas a result of the above items and continued leasing activity in our existing portfolio.

For the three months ended March 31, 2017, net cash used in investing activities primarily related to the investment in real estate of $34.7 million and capital expenditures of $12.9 million, partially offset by restricted cash, escrow deposits and other assets of $5.8 million and proceeds from the sale of real estate of $4.7 million. For the three months ended March 31, 2016, net cash used in investing activities primarily related to the investment in real estate of $158.7 million and capital expenditures of $8.8 million. We anticipate cash flows used in investing activities to increase as we continue to acquire more properties.

36

For the three months ended March 31, 2017, net cash used in financing activities primarily related to the net borrowings on our unsecured revolving credit facility of $82.0 million, partially offset by dividends paid to holders of our common stock of $42.5 million and payments on our secured mortgage loans of $40.2 million. For the three months ended March 31, 2016, net cash provided by financing activities primarily related to net borrowings of $78.0 million on our Unsecured Credit Agreement and the net proceeds of shares of common stock issued of $91.8 million, partially offset by dividends paid to holders of our common stock of $37.5 million.

Dividends

The amount of dividends HTA pays to its stockholders is determined by its Board of Directors, in its sole discretion, and is dependent on a number of factors, including funds available, our financial condition, capital expenditure requirements and annual dividend distribution requirements needed to maintain our status as a REIT under the Internal Revenue Code of 1986, as amended. HTA has paid monthly or quarterly dividends since February 2007, and if our investments produce sufficient cash flow, we expect to continue to pay dividends to our stockholders. Because our cash available for dividend distributions in any year may be less than 90% of our taxable income for the year, we may obtain the necessary funds through borrowings, issuing new securities or selling assets to pay out enough of our taxable income to satisfy our dividend distribution requirement. HTA’s organizational documents do not establish a limit on dividends that may constitute a return of capital for federal income tax purposes. The dividend HTA pays to its stockholders is equal to the distributions received from HTALP in accordance with the terms of HTALP’s partnership agreement. It is HTA’s intention to continue to pay dividends. However, HTA’s Board of Directors may reduce our dividend rate and HTA cannot guarantee the timing and amount of dividends that it may pay in the future, if any.

For the three months ended March 31, 2017, HTA paid cash dividends of $42.5 million. In April 2017, HTA paid cash dividends of $43.1 million for the quarter ended March 31, 2017. On April 26, 2017, HTA declared a quarterly cash dividend of $0.30 per share to be paid on July 11, 2017 to stockholders of record of its common stock on July 5, 2017.

Financing

We have historically maintained a low leveraged balance sheet and intend to continue to maintain this structure over the long run. However, our total leverage may fluctuate on a short term basis as we execute our business strategy. As of March 31, 2017, our leverage ratio, measured by debt to market capitalization, was 28.3%.

As of March 31, 2017, we had debt outstanding of $1.8 billion and the weighted average interest rate was 3.30% per annum, inclusive of the impact of our interest rate swaps. The following is a summary of our unsecured and secured debt. See Note 7 - Debt to our accompanying condensed consolidated financial statements for a further discussion of our debt.

Unsecured Revolving Credit Facility

As of March 31, 2017, $674.5 million was available on our $850.0 million unsecured revolving credit facility. Our unsecured revolving credit facility matures in January 2020.

Unsecured Term Loans

As of March 31, 2017, we had $500.0 million of unsecured term loans outstanding, comprised of a $300.0 million under our Unsecured Credit Agreement maturing in 2019 and a $200.0 million maturing in 2023. The $300.0 million term loan includes a one-year extension exercisable at the option of the borrower, subject to certain conditions.

Unsecured Senior Notes

As of March 31, 2017, we had $950.0 million of unsecured senior notes outstanding, comprised of $300.0 million maturing in 2021, $300.0 million maturing in 2023, and $350.0 million maturing in 2026.

Mortgage Loans

During the three months ended March 31, 2017, we made payments of $40.2 million on our mortgage loans and have $36.4 million of principal payments due on during the remainder of 2017.

Commitments and Contingencies

There have been no material changes from the commitments and contingencies disclosed in our 2016 Annual Report on Form 10-K.

Debt Service Requirements

We are required by the terms of our applicable loan agreements to meet certain financial covenants, such as minimum net worth and liquidity, and reporting requirements, among others. As of March 31, 2017, we believe that we were in compliance with all such covenants and we are not aware of any covenants that it is reasonably likely that we would not be able to meet.

37

Off-Balance Sheet Arrangements

As of and during the three months ended March 31, 2017, we had no off-balance sheet arrangements.

Inflation

We are exposed to inflation risk as income from future long-term leases is the primary source of our cash flows from operations. There are provisions in the majority of our tenant leases that protect us from the impact of normal inflation. These provisions include rent escalations, reimbursement billings for operating expense pass-through charges and real estate tax and insurance reimbursements on a per square foot allowance. However, due to the long-term nature of our leases, among other factors, the leases may not reset frequently enough to cover inflation.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

There were no material changes in the information regarding market risk that was provided in our 2016 Annual Report on Form 10-K. The table below presents, as of March 31, 2017, the principal amounts of our fixed and variable debt and the weighted average interest rates, excluding the impact of interest rate swaps, by year of expected maturity to evaluate the expected cash flows and sensitivity to interest rate changes (in thousands, except interest rates):

	Expected Maturity Date
	2017			2018			2019			2020			2021			Thereafter			Total
Fixed rate debt	$	35,679		$	3,671		$	9,720		$	22,672		$	303,333		$	739,570		$	1,114,645
Weighted average interest rate on fixed rate debt (per annum)	6.16		%	5.43		%	6.01		%	6.10		%	3.39		%	3.94		%	3.83		%
Variable rate debt	$	749		$	1,050		$	301,119		$	197,123		$	509		$	208,117		$	708,667
Weighted average interest rate on variable rate debt based on forward rates in effect as of March 31, 2017 (per annum)	2.89		%	3.42		%	3.08		%	3.28		%	4.86		%	4.22		%	2.29		%

As of March 31, 2017, we had $1.8 billion fixed and variable rate debt with interest rates ranging from 2.05% to 6.39% per annum and a weighted average interest rate of 3.23% per annum, excluding the impact of interest rate swaps. We had $1,114.6 million (excluding net premium/discount and deferred financing costs) of fixed rate debt with a weighted average interest rate of 3.83% per annum and $708.7 million (excluding net premium/discount and deferred financing costs) of variable rate debt with a weighted average interest rate of 2.29% per annum as of March 31, 2017, excluding the impact of interest rate swaps.

As of March 31, 2017, the fair value of our fixed rate debt was $1,120.6 million and the fair value of our variable rate debt was $711.1 million based upon prevailing market rates as of March 31, 2017.

As of March 31, 2017, we had interest rate swaps outstanding that effectively fix $190.4 million of our variable rate debt. Including the impact of these interest rate swaps, the effective rate on our variable rate and total debt is 2.47% and 3.30% per annum, respectively.

In addition to changes in interest rates, the value of our future properties is subject to fluctuations based on changes in local and regional economic conditions and changes in the creditworthiness of tenants, which may affect our ability to refinance our debt if necessary.

38

Item 4. Controls and Procedures

Healthcare Trust of America, Inc.

HTA’s management is responsible for establishing and maintaining disclosure controls and procedures that are designed to ensure that information required to be disclosed in its reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms, and that such information is accumulated and communicated to management, including HTA’s Chief Executive Officer (principal executive officer) and Chief Financial Officer (principal financial officer and principal accounting officer), to allow timely decisions regarding required disclosures.

As of March 31, 2017, an evaluation was conducted by HTA under the supervision and with the participation of its management, including HTA’s Chief Executive Officer and Chief Financial Officer, of the effectiveness of its disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on this evaluation, HTA’s Chief Executive Officer and the Chief Financial Officer concluded that HTA’s disclosure controls and procedures were effective as of March 31, 2017.

There were no changes in HTA’s internal control over financial reporting that occurred during the quarter ended March 31, 2017 that have materially affected, or are reasonably believed to be likely to materially affect, HTA’s internal control over financial reporting.

April 27, 2017

Healthcare Trust of America Holdings, LP

HTALP’s management is responsible for establishing and maintaining disclosure controls and procedures that are designed to ensure that information required to be disclosed in its reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms, and that such information is accumulated and communicated to management, including HTA’s Chief Executive Officer (principal executive officer) and Chief Financial Officer (principal financial officer and principal accounting officer), to allow timely decisions regarding required disclosures.

As of March 31, 2017, an evaluation was conducted by HTALP under the supervision and with the participation of its management, including HTA’s Chief Executive Officer and Chief Financial Officer, of the effectiveness of its disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on this evaluation, HTA’s Chief Executive Officer and the Chief Financial Officer, on behalf of HTA in its capacity as general partner of HTALP, concluded that HTALP’s disclosure controls and procedures were effective as of March 31, 2017.

There were no changes in HTALP’s internal control over financial reporting that occurred during the quarter ended March 31, 2017 that have materially affected, or are reasonably believed to be likely to materially affect, HTALP’s internal control over financial reporting.

April 27, 2017

39

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

We are subject to claims and litigation arising in the ordinary course of business. We do not believe any liability from any reasonably foreseeable disposition of such claims and litigation, individually or in the aggregate, would have a material adverse effect on our accompanying condensed consolidated financial statements.

Item 1A. Risk Factors

There have been no material changes from the risk factors previously disclosed in our 2016 Annual Report on Form 10-K.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Purchases of Equity Securities by the Issuer and Affiliated Purchasers

During the three months ended March 31, 2017, HTA repurchased shares of its common stock as follows:

Period	Total Number of Shares Purchased (1) (2)	Average Price Paid per Share (1) (2)		Total Number of Shares Purchased as Part of Publicly Announced Plan or Program	Maximum Approximate Dollar Value of Shares that May Yet be Purchased Under the Plans or Programs
January 1, 2017 to January 31, 2017	106,833	$	29.19	—	—
February 1, 2017 to February 28, 2017	—	—		—	—
March 1, 2017 to March 31, 2017	—	—		—	—
(1) Purchases mainly represent shares withheld to satisfy withholding obligations on the vesting of restricted shares. The price paid per share was the then closing price of our common stock on the NYSE.
(2) For each share of common stock redeemed by HTA, HTALP redeems a corresponding number of units in the operating partnership. Therefore, the units in the operating partnership repurchased by HTALP are the same as the shares of common stock repurchased by HTA as shown above.

Item 6. Exhibits

The exhibits listed on the Exhibit Index (following the signatures section of this Quarterly Report) are included, and incorporated by reference, in this Quarterly Report.

40

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrants have duly caused this report to be signed on their behalf by the undersigned thereunto duly authorized.

	Healthcare Trust of America, Inc.
By:	/s/ Scott D. Peters	Chief Executive Officer, President and Chairman
	Scott D. Peters	(Principal Executive Officer)
Date:	April 27, 2017
By:	/s/ Robert A. Milligan	Chief Financial Officer
	Robert A. Milligan	(Principal Financial Officer and Principal Accounting Officer)
Date:	April 27, 2017

	Healthcare Trust of America Holdings, LP
By:	Healthcare Trust of America, Inc.,
	its General Partner
By:	/s/ Scott D. Peters	Chief Executive Officer, President and Chairman
	Scott D. Peters	(Principal Executive Officer)
Date:	April 27, 2017
By:	/s/ Robert A. Milligan	Chief Financial Officer
	Robert A. Milligan	(Principal Financial Officer and Principal Accounting Officer)
Date:	April 27, 2017

41

EXHIBIT INDEX

The following exhibits are included, or incorporated by reference, in this Quarterly Report for the quarter ended March 31, 2017 (and are numbered in accordance with Item 601 of Regulation S-K).

31.1*	Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 for Healthcare Trust of America, Inc.
31.2*	Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 for Healthcare Trust of America, Inc.
31.3*	Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 for Healthcare Trust of America Holdings, LP.
31.4*	Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 for Healthcare Trust of America Holdings, LP.
32.1**	Certification of Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002 for Healthcare Trust of America Inc.
32.2**	Certification of Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002 for Healthcare Trust of America, Inc.
32.3**	Certification of Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002 for Healthcare Trust of America Holdings, LP.
32.4**	Certification of Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002 for Healthcare Trust of America Holdings, LP.
101.INS*	XBRL Instance Document.
101.SCH*	XBRL Taxonomy Extension Schema Document.
101.CAL*	XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*	XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*	XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*	XBRL Taxonomy Extension Presentation Linkbase Document.
*	Filed herewith.
**	Furnished herewith.

42

EX-31.1

Exhibit 31.1

CERTIFICATION

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Scott D. Peters, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Healthcare Trust of America, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

By:	/s/ Scott D. Peters
	Scott D. Peters
	Chief Executive Officer, President and Chairman

Date: April 27, 2017

EX-31.2

Exhibit 31.2

CERTIFICATION

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Robert A. Milligan, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Healthcare Trust of America, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

By:	/s/ Robert A. Milligan
	Robert A. Milligan
	Chief Financial Officer

Date: April 27, 2017

EX-31.3

Exhibit 31.3

CERTIFICATION

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Scott D. Peters, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Healthcare Trust of America Holdings, LP;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

By:	/s/ Scott D. Peters
	Scott D. Peters
	Chief Executive Officer, President and Chairman of Healthcare Trust of America, Inc., general partner of Healthcare Trust of America Holdings, LP

Date: April 27, 2017

EX-31.4

Exhibit 31.4

CERTIFICATION

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Robert A. Milligan, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Healthcare Trust of America Holdings, LP;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

By:	/s/ Robert A. Milligan
	Robert A. Milligan
	Chief Financial Officer of Healthcare Trust of America, Inc., general partner of Healthcare Trust of America Holdings, LP

Date: April 27, 2017

EX-32.1

Exhibit 32.1

CERTIFICATION

Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report on Form 10-Q of Healthcare Trust of America, Inc., or the Company, for the quarter ended March 31, 2017, as filed with the Securities and Exchange Commission on the date hereof, or the Report, I, Scott D. Peters, Chief Executive Officer, President and Chairman of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(i) the Report fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

By:	/s/ Scott D. Peters
	Scott D. Peters
	Chief Executive Officer, President and Chairman

Date: April 27, 2017

A signed original of this written statement required by Section 906 has been provided to Healthcare Trust of America, Inc. and will be retained by Healthcare Trust of America, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2

Exhibit 32.2

CERTIFICATION

Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report on Form 10-Q of Healthcare Trust of America, Inc., or the Company, for the quarter ended March 31, 2017, as filed with the Securities and Exchange Commission on the date hereof, or the Report, I, Robert A. Milligan, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(i) the Report fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

By:	/s/ Robert A. Milligan
	Robert A. Milligan
	Chief Financial Officer

Date: April 27, 2017

A signed original of this written statement required by Section 906 has been provided to Healthcare Trust of America, Inc. and will be retained by Healthcare Trust of America, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.3

Exhibit 32.3

CERTIFICATION

Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report on Form 10-Q of Healthcare Trust of America Holdings, LP, or the Company, for the quarter ended March 31, 2017, as filed with the Securities and Exchange Commission on the date hereof, or the Report, I, Scott D. Peters, Chief Executive Officer, President and Chairman of Healthcare Trust of America, Inc., general partner of Healthcare Trust of America Holdings, LP, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(i) the Report fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

By:	/s/ Scott D. Peters
	Scott D. Peters
	Chief Executive Officer, President and Chairman of Healthcare Trust of America, Inc., general partner of Healthcare Trust of America Holdings, LP

Date: April 27, 2017

A signed original of this written statement required by Section 906 has been provided to Healthcare Trust of America, Inc. and will be retained by Healthcare Trust of America, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.4

Exhibit 32.4

CERTIFICATION

Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report on Form 10-Q of Healthcare Trust of America Holdings, LP, or the Company, for the quarter ended March 31, 2017, as filed with the Securities and Exchange Commission on the date hereof, or the Report, I, Robert A. Milligan, Chief Financial Officer of Healthcare Trust of America, Inc., general partner of Healthcare Trust of America Holdings, LP, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(i) the Report fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

By:	/s/ Robert A. Milligan
	Robert A. Milligan
	Chief Financial Officer of Healthcare Trust of America, Inc., general partner of Healthcare Trust of America Holdings, LP

Date: April 27, 2017

A signed original of this written statement required by Section 906 has been provided to Healthcare Trust of America, Inc. and will be retained by Healthcare Trust of America, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

XML

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2017	Apr. 24, 2017
Entity Information [Line Items]
Entity Registrant Name	HEALTHCARE TRUST OF AMERICA, INC.
Entity Central Index Key	0001360604
Document Type	10-Q
Document Period End Date	Mar. 31, 2017
Amendment Flag	false
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		143,841,711
Healthcare Trust of America Holdings, LP (HTALP)
Entity Information [Line Items]
Entity Registrant Name	Healthcare Trust of America Holdings, LP
Entity Central Index Key	0001495491
Document Type	10-Q
Document Period End Date	Mar. 31, 2017
Amendment Flag	false
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer

XML

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Real estate investments:
Land	$ 392,714	$ 386,526
Building and improvements	3,500,633	3,466,516
Lease intangibles	467,559	467,571
Real estate investments, gross	4,360,906	4,320,613
Accumulated depreciation and amortization	(856,986)	(817,593)
Real estate investments, net	3,503,920	3,503,020
Cash and cash equivalents	16,034	11,231
Restricted cash and escrow deposits	8,043	13,814
Receivables and other assets, net	179,719	173,461
Other intangibles, net	45,301	46,318
Total assets	3,753,017	3,747,844
Liabilities:
Debt	1,811,208	1,768,905
Accounts payable and accrued liabilities	98,222	105,034
Derivative financial instruments - interest rate swaps	1,653	1,920
Security deposits, prepaid rent and other liabilities	51,409	49,859
Intangible liabilities, net	36,009	37,056
Total liabilities	1,998,501	1,962,774
Commitments and contingencies
Redeemable noncontrolling interests	4,661	4,653
Equity/Partners' Capital:
Preferred stock, $0.01 par value; 200,000,000 shares authorized; none issued and outstanding	0	0
Class A common stock, $0.01 par value; 1,000,000,000 shares authorized; 141,825,110 and 141,719,134 shares issued and outstanding as of March 31, 2017 and December 31, 2016, respectively	1,418	1,417
Additional paid-in capital	2,754,229	2,754,818
Accumulated other comprehensive loss	(85)	0
Cumulative dividends in excess of earnings	(1,098,561)	(1,068,961)
Total stockholders’ equity	1,657,001	1,687,274
Noncontrolling interests	92,854	93,143
Total equity	1,749,855	1,780,417
Total liabilities and equity/partners' capital	3,753,017	3,747,844
Healthcare Trust of America Holdings, LP (HTALP)
Real estate investments:
Land	392,714	386,526
Building and improvements	3,500,633	3,466,516
Lease intangibles	467,559	467,571
Real estate investments, gross	4,360,906	4,320,613
Accumulated depreciation and amortization	(856,986)	(817,593)
Real estate investments, net	3,503,920	3,503,020
Cash and cash equivalents	16,034	11,231
Restricted cash and escrow deposits	8,043	13,814
Receivables and other assets, net	179,719	173,461
Other intangibles, net	45,301	46,318
Total assets	3,753,017	3,747,844
Liabilities:
Debt	1,811,208	1,768,905
Accounts payable and accrued liabilities	98,222	105,034
Derivative financial instruments - interest rate swaps	1,653	1,920
Security deposits, prepaid rent and other liabilities	51,409	49,859
Intangible liabilities, net	36,009	37,056
Total liabilities	1,998,501	1,962,774
Commitments and contingencies
Redeemable noncontrolling interests	4,661	4,653
Equity/Partners' Capital:
Limited partners’ capital, 4,343,782 and 4,323,095 units issued and outstanding as of March 31, 2017 and December 31, 2016, respectively	92,584	92,873
General partner’s capital, 141,825,110 and 141,719,134 units issued and outstanding as of March 31, 2017 and December 31, 2016, respectively	1,657,271	1,687,544
Total partners’ capital	1,749,855	1,780,417
Total liabilities and equity/partners' capital	$ 3,753,017	$ 3,747,844

XML

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2017	Dec. 31, 2016
Equity:
Preferred stock, par value (usd per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	200,000,000	200,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Healthcare Trust of America Holdings, LP (HTALP)
Partners’ Capital:
Limited partner's capital, units issued (in shares)	4,343,782	4,323,095
Limited partner's capital, units outstanding (in shares)	4,343,782	4,323,095
General partner's capital, units issued (in shares)	141,825,110	141,719,134
General partner's capital, units outstanding (in shares)	141,825,110	141,719,134
Class A Common Stock
Equity:
Common stock, par value (usd per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	1,000,000,000	1,000,000,000
Common stock, shares issued (in shares)	141,825,110	141,719,134
Common stock, shares outstanding (in shares)	141,825,110	141,719,134

XML

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands		3 Months Ended
		Mar. 31, 2017	Mar. 31, 2016
Revenues:
Rental income		$ 123,993	$ 107,250
Interest and other operating income		354	65
Total revenues		124,347	107,315
Expenses:
Rental		39,020	33,353
General and administrative		8,423	6,773
Transaction		284	1,813
Depreciation and amortization		47,056	37,828
Total expenses		94,783	79,767
Income before other income (expense)		29,564	27,548
Interest expense:
Interest related to derivative financial instruments		(324)	(645)
Gain (loss) on change in fair value of derivative financial instruments, net		839	(2,792)
Total interest related to derivative financial instruments, including net change in fair value of derivative financial instruments		515	(3,437)
Interest related to debt		(16,058)	(14,128)
Gain on sale of real estate, net		3	0
Loss on extinguishment of debt, net		(32)	0
Other income		8	53
Net income		14,000	10,036
Net income attributable to noncontrolling interests	[1]	(455)	(176)
Net income attributable to common stockholders/unitholders		$ 13,545	$ 9,860
Earnings per common share/unit - basic:
Net income attributable to common stockholders/unitholders (in usd per share)		$ 0.10	$ 0.08
Earnings per common share/unit - diluted:
Net income attributable to common stockholders/unitholders (in usd per share)		$ 0.09	$ 0.08
Weighted average common shares/units outstanding:
Basic (in shares)		141,780	129,336
Diluted (in shares)		146,117	131,240
Dividends declared per common share (in usd per share)		$ 0.300	$ 0.295
Healthcare Trust of America Holdings, LP (HTALP)
Revenues:
Rental income		$ 123,993	$ 107,250
Interest and other operating income		354	65
Total revenues		124,347	107,315
Expenses:
Rental		39,020	33,353
General and administrative		8,423	6,773
Transaction		284	1,813
Depreciation and amortization		47,056	37,828
Total expenses		94,783	79,767
Income before other income (expense)		29,564	27,548
Interest expense:
Interest related to derivative financial instruments		(324)	(645)
Gain (loss) on change in fair value of derivative financial instruments, net		839	(2,792)
Total interest related to derivative financial instruments, including net change in fair value of derivative financial instruments		515	(3,437)
Interest related to debt		(16,058)	(14,128)
Gain on sale of real estate, net		3	0
Loss on extinguishment of debt, net		(32)	0
Other income		8	53
Net income		14,000	10,036
Net income attributable to noncontrolling interests		(30)	(31)
Net income attributable to common stockholders/unitholders		$ 13,970	$ 10,005
Earnings per common share/unit - basic:
Net income attributable to common stockholders/unitholders (in usd per share)		$ 0.10	$ 0.08
Earnings per common share/unit - diluted:
Net income attributable to common stockholders/unitholders (in usd per share)		$ 0.10	$ 0.08
Weighted average common shares/units outstanding:
Basic (in shares)		146,117	131,242
Diluted (in shares)		146,117	131,242
Dividends declared per common share (in usd per share)		$ 0.300	$ 0.295

[1] Includes amounts attributable to redeemable noncontrolling interests.

XML

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Net income	$ 14,000	$ 10,036
Other comprehensive loss
Change in unrealized losses on cash flow hedges	(88)	0
Total other comprehensive loss	(88)	0
Total comprehensive income	13,912	10,036
Comprehensive income attributable to noncontrolling interests	(422)	(145)
Total comprehensive income attributable to common stockholders	13,490	9,891
Healthcare Trust of America Holdings, LP (HTALP)
Net income	14,000	10,036
Other comprehensive loss
Change in unrealized losses on cash flow hedges	(88)	0
Total other comprehensive loss	(88)	0
Total comprehensive income	13,912	10,036
Comprehensive income attributable to noncontrolling interests	(30)	(31)
Total comprehensive income attributable to common stockholders	$ 13,882	$ 10,005

XML

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY - USD ($) $ in Thousands	Total	Class A Common Stock	Common Stock Class A Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Loss	Cumulative Dividends in Excess of Earnings	Total Stockholders’ Equity	Noncontrolling Interests
Beginning balance at Dec. 31, 2015	$ 1,406,958		$ 1,270	$ 2,328,806	$ 0	$ (950,652)	$ 1,379,424	$ 27,534
Beginning balance (in shares) at Dec. 31, 2015			127,027,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock	91,269		$ 34	91,235			91,269
Issuance of common stock (in shares)			3,418,000
Share-based award transactions, net	1,803		$ 2	1,801			1,803
Share-based award transactions, net (in shares)			191,000
Repurchase and cancellation of common stock	(1,901)			(1,901)			(1,901)
Repurchase and cancellation of common stock (in shares)			(70,000)
Redemption of noncontrolling interest and other	0		$ 1	2,197			2,198	(2,198)
Redemption of noncontrolling interest and other (in shares)			96,000
Dividends declared	(39,083)					(38,540)	(38,540)	(543)
Net income	10,005					9,860	9,860	145
Other comprehensive loss	0
Ending balance at Mar. 31, 2016	1,469,051		$ 1,307	2,422,138	0	(979,332)	1,444,113	24,938
Ending balance (in shares) at Mar. 31, 2016			130,662,000
Beginning balance at Dec. 31, 2016	1,780,417		$ 1,417	2,754,818	0	(1,068,961)	1,687,274	93,143
Beginning balance (in shares) at Dec. 31, 2016		141,719,134	141,719,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of operating partnership units in connection with an acquisition	610							610
Share-based award transactions, net	2,530		$ 2	2,528			2,530
Share-based award transactions, net (in shares)			213,000
Repurchase and cancellation of common stock	(3,118)		$ (1)	(3,117)			(3,118)
Repurchase and cancellation of common stock (in shares)			(107,000)
Dividends declared	(44,466)					(43,145)	(43,145)	(1,321)
Net income	13,970					13,545	13,545	425
Other comprehensive loss	(88)				(85)		(85)	(3)
Ending balance at Mar. 31, 2017	$ 1,749,855		$ 1,418	$ 2,754,229	$ (85)	$ (1,098,561)	$ 1,657,001	$ 92,854
Ending balance (in shares) at Mar. 31, 2017		141,825,110	141,825,000

XML

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN PARTNERS' CAPITAL - USD ($) shares in Thousands, $ in Thousands	Total	Healthcare Trust of America Holdings, LP (HTALP)	Healthcare Trust of America Holdings, LP (HTALP) General Partner’s Capital	Healthcare Trust of America Holdings, LP (HTALP) Limited Partners’ Capital
Balance as of beginning of period at Dec. 31, 2015		$ 1,406,958	$ 1,379,694	$ 27,264
Balance as of beginning of period (in units) at Dec. 31, 2015			127,027	1,930
Increase (Decrease) in Partners' Capital [Roll Forward]
Issuance of general partner units		91,269	$ 91,269
Issuance of general partner units (in units)			3,418
Share-based award transactions, net		1,803	$ 1,803
Share-based award transactions, net (in units)			191
Redemption and cancellation of general partner units		(1,901)	$ (1,901)
Redemption and cancellation of general partner units (in units)			(70)
Redemption of limited partner units and other		0	$ 2,198	$ (2,198)
Redemption of limited partner units and other (in units)			96	(96)
Distributions declared		(39,083)	$ (38,540)	$ (543)
Net income	$ 9,860	10,005	9,860	145
Other comprehensive loss	0	0
Balance as of end of period at Mar. 31, 2016		1,469,051	$ 1,444,383	$ 24,668
Balance as of end of period (in units) at Mar. 31, 2016			130,662	1,834
Balance as of beginning of period at Dec. 31, 2016		1,780,417	$ 1,687,544	$ 92,873
Balance as of beginning of period (in units) at Dec. 31, 2016			141,719	4,323
Increase (Decrease) in Partners' Capital [Roll Forward]
Issuance of limited partner units in connection with an acquisition		610		$ 610
Issuance of limited partner units in connection with an acquisition (in units)				21
Share-based award transactions, net		2,530	$ 2,530
Share-based award transactions, net (in units)			213
Redemption and cancellation of general partner units		(3,118)	$ (3,118)
Redemption and cancellation of general partner units (in units)			(107)
Distributions declared		(44,466)	$ (43,145)	$ (1,321)
Net income	13,545	13,970	13,545	425
Other comprehensive loss	$ (88)	(88)	(85)	(3)
Balance as of end of period at Mar. 31, 2017		$ 1,749,855	$ 1,657,271	$ 92,584
Balance as of end of period (in units) at Mar. 31, 2017			141,825	4,344

XML

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Cash flows from operating activities:
Net income	$ 14,000	$ 10,036
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation, amortization and other	46,213	37,091
Share-based compensation expense	2,530	1,803
Bad debt expense	103	92
Gain on sale of real estate, net	(3)	0
Loss on extinguishment of debt, net	32	0
Change in fair value of derivative financial instruments	(839)	2,792
Changes in operating assets and liabilities:
Receivables and other assets, net	(7,771)	(1,438)
Accounts payable and accrued liabilities	(7,934)	(10,370)
Security deposits, prepaid rent and other liabilities	682	446
Net cash provided by operating activities	47,013	40,452
Cash flows from investing activities:
Investments in real estate	(34,706)	(158,686)
Proceeds from the sale of real estate	4,746	0
Capital expenditures	(12,894)	(8,824)
Restricted cash, escrow deposits and other assets	5,771	(799)
Net cash used in investing activities	(37,083)	(168,309)
Cash flows from financing activities:
Borrowings on unsecured revolving credit facility	92,000	166,000
Payments on unsecured revolving credit facility	(10,000)	(88,000)
Payments on secured mortgage loans	(40,155)	(1,761)
Security deposits	14	729
Proceeds from issuance of common stock	0	91,757
Repurchase and cancellation of common stock	(3,118)	(1,901)
Dividends paid	(42,536)	(37,473)
Distributions paid to noncontrolling interest of limited partners	(1,332)	(737)
Net cash (used in) provided by financing activities	(5,127)	128,614
Net change in cash and cash equivalents	4,803	757
Cash and cash equivalents - beginning of period	11,231	13,070
Cash and cash equivalents - end of period	16,034	13,827
Healthcare Trust of America Holdings, LP (HTALP)
Cash flows from operating activities:
Net income	14,000	10,036
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation, amortization and other	46,213	37,091
Share-based compensation expense	2,530	1,803
Bad debt expense	103	92
Gain on sale of real estate, net	(3)	0
Loss on extinguishment of debt, net	32	0
Change in fair value of derivative financial instruments	(839)	2,792
Changes in operating assets and liabilities:
Receivables and other assets, net	(7,771)	(1,438)
Accounts payable and accrued liabilities	(7,934)	(10,370)
Security deposits, prepaid rent and other liabilities	682	446
Net cash provided by operating activities	47,013	40,452
Cash flows from investing activities:
Investments in real estate	(34,706)	(158,686)
Proceeds from the sale of real estate	4,746	0
Capital expenditures	(12,894)	(8,824)
Restricted cash, escrow deposits and other assets	5,771	(799)
Net cash used in investing activities	(37,083)	(168,309)
Cash flows from financing activities:
Borrowings on unsecured revolving credit facility	92,000	166,000
Payments on unsecured revolving credit facility	(10,000)	(88,000)
Payments on secured mortgage loans	(40,155)	(1,761)
Security deposits	14	729
Proceeds from issuance of general partner units	0	91,757
Repurchase and cancellation of general partner units	(3,118)	(1,901)
Distributions paid to general partner	(42,536)	(37,473)
Distributions paid to limited partners and redeemable noncontrolling interests	(1,332)	(737)
Net cash (used in) provided by financing activities	(5,127)	128,614
Net change in cash and cash equivalents	4,803	757
Cash and cash equivalents - beginning of period	11,231	13,070
Cash and cash equivalents - end of period	$ 16,034	$ 13,827

XML

Organization and Description of Business

3 Months Ended

Mar. 31, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization and Description of Business

Organization and Description of Business

HTA, a Maryland corporation, and HTALP, a Delaware limited partnership, were incorporated or formed, as applicable, on April 20, 2006. HTA operates as a REIT and is the general partner of HTALP, which is the operating partnership. As of March 31, 2017, HTA owned a 97.0% partnership interest and other limited partners, including some of HTA’s directors, executive officers and their affiliates, owned the remaining partnership interest (including the LTIP Units) in HTALP. As the sole general partner of HTALP, HTA has the full, exclusive and complete responsibility for HTALP’s day-to-day management and control. HTA operates in an umbrella partnership REIT structure in which HTALP and its subsidiaries hold substantially all of the assets. HTA’s only material asset is its ownership of partnership interests of HTALP. As a result, HTA does not conduct business itself, other than acting as the sole general partner of HTALP, issuing public equity from time to time and guaranteeing certain debts of HTALP. HTALP conducts the operations of the business and issues publicly-traded debt, but has no publicly-traded equity.

HTA is one of the largest publicly-traded REITs focused on medical office buildings (“MOBs”) in the U.S. as measured by the gross leasable area (“GLA”) of its MOBs. HTA conducts substantially all of its operations through HTALP. We invest in MOBs that we believe will serve the future of healthcare delivery, and MOBs that are primarily located on health system campuses, near university medical centers, or in core community outpatient locations. We also focus on our key markets that have certain demographic and macro-economic trends and where we can utilize our institutional property management and leasing platform to generate strong tenant relationships and operating cost efficiencies. Our primary objective is to maximize stockholder value with disciplined growth through strategic investments that provide an attractive risk-adjusted return for our stockholders by consistently increasing our cash flow. In pursuing this objective, we: (i) seek internal growth through proactive asset management, leasing and property management oversight; (ii) target accretive acquisitions of MOBs in markets with attractive demographics that complement our existing portfolio; and (iii) actively manage our balance sheet to maintain flexibility with conservative leverage.  Additionally, from time to time we consider, on an opportunistic basis, significant portfolio acquisitions that we believe fit our core business and could enhance our existing portfolio. HTA has qualified to be taxed as a REIT for federal income tax purposes and intends to continue to be taxed as a REIT.

Since 2006, we have invested $4.3 billion to create a portfolio of MOBs and other healthcare assets consisting of approximately 17.8 million square feet of GLA throughout the U.S. As of March 31, 2017, approximately 96% of our portfolio, based on GLA, was located on the campuses of, or aligned with, nationally or regionally recognized healthcare systems. Our portfolio is diversified geographically across 31 states, with no state having more than 13% of our total GLA as of March 31, 2017. We are concentrated in 15 to 20 key markets that are experiencing higher economic and demographic trends than other markets, on average, that we expect will drive demand for MOBs. Approximately 92% of our portfolio, based on GLA, is located in the top 75 metropolitan statistical areas (“MSAs”) with Boston, Hartford/New Haven, Dallas, Houston, Phoenix and Orange County/Los Angeles being our largest markets by investment.

Our principal executive office is located at 16435 North Scottsdale Road, Suite 320, Scottsdale, Arizona, 85254.

XML

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2017

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

The summary of significant accounting policies presented below is designed to assist in understanding our condensed consolidated financial statements. Such condensed consolidated financial statements and the accompanying notes are the representations of our management, who are responsible for their integrity and objectivity. These accounting policies conform to U.S. generally accepted accounting principles (“GAAP”) in all material respects and have been consistently applied in preparing our accompanying condensed consolidated financial statements.

Basis of Presentation

Our accompanying condensed consolidated financial statements include our accounts and those of our subsidiaries and any consolidated variable interest entities (“VIEs”). All inter-company balances and transactions have been eliminated in the accompanying condensed consolidated financial statements.

Interim Unaudited Financial Data

Our accompanying condensed consolidated financial statements have been prepared by us in accordance with GAAP in conjunction with the rules and regulations of the SEC. Certain information and footnote disclosures required for annual financial statements have been condensed or excluded pursuant to SEC rules and regulations. Accordingly, our accompanying condensed consolidated financial statements do not include all information and footnotes required by GAAP for complete financial statements. Our accompanying condensed consolidated financial statements reflect all adjustments, which are, in our opinion, of a normal recurring nature and necessary for a fair presentation of our financial position, results of operations and cash flows for the interim periods. Interim results of operations are not necessarily indicative of the results to be expected for the full year; such results may be less favorable for the full year. Our accompanying condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and the notes thereto included in our 2016 Annual Report on Form 10-K.

Principles of Consolidation

The consolidated financial statements include our accounts of those of our subsidiaries and consolidated joint venture arrangements. The portions of the operating partnership not owned by us are presented as non-controlling interests in our consolidated balance sheets and statements of operations, consolidated statements of equity, and consolidated statements of changes in partners’ capital. The portions of other joint venture arrangements not owned by us are presented as redeemable non-controlling interests in our consolidated balance sheets. In addition, as described in Note 1 - Organization and Description of Business, certain third parties have been issued limited partner units in HTALP (“OP Units”). Holders of OP Units are considered to be non-controlling interest holders in HTALP and their ownership interests are reflected as equity in the consolidated balance sheets. Further, a portion of the earnings and losses of HTALP are allocated to non-controlling interest holders based on their respective ownership percentages. Upon conversion of OP Units to common stock, any difference between the fair value of common shares issued and the carrying value of the OP Units converted is recorded as a component of equity. As of March 31, 2017 and December 31, 2016, there were approximately 4.3 million of OP Units issued and outstanding.

VIEs are entities where investors lack sufficient equity at risk for the entity to finance its activities without additional subordinated financial support or where equity investors, as a group, lack one of the following: (i) the power to direct the activities that most significantly impact the entity’s economic performance; (ii) the obligation to absorb the expected losses of the entity; and (iii) the right to receive the expected returns of the entity. We consolidate our investment in VIEs when we determine that we are the primary beneficiary. A primary beneficiary is one that has both: (i) the power to direct the activities of the VIE that most significantly impacts the entity’s economic performance; and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could be significant to the entity. Our operating partnership (HTALP) and other joint venture arrangements are VIEs, because the limited partners in those partnerships, although entitled to vote on certain matters, do not possess kick-out rights or substantive participating rights. Additionally, we determined that we are the primary beneficiary of our VIEs. Accordingly, we consolidate our interests in the HTALP operating partnership and other joint venture arrangements. However, because we hold what is deemed a majority voting interest in the operating partnership and other joint venture arrangements, it qualifies for the exemption from providing certain disclosure requirements associated with investments in VIEs. We will evaluate on an ongoing basis the need to consolidate entities based on the standards set forth in GAAP as described above.

Investments in Real Estate

Depreciation expense of buildings and improvements for the three months ended March 31, 2017 and 2016 was $32.7 million and $25.7 million, respectively.

Recently Issued or Adopted Accounting Pronouncements

The following table provides a brief description of recently adopted accounting pronouncements:

Accounting Pronouncement	Description	Effective Date	Effect on financial statements
ASU 2017-01 Business Combinations: Clarifying the Definition of a Business (Issued January 2017)	ASU 2017-01 clarifies the definition of a business by adding guidance to assist entities evaluate whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The definition of a business affects many areas of accounting, including, but not limited to, acquisitions, disposals, goodwill and consolidation.	ASU 2017-01 is effective for fiscal years beginning after December 15, 2017 with early adoption permitted.	We adopted ASU 2017-01 as of January 1, 2017 on a prospective basis. We expect that the majority of our future investments in real estate will be accounted for as asset acquisitions under ASU 2017-01. The adoption of ASU 2017-01 will impact how we account for acquisition-related expenses and contingent consideration which may result in lower acquisition-related expenses and eliminate fair value adjustments related to future contingent consideration arrangements.

The following table provides a brief description of recently issued accounting pronouncements:

Accounting Pronouncement	Description	Effective Date	Effect on financial statements
ASU 2014-09 Revenue from Contracts with Customers (Issued May 2014)	ASU 2014-09 is a comprehensive new revenue recognition model requiring a company to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration (i.e., payment) to which the company expects to be entitled in exchange for those goods or services. In adopting ASU 2014-09, companies may use either a full retrospective or a modified retrospective approach.	In July 2015, the FASB deferred the effective date of ASU 2014-09 to the first interim period within annual reporting periods beginning after December 15, 2017 along with the right of early adoption as of the original effective date.	We have identified our revenue streams and are in the process of evaluating the impact on our consolidated financial statements and internal accounting processes; however, the majority of our revenues are derived from real estate lease contracts, as discussed in relation to ASU 2016-02 below. We will adopt ASU 2014-09 effective January 1, 2018 using the retrospective approach and the adoption is not expected to have a material impact on our consolidated financial statements.
ASU 2016-02 Leases (Issued February 2016)	ASU 2016-02 will supersede the existing guidance for lease accounting and states that companies will be required to recognize lease assets and lease liabilities on the balance sheet and disclose key information about leasing arrangements. ASU 2016-02 requires qualitative and quantitative disclosures to supplement the amounts recorded in the financial statements so that users can understand the nature of the entity’s leasing activities, including significant judgments and changes in judgments. Within ASU 2016-02 lessor accounting remained fairly unchanged. In adopting ASU 2016-02, companies will be required to use a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements.	ASU 2016-02 is effective for the fiscal years beginning after December 15, 2018 with early adoption permitted.	We will adopt ASU 2016-02 as of January 1, 2019 using the modified retrospective approach.  We are currently evaluating the full impact of ASU 2016-02 will have on our consolidated financial statements and disclosures, however, we anticipate there to be a significant increase in our assets and liabilities on our consolidated balance sheets due to the recognition of our current ground leases which represented rental expense of $7.6 million and have an average remaining term of 48.2 years for the year ended December 31, 2016.  In addition, we anticipate there to be a material impact on our consolidated balance sheets and statements of operations as certain leasing costs will no longer qualify for capitalization over the life of the lease, but instead will be required to be expensed as incurred.
ASU 2016-13 Financial Instruments Credit Losses: Measurement of Credit Losses on Financial Instruments (Issued June 2016)	ASU 2016-13 is intended to improve financial reporting by requiring more timely recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. ASU 2016-13 requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected through an allowance for credit losses that is deducted from the amortized cost basis.	ASU 2016-13 is effective for fiscal years beginning after December 15, 2019 with early adoption permitted.	We do not anticipate early adoption or for there to be a material impact, however, we are evaluating the impact of adopting ASU 2016-13 on our consolidated financial statements.
ASU 2016-15 Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments (Issued August 2016)	ASU 2016-15 includes multiple provisions intended to clarify various aspects of cash flow presentation by making eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows.	ASU 2016-15 is effective for fiscal years beginning after December 15, 2017 with early adoption permitted.	We will adopt ASU 2016-15 as of the year ended December 31, 2017. We do not anticipate there to be a material impact, however, we are still evaluating the impact ASU 2016-15 will have on our consolidated financial statements.

Accounting Pronouncement	Description	Effective Date	Effect on financial statements
ASU 2016-18 Statement of Cash Flows: Restricted Cash (Issued November 2016)	ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows.	ASU 2016-18 is effective for fiscal years beginning after December 15, 2017 with early adoption permitted.	We will adopt ASU 2016-18 as of the year ended December 31, 2017. We do not anticipate there to be a material impact on our consolidated financial statements, however, we are still evaluating the impact ASU 2016-18 will have on our consolidated financial statements.
ASU 2017-05 Other Income: Clarifying the Scope of Asset Derecognition Guidance and Accounting for Partial Sales of Nonfinancial Assets (Issued February 2017)	ASU 2017-05 defines an in-substance nonfinancial asset, unifies guidance related to partial sales of nonfinancial assets, eliminates rules specifically addressing the sales of real estate, removes exception to the financial asset derecognition model and clarifies the accounting for contributions of nonfinancial assets to joint ventures.	ASU 2017-05 is effective for fiscal years beginning after December 15, 2017 with early adoption permitted.	We do not anticipate early adoption, however, we are evaluating the impact of adopting ASU 2017-05 on our consolidated financial statements.

XML

Investments in Real Estate

3 Months Ended

Mar. 31, 2017

Investments [Abstract]

Investments in Real Estate

Investments in Real Estate

For the three months ended March 31, 2017, our investments had an aggregate purchase price of $39.0 million. We incurred $0.3 million of costs attributable to these investments, which were capitalized in accordance with the adoption of ASU 2017-01 during the three months ended March 31, 2017. As part of one of our acquisitions, we issued 20,687 OP Units with a market value at the time of issuance of $0.6 million.

The following investments were determined to be individually not significant, but significant on a collective basis. The allocations for these investments are set forth below in the aggregate for the three months ended March 31, 2017 and 2016, respectively (in thousands):

	Three Months Ended March 31,
	2017			2016
Land	$	4,934		$	17,315
Building and improvements	29,762			128,945
In place leases	3,185			15,919
Below market leases	(65		)	(5,382		)
Above market leases	—			840
Below market leasehold interests	—			1,099
Above market leasehold interests	—			(50		)
Net assets acquired	37,816			158,686
Other, net	1,230			3,321
Aggregate purchase price	$	39,046		$	162,007

The acquired intangible assets and liabilities referenced above had weighted average lives of the following for the three months ended March 31, 2017 and 2016, respectively (in years):

	Three Months Ended March 31,
	2017	2016
Acquired intangible assets	11.3	10.5
Acquired intangible liabilities	10.2	8.9

Subsequent to March 31, 2017, we executed a purchase and sale agreement with a purchase price of $150.0 million consisting of approximately 592,000 square feet of GLA located within certain of our 15 to 20 key markets.

XML

Dispositions

3 Months Ended

Mar. 31, 2017

Disposal Group, Not Discontinued Operation, Disposal Disclosures [Abstract]

Dispositions

Dispositions

During the three months ended March 31, 2017, we completed the disposition of an MOB located in Texas for a gross sales price of $5.0 million, representing approximately 48,000 square feet of GLA.

XML

Intangible Assets and Liabilities

3 Months Ended

Mar. 31, 2017

Identified Intangibles, Net [Abstract]

Intangible Assets and Liabilities

Intangible Assets and Liabilities

Intangible assets and liabilities consisted of the following as of March 31, 2017 and December 31, 2016, respectively (in thousands, except weighted average remaining amortization):

	March 31, 2017				December 31, 2016
	Balance			Weighted Average Remaining Amortization in Years	Balance			Weighted Average Remaining Amortization in Years
Assets:
In place leases	$	296,018		9.9	$	294,597		9.7
Tenant relationships	171,541			10.6	172,974			10.6
Above market leases	28,149			6.3	28,401			6.3
Below market leasehold interests	38,136			60.3	38,136			60.4
	533,844				534,108
Accumulated amortization	(266,758		)		(256,305		)
Total	$	267,086		16.4	$	277,803		16.1
Liabilities:
Below market leases	$	34,081		19.0	$	34,370		18.6
Above market leasehold interests	11,632			52.8	11,632			53.0
	45,713				46,002
Accumulated amortization	(9,704		)		(8,946		)
Total	$	36,009		29.0	$	37,056		28.5

The following is a summary of the net intangible amortization for the three months ended March 31, 2017 and 2016, respectively (in thousands):

	Three Months Ended March 31,
	2017			2016
Amortization recorded against rental income related to above and (below) market leases	$	(223	)	$	337
Rental expense related to above and (below) market leasehold interests	129			96
Amortization expense related to in place leases and tenant relationships	12,730			10,767

XML

Receivables and Other Assets

3 Months Ended

Mar. 31, 2017

Receivables and Other Assets [Abstract]

Receivables and Other Assets

Receivables and Other Assets

Receivables and other assets consisted of the following as of March 31, 2017 and December 31, 2016, respectively (in thousands):

	March 31, 2017		December 31, 2016
Tenant receivables, net	$	8,750	$	8,722
Other receivables, net	8,949		9,233
Deferred financing costs, net	3,867		4,198
Deferred leasing costs, net	21,906		20,811
Straight-line rent receivables, net	76,287		74,052
Prepaid expenses, deposits, equipment and other, net	58,926		55,904
Derivative financial instruments - interest rate swaps	1,034		541
Total	$	179,719	$	173,461

The following is a summary of the amortization of deferred leasing costs and financing costs for the three months ended March 31, 2017 and 2016, respectively (in thousands):

	Three Months Ended March 31,
	2017		2016
Amortization expense related to deferred leasing costs	$	1,262	$	1,052
Interest expense related to deferred financing costs	331		331

XML

Debt

3 Months Ended

Mar. 31, 2017

Debt Disclosure [Abstract]

Debt

Debt

Debt consisted of the following as of March 31, 2017 and December 31, 2016, respectively (in thousands):

	March 31, 2017			December 31, 2016
Unsecured revolving credit facility	$	170,000		$	88,000
Unsecured term loans	500,000			500,000
Unsecured senior notes	950,000			950,000
Fixed rate mortgages loans	164,646			204,562
Variable rate mortgages loans	38,666			38,904
	1,823,312			1,781,466
Deferred financing costs, net	(9,042		)	(9,527		)
Discount, net	(3,062		)	(3,034		)
Total	$	1,811,208		$	1,768,905

Unsecured Credit Agreement

Unsecured Revolving Credit Facility

In 2015, we entered into an $850.0 million Unsecured Credit Agreement. The actual amount of credit available to us is a function of certain loan-to-value and debt service coverage ratios set forth in the unsecured revolving credit facility. The maximum principal amount of the unsecured revolving credit facility may be increased, subject to additional financing being provided by our existing lenders or new lenders being added to the unsecured revolving credit facility. The unsecured revolving credit facility matures on January 31, 2020 and is guaranteed by HTA.

Borrowings under the unsecured revolving credit facility accrue interest at a rate equal to adjusted LIBOR, plus a margin ranging from 0.88% to 1.55% per annum based on our credit rating. We also pay a facility fee ranging from 0.13% to 0.30% per annum on the aggregate commitments under the unsecured revolving credit facility. As of March 31, 2017, the margin associated with our borrowings was 1.05% per annum and the facility fee was 0.20% per annum.

Unsecured Term Loan

As of March 31, 2017, we had a $300.0 million unsecured term loan outstanding that was guaranteed by HTA. Borrowings accrue interest equal to adjusted LIBOR, plus a margin ranging from 0.90% to 1.80% per annum based on our credit rating. The margin associated with our borrowings as of March 31, 2017 was 1.15% per annum. Including the impact of the interest rate swaps associated with our unsecured term loan, the interest rate was 2.15% per annum, based on our current credit rating. The unsecured term loan matures on January 31, 2019, and includes a one-year extension exercisable at the option of the borrower, subject to certain conditions.

$200.0 Million Unsecured Term Loan

As of March 31, 2017, HTALP had a $200.0 million unsecured term loan outstanding maturing on September 26, 2023. Borrowings under the unsecured term loan accrue interest at a rate equal to LIBOR, plus a margin ranging from 1.50% to 2.45% per annum based on our credit rating. The margin associated with our borrowings as of March 31, 2017 was 1.65% per annum. HTALP had interest rate swaps in place that fix the interest rate at 2.87% per annum, based on our current credit rating.

$300.0 Million Unsecured Senior Notes due 2021

As of March 31, 2017, HTALP had $300.0 million unsecured senior notes outstanding that are guaranteed by HTA and that mature on July 15, 2021. The unsecured senior notes are registered under the Securities Act of 1933, as amended (the “Securities Act”), bear interest at 3.38% per annum and are payable semi-annually. The unsecured senior notes were offered at 99.21% of the principal amount thereof, with an effective yield to maturity of 3.50% per annum.

$300.0 Million Unsecured Senior Notes due 2023

As of March 31, 2017, HTALP had $300.0 million of unsecured senior notes outstanding that are guaranteed by HTA and that mature on April 15, 2023. The unsecured senior notes are registered under the Securities Act, bear interest at 3.70% per annum and are payable semi-annually. The unsecured senior notes were offered at 99.19% of the principal amount thereof, with an effective yield to maturity of 3.80% per annum.

$350.0 Million Unsecured Senior Notes due 2026

As of March 31, 2017, HTALP had $350.0 million of unsecured senior notes outstanding that are guaranteed by HTA and that mature on August 1, 2026. The unsecured senior notes are registered under the Securities Act, bear interest at 3.50% per annum and are payable semi-annually. The unsecured senior notes were offered at 99.72% of the principal amount thereof, with an effective yield to maturity of 3.53% per annum.

Fixed and Variable Rate Mortgages

As of March 31, 2017, HTALP and its subsidiaries had fixed and variable rate mortgages loans with interest rates ranging from 2.45% to 6.39% per annum and a weighted average interest rate of 5.01% per annum. Including the impact of the interest rate swap associated with our variable rate mortgages, the weighted average interest rate was 5.41% per annum.

Future Debt Maturities

The following table summarizes the debt maturities and scheduled principal repayments of our indebtedness as of March 31, 2017 (in thousands):

Year	Amount
2017	$	36,428
2018	4,721
2019	310,839
2020	219,795
2021	303,842
Thereafter	947,687
Total	$	1,823,312

The above scheduled debt maturities do not include the extension available to us under the Unsecured Credit Agreement as discussed above.

Deferred Financing Costs

As of March 31, 2017, the future amortization of deferred financing costs is as follows (in thousands):

Year	Amount
2017	$	1,362
2018	1,775
2019	1,780
2020	1,338
2021	1,060
Thereafter	1,727
Total	$	9,042

We are required by the terms of our applicable debt agreements to meet various affirmative and negative covenants that we believe are customary for these types of facilities, such as limitations on the incurrence of debt by us and our subsidiaries that own unencumbered assets, limitations on the nature of HTALP’s business, and limitations on distributions by HTALP and its subsidiaries that own unencumbered assets. Our debt agreements also impose various financial covenants on us, such as a maximum ratio of total indebtedness to total asset value, a minimum ratio of EBITDA to fixed charges, a minimum tangible net worth covenant, a maximum ratio of unsecured indebtedness to unencumbered asset value, rent coverage ratios and a minimum ratio of unencumbered net operating income to unsecured interest expense. As of March 31, 2017, we believe that we were in compliance with all such financial covenants and reporting requirements. In addition, certain of our debt agreements include events of default provisions that we believe are customary for these types of facilities, including restricting HTA from making dividend distributions to its stockholders in the event HTA is in default thereunder, except to the extent necessary for HTA to maintain its REIT status.

XML

Derivative Financial Instruments and Hedging Activities

3 Months Ended

Mar. 31, 2017

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Financial Instruments and Hedging Activities

Derivative Financial Instruments and Hedging Activities

Risk Management Objective of Using Derivative Financial Instruments

We may use derivative financial instruments, including interest rate swaps, caps, options, floors and other interest rate derivative contracts, to hedge all or a portion of the interest rate risk associated with our borrowings. The principal objective of such arrangements is to minimize the risks and/or costs associated with our operating and financial structure as well as to hedge specific anticipated transactions. We do not intend to utilize derivatives for speculative or other purposes other than interest rate risk management. The use of derivative financial instruments carries certain risks, including the risk that the counterparties to these contractual arrangements are not able to perform under the agreements. To mitigate this risk, we only enter into derivative financial instruments with counterparties with high credit ratings and with major financial institutions with which we and our affiliates may also have other financial relationships. We do not anticipate that any of the counterparties will fail to meet their obligations. We record counterparty credit risk valuation adjustments on interest rate swap derivative assets in order to properly reflect the credit quality of the counterparty. In addition, our fair value of interest rate swap derivative liabilities is adjusted to reflect the impact of our credit quality. As of March 31, 2017, there have been no termination events or events of default related to our interest rate swaps.

Cash Flow Hedges of Interest Rate Risk

Our objectives in using interest rate derivatives are to add stability to interest expense and to manage our exposure to interest rate movements. To accomplish this objective, we primarily use interest rate swaps as part of our interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable rate amounts from a counterparty in exchange for us making fixed rate payments over the life of the agreements without exchange of the underlying notional amount.

The effective portion of changes in the fair value of derivatives designated and that qualify as cash flow hedges is recorded in accumulated other comprehensive income in the accompanying condensed consolidated balance sheets and is subsequently reclassified into earnings in the period that the hedged forecasted transaction affects earnings. During the three months ended March 31, 2017, such derivatives were used to hedge the variable cash flows associated with variable rate debt. The ineffective portion of the change in fair value of the derivatives is recognized directly in earnings. During the three months ended March 31, 2017, we recorded approximately $6,000 of hedge ineffectiveness in earnings. We designated our derivative financial instruments as cash flow hedges in March 2017.

Amounts reported in accumulated other comprehensive income in the accompanying condensed consolidated balance sheets related to derivatives will be reclassified to interest expense as interest payments are made on our variable rate debt. During the next twelve months, we estimate that an additional $0.7 million will be reclassified from other comprehensive income in the accompanying condensed consolidated balance sheets as an increase to interest related to derivative financial instruments in the accompanying condensed consolidated statements of operations.

As of March 31, 2017, we had the following outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk (in thousands, except number of instruments):

Interest Rate Swaps	March 31, 2017
Number of instruments	5
Notional amount	$	190,396

The table below presents the fair value of our derivative financial instruments designated as a hedge as well as our classification in the accompanying condensed consolidated balance sheets as of March 31, 2017 (in thousands). In March 2017, we designated our derivative financial instruments as cash flow hedges. As such, prior to March 2017 we did not have derivatives designated as hedging instruments.

	Asset Derivatives					Liability Derivatives
		Fair Value at:					Fair Value at:
Derivatives Designated as Hedging Instruments:	Balance Sheet Location	March 31, 2017		December 31, 2016		Balance Sheet Location	March 31, 2017		December 31, 2016
Interest rate swaps	Receivables and other assets	$	1,034	$	—	Derivative financial instruments	$	1,653	$	—

The table below presents the gain or loss recognized on our derivative financial instruments designated as hedges as well as our classification in the accompanying condensed consolidated statements of operations for the three months ended March 31, 2017 (in thousands). In March 2017, we designated our derivative financial instruments as cash flow hedges. As such, prior to March 2017 we did not have derivatives designated as hedging instruments.

	Gain (Loss) Recognized in OCI on Derivative (Effective Portion):						Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion):						Gain (Loss) Recognized in Income on Derivative (Ineffective Portion and Amount Excluded from Effectiveness Testing):
	Three Months Ended March 31,						Three Months Ended March 31,						Three Months Ended March 31,
Derivatives Cash Flow Hedging Relationships:	2017			2016		Statement of Operations Location	2017			2016		Statement of Operations Location	2017			2016
Interest rate swaps	$	(164	)	$	—	Interest related to derivative financial instruments	$	(76	)	$	—	Interest related to derivative financial instruments	$	(6	)	$	—

Non-Designated Hedges

Derivatives not designated as hedges are not speculative and are used to manage our exposure to interest rate movements and other identified risks, but do not meet the strict hedge accounting requirements of ASC 815 - Derivatives and Hedging. Changes in the fair value of derivatives not designated in hedging relationships are recorded directly in earnings. Changes in the fair value of derivatives not designated in hedging relationships are recorded directly to gain or loss on change in fair value of derivative financial instruments in the accompanying condensed consolidated statements of operations. As of March 31, 2017, we recorded a gain on change in fair value of derivative financial instruments of $0.8 million.

The table below presents the fair value of our derivative financial instruments not designated as hedges as well as our classification in the accompanying condensed consolidated balance sheets as of December 31, 2016 (in thousands). In March 2017, we designated our derivative financial instruments as cash flow hedges. As such, as of March 2017 we did not have derivatives not designated as hedging instruments.

	Asset Derivatives					Liability Derivatives
		Fair Value at:					Fair Value at:
Derivatives NOT Designated as Hedging Instruments:	Balance Sheet Location	March 31, 2017		December 31, 2016		Balance Sheet Location	March 31, 2017		December 31, 2016
Interest rate swaps	Receivables and other assets	$	—	$	541	Derivative financial instruments	$	—	$	1,920

Tabular Disclosure of Offsetting Derivatives

The table below details a gross presentation, the effects of offsetting and net presentation of our derivatives as of March 31, 2017 and December 31, 2016, respectively (in thousands). The net amounts of derivative assets or liabilities can be reconciled to the tabular disclosure of fair value. The tabular disclosure of fair value provides the location that derivative assets or liabilities are presented in the consolidated balance sheets.

	Offsetting of Derivative Assets
	Gross Amounts of Recognized Assets		Gross Amounts in the Consolidated Balance Sheets		Net Amounts of Assets Presented in the Consolidated Balance Sheets		Financial Instruments		Cash Collateral Received		Net Amount
March 31, 2017	$	1,034	$	—	$	1,034	$	—	$	—	$	1,034
December 31, 2016	541		—		541		—		—		541

	Offsetting of Derivative Liabilities
	Gross Amounts of Recognized Liabilities		Gross Amounts in the Consolidated Balance Sheets		Net Amounts of Liabilities Presented in the Consolidated Balance Sheets		Financial Instruments		Cash Collateral Received		Net Amount
March 31, 2017	$	1,653	$	—	$	1,653	$	—	$	—	$	1,653
December 31, 2016	1,920		—		1,920		—		—		1,920

Credit Risk Related Contingent Features

We have agreements with each of our derivative counterparties that contain a provision where if we default on any of our indebtedness, including default where repayment of the indebtedness has not been accelerated by the lender, then we could also be declared in default on our derivative obligations.

We also have agreements with each of our derivative counterparties that incorporate provisions from our indebtedness with a lender affiliate of the derivative counterparty requiring it to maintain certain minimum financial covenant ratios on our indebtedness. Failure to comply with the covenant provisions would result in us being in default on any derivative instrument obligations covered by the agreement.

As of March 31, 2017, the fair value of derivatives in a net liability position including accrued interest but excluding any adjustment for nonperformance risk related to these agreements was $1.8 million. As of March 31, 2017, we have not posted any collateral related to these agreements and were not in breach of any agreement provisions. If we had breached any of these provisions, we could have been required to settle our obligations under the agreements at an aggregate termination value of $1.8 million at March 31, 2017.

XML

Commitments and Contingencies

3 Months Ended

Mar. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Commitments and Contingencies

Litigation

We engage in litigation from time to time with various parties as a routine part of our business, including tenant defaults. However, we are not presently subject to any material litigation nor, to our knowledge, is any material litigation threatened against us, which if determined unfavorably to us, would have a material effect on our condensed consolidated financial position, results of operations or cash flows.

Environmental Matters

We follow the policy of monitoring our properties for the presence of hazardous or toxic substances. While there can be no assurance that a material environmental liability does not exist at our properties, we are not currently aware of any environmental liability with respect to our properties that would have a material effect on our condensed consolidated financial position, results of operations or cash flows. Further, we are not aware of any material environmental liability or any unasserted claim or assessment with respect to an environmental liability at our properties that we believe would require additional disclosure or the recording of a loss contingency.

Other

Our other commitments and contingencies include the usual obligations of real estate owners and operators in the normal course of business. In our opinion, these matters are not expected to have a material effect on our condensed consolidated financial position, results of operations or cash flows.

XML

Stockholders' Equity and Partners' Capital

3 Months Ended

Mar. 31, 2017

Equity [Abstract]

Stockholders' Equity and Partners' Capital

Stockholders’ Equity and Partners’ Capital

HTALP’s partnership agreement provides that it will distribute cash flow from operations and net sale proceeds to its partners in accordance with their overall ownership interests at such times and in such amounts as the general partner determines. Dividend distributions are made such that a holder of one partnership unit in HTALP will receive distributions from HTALP in an amount equal to the dividend distributions paid to the holder of one share of HTA’s common stock. In addition, for each share of common stock issued or redeemed by HTA, HTALP issues or redeems a corresponding number of partnership units.

Common Stock Offerings

In January 2016, HTA entered into a new equity distribution agreement with respect to its at-the-market (“ATM”) offering program of common stock with an aggregate sales amount of up to $300.0 million. As of March 31, 2017, $177.1 million remained available for issuance under the ATM.

Subsequent to March 31, 2017, HTA issued and sold 1,998,000 shares of its common stock for $62.3 million at an average price of $31.20 per share.

Common Unit Offerings

During the three months ended March 31, 2017, HTA issued 20,687 OP Units in HTALP for approximately $0.6 million in connection with an acquisition transaction.

Common Stock Dividends

See our accompanying condensed consolidated statements of operations for the dividends declared during the three months ended March 31, 2017 and 2016. On April 26, 2017, HTA declared a quarterly cash dividend of $0.30 per share to be paid on July 11, 2017 to stockholders of record of its common stock on July 5, 2017.

Incentive Plan

HTA’s Amended and Restated 2006 Incentive Plan (the “Plan”) permits the grant of incentive awards to our employees, officers, non-employee directors and consultants as selected by our Board of Directors. The Plan authorizes the granting of awards in any of the following forms: options; stock appreciation rights; restricted stock; restricted or deferred stock units; performance awards; dividend equivalents; other stock-based awards, including units in HTALP; and cash-based awards. Subject to adjustment as provided in the Plan, the aggregate number of awards reserved and available for issuance under the Plan is 5,000,000. As of March 31, 2017, there were 1,710,501 awards available for grant under the Plan.

LTIP Units

Awards under the LTIP consist of Series C units inHTALPand were subject to the achievement of certain performance and market conditions in order to vest. Once vested, the Series C units were converted into common units of HTALP, which may be converted into shares of HTA’s common stock. The LTIP awards were fully expensed or forfeited in 2015.

Restricted Common Stock

For the three months ended March 31, 2017 and 2016, we recognized compensation expense of $2.5 million and $1.8 million, respectively, which was recorded in general and administrative expenses in the accompanying condensed consolidated statements of operations.

As of March 31, 2017, there was $11.1 million of unrecognized compensation expense, net of estimated forfeitures, which will be recognized over a remaining weighted average period of 2.1 years.

The following is a summary of our restricted common stock activity as of March 31, 2017 and 2016, respectively:

	March 31, 2017				March 31, 2016
	Restricted Common Stock		Weighted Average Grant Date Fair Value		Restricted Common Stock		Weighted Average Grant Date Fair Value
Beginning balance	640,870		$	27.36	487,850		$	23.13
Granted	215,333		29.31		194,151		27.17
Vested	(229,621	)	24.88		(162,140	)	22.65
Forfeited	(2,524	)	29.96		(3,244	)	24.23
Ending balance	624,058		$	28.94	516,617		$	24.79

XML

Fair Value of Financial Instruments

3 Months Ended

Mar. 31, 2017

Fair Value Disclosures [Abstract]

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Financial Instruments Reported at Fair Value - Recurring

The table below presents our assets and liabilities measured at fair value on a recurring basis as of March 31, 2017, aggregated by the applicable level in the fair value hierarchy (in thousands):

	Level 1		Level 2		Level 3		Total
Assets:
Derivative financial instruments	$	—	$	1,034	$	—	$	1,034
Liabilities:
Derivative financial instruments	$	—	$	1,653	$	—	$	1,653

The table below presents our assets and liabilities measured at fair value on a recurring basis as of December 31, 2016, aggregated by the applicable level in the fair value hierarchy (in thousands):

	Level 1		Level 2		Level 3		Total
Assets:
Derivative financial instruments	$	—	$	541	$	—	$	541
Liabilities:
Derivative financial instruments	$	—	$	1,920	$	—	$	1,920

Financial Instruments Reported at Fair Value - Non-Recurring

As of March 31, 2017, there were noassets measured at fair value on a non-recurring basis. The table below presents our assets measured at fair value on a non-recurring basis as of December 31, 2016, aggregated by the applicable level in the fair value hierarchy (in thousands):

	Level 1		Level 2		Level 3		Total
Assets:
MOB (1)	$	—	$	8,191	$	—	$	8,191
(1) During the year ended December 31, 2016, we recognized impairment charges of $1.3 million and $1.8 million to the carrying value of two MOBs. The estimated fair value as of December 31, 2016 for these MOBs was based upon a pending sales agreement and real estate market comparables.

There have been no transfers of assets or liabilities between levels. We will record any such transfers at the end of the reporting period in which a change of event occurs that results in a transfer. Although we have determined that the majority of the inputs used to value our interest rate swap derivatives fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with these instruments utilize Level 3 inputs, such as estimates of current credit spreads to evaluate the likelihood of default by us and our counterparties. However, we have assessed the significance of the impact of the credit valuation adjustments on the overall valuation of our interest rate swap derivative positions and have determined that the credit valuation adjustments are not significant to their overall valuation. As a result, we have determined that our interest rate swap derivative valuations in their entirety are classified in Level 2 of the fair value hierarchy.

Financial Instruments Disclosed at Fair Value

We consider the carrying values of cash and cash equivalents, tenant and other receivables, restricted cash and escrow deposits and accounts payable, and accrued liabilities, to approximate fair value for these financial instruments because of the short period of time between origination of the instruments and their expected realization. All of these financial instruments are considered Level 2.

The fair value of debt is estimated using borrowing rates available to us with similar terms and maturities, which is considered a Level 2 input. As of March 31, 2017, the fair value of the debt was $1,831.7 million compared to the carrying value of $1,811.2 million. As of December 31, 2016, the fair value of the debt was $1,784.0 million compared to the carrying value of $1,768.9 million.

XML

Per Share Data of HTA

3 Months Ended

Mar. 31, 2017

HTA, Inc.

Earnings Per Share

Per Share Data of HTA

Per Share Data of HTA

HTA includes unvested share-based payment awards that contain non-forfeitable rights to dividends or dividend equivalents as “participating securities” pursuant to the two-class method. The resulting classes are our common stock and restricted stock. For the three months ended March 31, 2017 and 2016, all of HTA’s earnings were distributed and the calculated earnings per share amount would be the same for all classes.

The following is the reconciliation of the numerator and denominator used in basic and diluted earnings per share of HTA for the three months ended March 31, 2017 and 2016, respectively (in thousands, except per share data):

	Three Months Ended March 31,
	2017			2016
Numerator:
Net income	$	14,000		$	10,036
Net income attributable to noncontrolling interests	(455		)	(176		)
Net income attributable to common stockholders	$	13,545		$	9,860
Denominator:
Weighted average shares outstanding - basic	141,780			129,336
Dilutive shares	4,337			1,904
Weighted average shares outstanding - diluted	146,117			131,240
Earnings per common share - basic
Net income attributable to common stockholders	$	0.10		$	0.08
Earnings per common share - diluted
Net income attributable to common stockholders	$	0.09		$	0.08

XML

Per Unit Data of HTALP

3 Months Ended

Mar. 31, 2017

Healthcare Trust of America Holdings, LP (HTALP)

Earnings Per Share

Per Unit Data of HTALP

Per Unit Data of HTALP

The following is the reconciliation of the numerator and denominator used in basic and diluted earnings per unit of HTALP for the three months ended March 31, 2017 and 2016, respectively (in thousands, except per unit data):

	Three Months Ended March 31,
	2017			2016
Numerator:
Net income	$	14,000		$	10,036
Net income attributable to noncontrolling interests	(30		)	(31		)
Net income attributable to common unitholders	$	13,970		$	10,005
Denominator:
Weighted average units outstanding - basic	146,117			131,242
Dilutive units	—			—
Weighted average units outstanding - diluted	146,117			131,242
Earnings per common unit - basic:
Net income attributable to common unitholders	$	0.10		$	0.08
Earnings per common unit - diluted:
Net income attributable to common unitholders	$	0.10		$	0.08

XML

Supplemental Cash Flow Information

3 Months Ended

Mar. 31, 2017

Supplemental Cash Flow Elements [Abstract]

Supplemental Cash Flow Information

Supplemental Cash Flow Information

The following is the supplemental cash flow information for the three months ended March 31, 2017 and 2016, respectively (in thousands):

	Three Months Ended March 31,
	2017		2016
Supplemental Disclosure of Cash Flow Information:
Interest paid	$	19,186	$	13,062
Income taxes paid	60		88
Supplemental Disclosure of Noncash Investing and Financing Activities:
Accrued capital expenditures	$	5,696	$	5,688
Dividend distributions declared, but not paid	44,489		38,784
Issuance of operating partnership units in connection with an acquisition	610		—
Note receivable retired in connection with an acquisition	2,494		—

XML

Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2017

Accounting Policies [Abstract]

Basis of Presentation

Our accompanying condensed consolidated financial statements include our accounts and those of our subsidiaries and any consolidated variable interest entities (“VIEs”). All inter-company balances and transactions have been eliminated in the accompanying condensed consolidated financial statements.

Interim Unaudited Financial Data

Our accompanying condensed consolidated financial statements have been prepared by us in accordance with GAAP in conjunction with the rules and regulations of the SEC. Certain information and footnote disclosures required for annual financial statements have been condensed or excluded pursuant to SEC rules and regulations. Accordingly, our accompanying condensed consolidated financial statements do not include all information and footnotes required by GAAP for complete financial statements. Our accompanying condensed consolidated financial statements reflect all adjustments, which are, in our opinion, of a normal recurring nature and necessary for a fair presentation of our financial position, results of operations and cash flows for the interim periods. Interim results of operations are not necessarily indicative of the results to be expected for the full year; such results may be less favorable for the full year. Our accompanying condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and the notes thereto included in our 2016 Annual Report on Form 10-K.

Principles of Consolidation

The consolidated financial statements include our accounts of those of our subsidiaries and consolidated joint venture arrangements. The portions of the operating partnership not owned by us are presented as non-controlling interests in our consolidated balance sheets and statements of operations, consolidated statements of equity, and consolidated statements of changes in partners’ capital. The portions of other joint venture arrangements not owned by us are presented as redeemable non-controlling interests in our consolidated balance sheets. In addition, as described in Note 1 - Organization and Description of Business, certain third parties have been issued limited partner units in HTALP (“OP Units”). Holders of OP Units are considered to be non-controlling interest holders in HTALP and their ownership interests are reflected as equity in the consolidated balance sheets. Further, a portion of the earnings and losses of HTALP are allocated to non-controlling interest holders based on their respective ownership percentages. Upon conversion of OP Units to common stock, any difference between the fair value of common shares issued and the carrying value of the OP Units converted is recorded as a component of equity. As of March 31, 2017 and December 31, 2016, there were approximately 4.3 million of OP Units issued and outstanding.

VIEs are entities where investors lack sufficient equity at risk for the entity to finance its activities without additional subordinated financial support or where equity investors, as a group, lack one of the following: (i) the power to direct the activities that most significantly impact the entity’s economic performance; (ii) the obligation to absorb the expected losses of the entity; and (iii) the right to receive the expected returns of the entity. We consolidate our investment in VIEs when we determine that we are the primary beneficiary. A primary beneficiary is one that has both: (i) the power to direct the activities of the VIE that most significantly impacts the entity’s economic performance; and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could be significant to the entity. Our operating partnership (HTALP) and other joint venture arrangements are VIEs, because the limited partners in those partnerships, although entitled to vote on certain matters, do not possess kick-out rights or substantive participating rights. Additionally, we determined that we are the primary beneficiary of our VIEs. Accordingly, we consolidate our interests in the HTALP operating partnership and other joint venture arrangements. However, because we hold what is deemed a majority voting interest in the operating partnership and other joint venture arrangements, it qualifies for the exemption from providing certain disclosure requirements associated with investments in VIEs. We will evaluate on an ongoing basis the need to consolidate entities based on the standards set forth in GAAP as described above.

Recently Issued or Adopted Accounting Pronouncements

The following table provides a brief description of recently adopted accounting pronouncements:

Accounting Pronouncement	Description	Effective Date	Effect on financial statements
ASU 2017-01 Business Combinations: Clarifying the Definition of a Business (Issued January 2017)	ASU 2017-01 clarifies the definition of a business by adding guidance to assist entities evaluate whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The definition of a business affects many areas of accounting, including, but not limited to, acquisitions, disposals, goodwill and consolidation.	ASU 2017-01 is effective for fiscal years beginning after December 15, 2017 with early adoption permitted.	We adopted ASU 2017-01 as of January 1, 2017 on a prospective basis. We expect that the majority of our future investments in real estate will be accounted for as asset acquisitions under ASU 2017-01. The adoption of ASU 2017-01 will impact how we account for acquisition-related expenses and contingent consideration which may result in lower acquisition-related expenses and eliminate fair value adjustments related to future contingent consideration arrangements.

The following table provides a brief description of recently issued accounting pronouncements:

Accounting Pronouncement	Description	Effective Date	Effect on financial statements
ASU 2014-09 Revenue from Contracts with Customers (Issued May 2014)	ASU 2014-09 is a comprehensive new revenue recognition model requiring a company to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration (i.e., payment) to which the company expects to be entitled in exchange for those goods or services. In adopting ASU 2014-09, companies may use either a full retrospective or a modified retrospective approach.	In July 2015, the FASB deferred the effective date of ASU 2014-09 to the first interim period within annual reporting periods beginning after December 15, 2017 along with the right of early adoption as of the original effective date.	We have identified our revenue streams and are in the process of evaluating the impact on our consolidated financial statements and internal accounting processes; however, the majority of our revenues are derived from real estate lease contracts, as discussed in relation to ASU 2016-02 below. We will adopt ASU 2014-09 effective January 1, 2018 using the retrospective approach and the adoption is not expected to have a material impact on our consolidated financial statements.
ASU 2016-02 Leases (Issued February 2016)	ASU 2016-02 will supersede the existing guidance for lease accounting and states that companies will be required to recognize lease assets and lease liabilities on the balance sheet and disclose key information about leasing arrangements. ASU 2016-02 requires qualitative and quantitative disclosures to supplement the amounts recorded in the financial statements so that users can understand the nature of the entity’s leasing activities, including significant judgments and changes in judgments. Within ASU 2016-02 lessor accounting remained fairly unchanged. In adopting ASU 2016-02, companies will be required to use a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements.	ASU 2016-02 is effective for the fiscal years beginning after December 15, 2018 with early adoption permitted.	We will adopt ASU 2016-02 as of January 1, 2019 using the modified retrospective approach.  We are currently evaluating the full impact of ASU 2016-02 will have on our consolidated financial statements and disclosures, however, we anticipate there to be a significant increase in our assets and liabilities on our consolidated balance sheets due to the recognition of our current ground leases which represented rental expense of $7.6 million and have an average remaining term of 48.2 years for the year ended December 31, 2016.  In addition, we anticipate there to be a material impact on our consolidated balance sheets and statements of operations as certain leasing costs will no longer qualify for capitalization over the life of the lease, but instead will be required to be expensed as incurred.
ASU 2016-13 Financial Instruments Credit Losses: Measurement of Credit Losses on Financial Instruments (Issued June 2016)	ASU 2016-13 is intended to improve financial reporting by requiring more timely recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. ASU 2016-13 requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected through an allowance for credit losses that is deducted from the amortized cost basis.	ASU 2016-13 is effective for fiscal years beginning after December 15, 2019 with early adoption permitted.	We do not anticipate early adoption or for there to be a material impact, however, we are evaluating the impact of adopting ASU 2016-13 on our consolidated financial statements.
ASU 2016-15 Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments (Issued August 2016)	ASU 2016-15 includes multiple provisions intended to clarify various aspects of cash flow presentation by making eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows.	ASU 2016-15 is effective for fiscal years beginning after December 15, 2017 with early adoption permitted.	We will adopt ASU 2016-15 as of the year ended December 31, 2017. We do not anticipate there to be a material impact, however, we are still evaluating the impact ASU 2016-15 will have on our consolidated financial statements.

Accounting Pronouncement	Description	Effective Date	Effect on financial statements
ASU 2016-18 Statement of Cash Flows: Restricted Cash (Issued November 2016)	ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows.	ASU 2016-18 is effective for fiscal years beginning after December 15, 2017 with early adoption permitted.	We will adopt ASU 2016-18 as of the year ended December 31, 2017. We do not anticipate there to be a material impact on our consolidated financial statements, however, we are still evaluating the impact ASU 2016-18 will have on our consolidated financial statements.
ASU 2017-05 Other Income: Clarifying the Scope of Asset Derecognition Guidance and Accounting for Partial Sales of Nonfinancial Assets (Issued February 2017)	ASU 2017-05 defines an in-substance nonfinancial asset, unifies guidance related to partial sales of nonfinancial assets, eliminates rules specifically addressing the sales of real estate, removes exception to the financial asset derecognition model and clarifies the accounting for contributions of nonfinancial assets to joint ventures.	ASU 2017-05 is effective for fiscal years beginning after December 15, 2017 with early adoption permitted.	We do not anticipate early adoption, however, we are evaluating the impact of adopting ASU 2017-05 on our consolidated financial statements.

XML

Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2017

Accounting Policies [Abstract]

Description of Recently Issued Accounting Pronouncements

The following table provides a brief description of recently adopted accounting pronouncements:

Accounting Pronouncement	Description	Effective Date	Effect on financial statements
ASU 2017-01 Business Combinations: Clarifying the Definition of a Business (Issued January 2017)	ASU 2017-01 clarifies the definition of a business by adding guidance to assist entities evaluate whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The definition of a business affects many areas of accounting, including, but not limited to, acquisitions, disposals, goodwill and consolidation.	ASU 2017-01 is effective for fiscal years beginning after December 15, 2017 with early adoption permitted.	We adopted ASU 2017-01 as of January 1, 2017 on a prospective basis. We expect that the majority of our future investments in real estate will be accounted for as asset acquisitions under ASU 2017-01. The adoption of ASU 2017-01 will impact how we account for acquisition-related expenses and contingent consideration which may result in lower acquisition-related expenses and eliminate fair value adjustments related to future contingent consideration arrangements.

The following table provides a brief description of recently issued accounting pronouncements:

Accounting Pronouncement	Description	Effective Date	Effect on financial statements
ASU 2014-09 Revenue from Contracts with Customers (Issued May 2014)	ASU 2014-09 is a comprehensive new revenue recognition model requiring a company to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration (i.e., payment) to which the company expects to be entitled in exchange for those goods or services. In adopting ASU 2014-09, companies may use either a full retrospective or a modified retrospective approach.	In July 2015, the FASB deferred the effective date of ASU 2014-09 to the first interim period within annual reporting periods beginning after December 15, 2017 along with the right of early adoption as of the original effective date.	We have identified our revenue streams and are in the process of evaluating the impact on our consolidated financial statements and internal accounting processes; however, the majority of our revenues are derived from real estate lease contracts, as discussed in relation to ASU 2016-02 below. We will adopt ASU 2014-09 effective January 1, 2018 using the retrospective approach and the adoption is not expected to have a material impact on our consolidated financial statements.
ASU 2016-02 Leases (Issued February 2016)	ASU 2016-02 will supersede the existing guidance for lease accounting and states that companies will be required to recognize lease assets and lease liabilities on the balance sheet and disclose key information about leasing arrangements. ASU 2016-02 requires qualitative and quantitative disclosures to supplement the amounts recorded in the financial statements so that users can understand the nature of the entity’s leasing activities, including significant judgments and changes in judgments. Within ASU 2016-02 lessor accounting remained fairly unchanged. In adopting ASU 2016-02, companies will be required to use a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements.	ASU 2016-02 is effective for the fiscal years beginning after December 15, 2018 with early adoption permitted.	We will adopt ASU 2016-02 as of January 1, 2019 using the modified retrospective approach.  We are currently evaluating the full impact of ASU 2016-02 will have on our consolidated financial statements and disclosures, however, we anticipate there to be a significant increase in our assets and liabilities on our consolidated balance sheets due to the recognition of our current ground leases which represented rental expense of $7.6 million and have an average remaining term of 48.2 years for the year ended December 31, 2016.  In addition, we anticipate there to be a material impact on our consolidated balance sheets and statements of operations as certain leasing costs will no longer qualify for capitalization over the life of the lease, but instead will be required to be expensed as incurred.
ASU 2016-13 Financial Instruments Credit Losses: Measurement of Credit Losses on Financial Instruments (Issued June 2016)	ASU 2016-13 is intended to improve financial reporting by requiring more timely recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. ASU 2016-13 requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected through an allowance for credit losses that is deducted from the amortized cost basis.	ASU 2016-13 is effective for fiscal years beginning after December 15, 2019 with early adoption permitted.	We do not anticipate early adoption or for there to be a material impact, however, we are evaluating the impact of adopting ASU 2016-13 on our consolidated financial statements.
ASU 2016-15 Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments (Issued August 2016)	ASU 2016-15 includes multiple provisions intended to clarify various aspects of cash flow presentation by making eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows.	ASU 2016-15 is effective for fiscal years beginning after December 15, 2017 with early adoption permitted.	We will adopt ASU 2016-15 as of the year ended December 31, 2017. We do not anticipate there to be a material impact, however, we are still evaluating the impact ASU 2016-15 will have on our consolidated financial statements.

Accounting Pronouncement	Description	Effective Date	Effect on financial statements
ASU 2016-18 Statement of Cash Flows: Restricted Cash (Issued November 2016)	ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows.	ASU 2016-18 is effective for fiscal years beginning after December 15, 2017 with early adoption permitted.	We will adopt ASU 2016-18 as of the year ended December 31, 2017. We do not anticipate there to be a material impact on our consolidated financial statements, however, we are still evaluating the impact ASU 2016-18 will have on our consolidated financial statements.
ASU 2017-05 Other Income: Clarifying the Scope of Asset Derecognition Guidance and Accounting for Partial Sales of Nonfinancial Assets (Issued February 2017)	ASU 2017-05 defines an in-substance nonfinancial asset, unifies guidance related to partial sales of nonfinancial assets, eliminates rules specifically addressing the sales of real estate, removes exception to the financial asset derecognition model and clarifies the accounting for contributions of nonfinancial assets to joint ventures.	ASU 2017-05 is effective for fiscal years beginning after December 15, 2017 with early adoption permitted.	We do not anticipate early adoption, however, we are evaluating the impact of adopting ASU 2017-05 on our consolidated financial statements.

XML

Investments in Real Estate (Tables)

3 Months Ended

Mar. 31, 2017

Investments [Abstract]

Schedule of Purchase Price Allocation

The allocations for these investments are set forth below in the aggregate for the three months ended March 31, 2017 and 2016, respectively (in thousands):

	Three Months Ended March 31,
	2017			2016
Land	$	4,934		$	17,315
Building and improvements	29,762			128,945
In place leases	3,185			15,919
Below market leases	(65		)	(5,382		)
Above market leases	—			840
Below market leasehold interests	—			1,099
Above market leasehold interests	—			(50		)
Net assets acquired	37,816			158,686
Other, net	1,230			3,321
Aggregate purchase price	$	39,046		$	162,007

Schedule of Weighted Average Lives of Acquired Intangible Assets and Liabilities

The acquired intangible assets and liabilities referenced above had weighted average lives of the following for the three months ended March 31, 2017 and 2016, respectively (in years):

	Three Months Ended March 31,
	2017	2016
Acquired intangible assets	11.3	10.5
Acquired intangible liabilities	10.2	8.9

XML

Intangible Assets and Liabilities (Tables)

3 Months Ended

Mar. 31, 2017

Identified Intangibles, Net [Abstract]

Schedule of Intangible Assets and Liabilities

Intangible assets and liabilities consisted of the following as of March 31, 2017 and December 31, 2016, respectively (in thousands, except weighted average remaining amortization):

	March 31, 2017				December 31, 2016
	Balance			Weighted Average Remaining Amortization in Years	Balance			Weighted Average Remaining Amortization in Years
Assets:
In place leases	$	296,018		9.9	$	294,597		9.7
Tenant relationships	171,541			10.6	172,974			10.6
Above market leases	28,149			6.3	28,401			6.3
Below market leasehold interests	38,136			60.3	38,136			60.4
	533,844				534,108
Accumulated amortization	(266,758		)		(256,305		)
Total	$	267,086		16.4	$	277,803		16.1
Liabilities:
Below market leases	$	34,081		19.0	$	34,370		18.6
Above market leasehold interests	11,632			52.8	11,632			53.0
	45,713				46,002
Accumulated amortization	(9,704		)		(8,946		)
Total	$	36,009		29.0	$	37,056		28.5

Summary of Net Intangible Amortization

The following is a summary of the net intangible amortization for the three months ended March 31, 2017 and 2016, respectively (in thousands):

	Three Months Ended March 31,
	2017			2016
Amortization recorded against rental income related to above and (below) market leases	$	(223	)	$	337
Rental expense related to above and (below) market leasehold interests	129			96
Amortization expense related to in place leases and tenant relationships	12,730			10,767

XML

Receivables and Other Assets (Tables)

3 Months Ended

Mar. 31, 2017

Receivables and Other Assets [Abstract]

Schedule of Receivables and Other Assets

Receivables and other assets consisted of the following as of March 31, 2017 and December 31, 2016, respectively (in thousands):

	March 31, 2017		December 31, 2016
Tenant receivables, net	$	8,750	$	8,722
Other receivables, net	8,949		9,233
Deferred financing costs, net	3,867		4,198
Deferred leasing costs, net	21,906		20,811
Straight-line rent receivables, net	76,287		74,052
Prepaid expenses, deposits, equipment and other, net	58,926		55,904
Derivative financial instruments - interest rate swaps	1,034		541
Total	$	179,719	$	173,461

Summary of Amortization of Deferred Leasing Costs and Deferred Financing Costs

The following is a summary of the amortization of deferred leasing costs and financing costs for the three months ended March 31, 2017 and 2016, respectively (in thousands):

	Three Months Ended March 31,
	2017		2016
Amortization expense related to deferred leasing costs	$	1,262	$	1,052
Interest expense related to deferred financing costs	331		331

XML

Debt (Tables)

3 Months Ended

Mar. 31, 2017

Debt Disclosure [Abstract]

Schedule of Debt

Debt consisted of the following as of March 31, 2017 and December 31, 2016, respectively (in thousands):

	March 31, 2017			December 31, 2016
Unsecured revolving credit facility	$	170,000		$	88,000
Unsecured term loans	500,000			500,000
Unsecured senior notes	950,000			950,000
Fixed rate mortgages loans	164,646			204,562
Variable rate mortgages loans	38,666			38,904
	1,823,312			1,781,466
Deferred financing costs, net	(9,042		)	(9,527		)
Discount, net	(3,062		)	(3,034		)
Total	$	1,811,208		$	1,768,905

Summary of Debt Maturities and Scheduled Principal Debt Repayments

The following table summarizes the debt maturities and scheduled principal repayments of our indebtedness as of March 31, 2017 (in thousands):

Year	Amount
2017	$	36,428
2018	4,721
2019	310,839
2020	219,795
2021	303,842
Thereafter	947,687
Total	$	1,823,312

Schedule of Amortization of Deferred Financing Costs

As of March 31, 2017, the future amortization of deferred financing costs is as follows (in thousands):

Year	Amount
2017	$	1,362
2018	1,775
2019	1,780
2020	1,338
2021	1,060
Thereafter	1,727
Total	$	9,042

XML

Derivative Financial Instruments and Hedging Activities (Tables)

3 Months Ended

Mar. 31, 2017

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Interest Rate Derivatives

As of March 31, 2017, we had the following outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk (in thousands, except number of instruments):

Interest Rate Swaps	March 31, 2017
Number of instruments	5
Notional amount	$	190,396

The table below presents the fair value of our derivative financial instruments designated as a hedge as well as our classification in the accompanying condensed consolidated balance sheets as of March 31, 2017 (in thousands). In March 2017, we designated our derivative financial instruments as cash flow hedges. As such, prior to March 2017 we did not have derivatives designated as hedging instruments.

	Asset Derivatives					Liability Derivatives
		Fair Value at:					Fair Value at:
Derivatives Designated as Hedging Instruments:	Balance Sheet Location	March 31, 2017		December 31, 2016		Balance Sheet Location	March 31, 2017		December 31, 2016
Interest rate swaps	Receivables and other assets	$	1,034	$	—	Derivative financial instruments	$	1,653	$	—

The table below presents the gain or loss recognized on our derivative financial instruments designated as hedges as well as our classification in the accompanying condensed consolidated statements of operations for the three months ended March 31, 2017 (in thousands). In March 2017, we designated our derivative financial instruments as cash flow hedges. As such, prior to March 2017 we did not have derivatives designated as hedging instruments.

	Gain (Loss) Recognized in OCI on Derivative (Effective Portion):						Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion):						Gain (Loss) Recognized in Income on Derivative (Ineffective Portion and Amount Excluded from Effectiveness Testing):
	Three Months Ended March 31,						Three Months Ended March 31,						Three Months Ended March 31,
Derivatives Cash Flow Hedging Relationships:	2017			2016		Statement of Operations Location	2017			2016		Statement of Operations Location	2017			2016
Interest rate swaps	$	(164	)	$	—	Interest related to derivative financial instruments	$	(76	)	$	—	Interest related to derivative financial instruments	$	(6	)	$	—

Gross Fair Value of Derivative Financial Instruments

The table below presents the fair value of our derivative financial instruments not designated as hedges as well as our classification in the accompanying condensed consolidated balance sheets as of December 31, 2016 (in thousands). In March 2017, we designated our derivative financial instruments as cash flow hedges. As such, as of March 2017 we did not have derivatives not designated as hedging instruments.

	Asset Derivatives					Liability Derivatives
		Fair Value at:					Fair Value at:
Derivatives NOT Designated as Hedging Instruments:	Balance Sheet Location	March 31, 2017		December 31, 2016		Balance Sheet Location	March 31, 2017		December 31, 2016
Interest rate swaps	Receivables and other assets	$	—	$	541	Derivative financial instruments	$	—	$	1,920

Schedule of Derivative Assets Subject to Master Netting Arrangements

The table below details a gross presentation, the effects of offsetting and net presentation of our derivatives as of March 31, 2017 and December 31, 2016, respectively (in thousands). The net amounts of derivative assets or liabilities can be reconciled to the tabular disclosure of fair value. The tabular disclosure of fair value provides the location that derivative assets or liabilities are presented in the consolidated balance sheets.

	Offsetting of Derivative Assets
	Gross Amounts of Recognized Assets		Gross Amounts in the Consolidated Balance Sheets		Net Amounts of Assets Presented in the Consolidated Balance Sheets		Financial Instruments		Cash Collateral Received		Net Amount
March 31, 2017	$	1,034	$	—	$	1,034	$	—	$	—	$	1,034
December 31, 2016	541		—		541		—		—		541

Schedule of Derivative Liabilities Subject to Master Netting Arrangements

	Offsetting of Derivative Liabilities
	Gross Amounts of Recognized Liabilities		Gross Amounts in the Consolidated Balance Sheets		Net Amounts of Liabilities Presented in the Consolidated Balance Sheets		Financial Instruments		Cash Collateral Received		Net Amount
March 31, 2017	$	1,653	$	—	$	1,653	$	—	$	—	$	1,653
December 31, 2016	1,920		—		1,920		—		—		1,920

XML

Stockholders' Equity and Partners' Capital (Tables)

3 Months Ended

Mar. 31, 2017

Equity [Abstract]

Schedule of Restricted Common Stock Activity

The following is a summary of our restricted common stock activity as of March 31, 2017 and 2016, respectively:

	March 31, 2017				March 31, 2016
	Restricted Common Stock		Weighted Average Grant Date Fair Value		Restricted Common Stock		Weighted Average Grant Date Fair Value
Beginning balance	640,870		$	27.36	487,850		$	23.13
Granted	215,333		29.31		194,151		27.17
Vested	(229,621	)	24.88		(162,140	)	22.65
Forfeited	(2,524	)	29.96		(3,244	)	24.23
Ending balance	624,058		$	28.94	516,617		$	24.79

XML

Fair Value of Financial Instruments (Tables)

3 Months Ended

Mar. 31, 2017

Fair Value Disclosures [Abstract]

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

The table below presents our assets and liabilities measured at fair value on a recurring basis as of March 31, 2017, aggregated by the applicable level in the fair value hierarchy (in thousands):

	Level 1		Level 2		Level 3		Total
Assets:
Derivative financial instruments	$	—	$	1,034	$	—	$	1,034
Liabilities:
Derivative financial instruments	$	—	$	1,653	$	—	$	1,653

The table below presents our assets and liabilities measured at fair value on a recurring basis as of December 31, 2016, aggregated by the applicable level in the fair value hierarchy (in thousands):

	Level 1		Level 2		Level 3		Total
Assets:
Derivative financial instruments	$	—	$	541	$	—	$	541
Liabilities:
Derivative financial instruments	$	—	$	1,920	$	—	$	1,920

Schedule of Fair Value, Assets Measured on Non-Recurring Basis

The table below presents our assets measured at fair value on a non-recurring basis as of December 31, 2016, aggregated by the applicable level in the fair value hierarchy (in thousands):

	Level 1		Level 2		Level 3		Total
Assets:
MOB (1)	$	—	$	8,191	$	—	$	8,191
(1) During the year ended December 31, 2016, we recognized impairment charges of $1.3 million and $1.8 million to the carrying value of two MOBs. The estimated fair value as of December 31, 2016 for these MOBs was based upon a pending sales agreement and real estate market comparables.

XML

Per Share Data of HTA (Tables)

3 Months Ended

Mar. 31, 2017

HTA, Inc.

Earnings Per Share

Schedule of Earnings Per Share, Basic and Diluted

The following is the reconciliation of the numerator and denominator used in basic and diluted earnings per share of HTA for the three months ended March 31, 2017 and 2016, respectively (in thousands, except per share data):

	Three Months Ended March 31,
	2017			2016
Numerator:
Net income	$	14,000		$	10,036
Net income attributable to noncontrolling interests	(455		)	(176		)
Net income attributable to common stockholders	$	13,545		$	9,860
Denominator:
Weighted average shares outstanding - basic	141,780			129,336
Dilutive shares	4,337			1,904
Weighted average shares outstanding - diluted	146,117			131,240
Earnings per common share - basic
Net income attributable to common stockholders	$	0.10		$	0.08
Earnings per common share - diluted
Net income attributable to common stockholders	$	0.09		$	0.08

XML

Per Unit Data of HTALP (Tables)

3 Months Ended

Mar. 31, 2017

Healthcare Trust of America Holdings, LP (HTALP)

Earnings Per Share

Schedule of Earnings Per Unit, Basic and Diluted

The following is the reconciliation of the numerator and denominator used in basic and diluted earnings per unit of HTALP for the three months ended March 31, 2017 and 2016, respectively (in thousands, except per unit data):

	Three Months Ended March 31,
	2017			2016
Numerator:
Net income	$	14,000		$	10,036
Net income attributable to noncontrolling interests	(30		)	(31		)
Net income attributable to common unitholders	$	13,970		$	10,005
Denominator:
Weighted average units outstanding - basic	146,117			131,242
Dilutive units	—			—
Weighted average units outstanding - diluted	146,117			131,242
Earnings per common unit - basic:
Net income attributable to common unitholders	$	0.10		$	0.08
Earnings per common unit - diluted:
Net income attributable to common unitholders	$	0.10		$	0.08

XML

Supplemental Cash Flow Information (Tables)

3 Months Ended

Mar. 31, 2017

Supplemental Cash Flow Elements [Abstract]

Schedule of Supplemental Cash Flow Information

The following is the supplemental cash flow information for the three months ended March 31, 2017 and 2016, respectively (in thousands):

	Three Months Ended March 31,
	2017		2016
Supplemental Disclosure of Cash Flow Information:
Interest paid	$	19,186	$	13,062
Income taxes paid	60		88
Supplemental Disclosure of Noncash Investing and Financing Activities:
Accrued capital expenditures	$	5,696	$	5,688
Dividend distributions declared, but not paid	44,489		38,784
Issuance of operating partnership units in connection with an acquisition	610		—
Note receivable retired in connection with an acquisition	2,494		—

XML

Organization and Description of Business (Details) ft² in Millions, $ in Billions	3 Months Ended
	Mar. 31, 2017 USD ($) ft² market States
Organization, Consolidation and Presentation of Financial Statements [Abstract]
General partnership interest (as a percent)	97.00%
Purchased property inception to current date | $	$ 4.3
Gross leasable area of real estate in portfolio (in square feet) | ft²	17.8
Concentration Risk [Line Items]
Percentage of gross leasable area on-campus/aligned	96.00%
Number of states in which the Company operates | States	31
Maximum state gross leasable area (as a percent)	13.00%
Percentage of gross leasable area located in the top 75 Metro statistical areas	92.00%
Minimum
Concentration Risk [Line Items]
Number of markets where the Company is concentrated	15
Maximum
Concentration Risk [Line Items]
Number of markets where the Company is concentrated	20

XML

Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Partners' Capital Notes [Abstract]
Rental expense	$ 39,020	$ 33,353
Building and Building Improvements
Partners' Capital Notes [Abstract]
Depreciation expense	$ 32,700	25,700
Ground Lease
Partners' Capital Notes [Abstract]
Rental expense			$ 7,600
Finite-lived intangible asset (in years)			48 years 2 months 12 days
Healthcare Trust of America Holdings, LP (HTALP)
Partners' Capital Notes [Abstract]
Limited partner's capital, units issued (in shares)	4,343,782		4,323,095
Limited partner's capital, units outstanding (in shares)	4,343,782		4,323,095
Rental expense	$ 39,020	$ 33,353

XML

Investments in Real Estate - Acquisitions (Details) ft² in Thousands, $ in Thousands	1 Months Ended	3 Months Ended
	Apr. 27, 2017 USD ($) ft²	Mar. 31, 2017 USD ($) market shares	Mar. 31, 2016 USD ($)
Business Acquisition [Line Items]
Closing costs		$ 300
Land		4,934	$ 17,315
Building and improvements		29,762	128,945
In place leases		3,185	15,919
Below market leases		(65)	(5,382)
Above market leases		0	840
Below market leasehold interests		0	1,099
Above market leasehold interests		0	(50)
Net assets acquired		37,816	158,686
Other, net		1,230	3,321
Aggregate purchase price		$ 39,046	$ 162,007
Minimum
Business Acquisition [Line Items]
Number of markets where the Company is concentrated | market		15
Maximum
Business Acquisition [Line Items]
Number of markets where the Company is concentrated | market		20
Subsequent Event
Business Acquisition [Line Items]
Aggregate purchase price	$ 150,000
Gross leasable area to be sold (in square feet) | ft²	592
Healthcare Trust of America Holdings, LP (HTALP)
Business Acquisition [Line Items]
Number of operating partnership units issued in acquisition (shares) | shares		20,687
Market value of operating partnership units issued in acquisition		$ 600

XML

Investments in Real Estate - Weighted Average Lives (Details)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Investments [Abstract]
Acquired intangible assets	11 years 3 months 18 days	10 years 6 months
Acquired intangible liabilities	10 years 2 months 12 days	8 years 10 months 24 days

XML

Dispositions (Details) ft² in Thousands, $ in Millions	3 Months Ended
	Mar. 31, 2017 USD ($) ft²
Disposal Group, Not Discontinued Operation, Disposal Disclosures [Abstract]
Aggregate gross sales price of MOBs disposed | $	$ 5.0
Area of MOB sold (in square feet) | ft²	48

XML

Intangible Assets and Liabilities - Summary of Intangible Assets and Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Assets:
Gross	$ 533,844	$ 534,108
Accumulated amortization	(266,758)	(256,305)
Total	$ 267,086	$ 277,803
Weighted Average Remaining Amortization in Years	16 years 4 months 24 days	16 years 1 month 6 days
Liabilities:
Gross	$ 45,713	$ 46,002
Accumulated amortization	(9,704)	(8,946)
Total	$ 36,009	$ 37,056
Weighted Average Remaining Amortization in Years	29 years	28 years 6 months
Below market leases
Liabilities:
Gross	$ 34,081	$ 34,370
Weighted Average Remaining Amortization in Years	19 years	18 years 7 months 6 days
Above market leasehold interests
Liabilities:
Gross	$ 11,632	$ 11,632
Weighted Average Remaining Amortization in Years	52 years 9 months 18 days	53 years
In place leases
Assets:
Gross	$ 296,018	$ 294,597
Weighted Average Remaining Amortization in Years	9 years 10 months 24 days	9 years 8 months 12 days
Tenant relationships
Assets:
Gross	$ 171,541	$ 172,974
Weighted Average Remaining Amortization in Years	10 years 7 months 6 days	10 years 7 months 6 days
Above market leases
Assets:
Gross	$ 28,149	$ 28,401
Weighted Average Remaining Amortization in Years	6 years 3 months 18 days	6 years 3 months 18 days
Below market leasehold interests
Assets:
Gross	$ 38,136	$ 38,136
Weighted Average Remaining Amortization in Years	60 years 3 months 18 days	60 years 4 months 24 days

XML

Intangible Assets and Liabilities - Summary of Intangible Amortization (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Amortization recorded against rental income related to above and (below) market leases
Schedule of Finite-Lived Intangible Assets and Liabilities [Line Items]
Amortization of intangible assets and liabilities	$ (223)	$ 337
Rental expense related to above and (below) market leasehold interests
Schedule of Finite-Lived Intangible Assets and Liabilities [Line Items]
Amortization of intangible assets and liabilities	129	96
Amortization expense related to in place leases and tenant relationships
Schedule of Finite-Lived Intangible Assets and Liabilities [Line Items]
Amortization of intangible assets and liabilities	$ 12,730	$ 10,767

XML

Receivables and Other Assets - Schedule of Receivables and Other Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Receivables and Other Assets [Abstract]
Tenant receivables, net	$ 8,750	$ 8,722
Other receivables, net	8,949	9,233
Deferred financing costs, net	3,867	4,198
Deferred leasing costs, net	21,906	20,811
Straight-line rent receivables, net	76,287	74,052
Prepaid expenses, deposits, equipment and other, net	58,926	55,904
Derivative financial instruments - interest rate swaps	1,034	541
Total	$ 179,719	$ 173,461

XML

Receivables and Other Assets - Amortization (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Receivables and Other Assets [Abstract]
Amortization expense related to deferred leasing costs	$ 1,262	$ 1,052
Interest expense related to deferred financing costs	$ 331	$ 331

XML

Debt - Schedule of Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Debt Instrument
Total debt, gross	$ 1,823,312	$ 1,781,466
Deferred financing costs, net	(9,042)	(9,527)
Discount, net	(3,062)	(3,034)
Total	1,811,208	1,768,905
Unsecured term loans
Debt Instrument
Total debt, gross	500,000	500,000
Unsecured senior notes
Debt Instrument
Total debt, gross	950,000	950,000
Mortgages | Fixed rate mortgages loans
Debt Instrument
Total debt, gross	164,646	204,562
Mortgages | Variable rate mortgages loans
Debt Instrument
Total debt, gross	38,666	38,904
Unsecured revolving credit facility
Debt Instrument
Unsecured revolving credit facility	$ 170,000	$ 88,000

XML

Debt - Principal Maturity Schedule (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Debt Disclosure [Abstract]
2017	$ 36,428
2018	4,721
2019	310,839
2020	219,795
2021	303,842
Thereafter	947,687
Total	$ 1,823,312	$ 1,781,466

XML

Debt - Amortization of Deferred Financing Costs (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Debt Disclosure [Abstract]
2017	$ 1,362
2018	1,775
2019	1,780
2020	1,338
2021	1,060
Thereafter	1,727
Total	$ 9,042	$ 9,527

XML

Debt - Textuals (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2015	Dec. 31, 2016
Debt Instrument
Outstanding amount	$ 1,823,312,000		$ 1,781,466,000
Unsecured term loans
Debt Instrument
Outstanding amount	$ 500,000,000		500,000,000
Unsecured term loans | $300.0 Million Unsecured Term Loan
Debt Instrument
Basis spread on variable rate (as a percent)	1.15%
Outstanding amount	$ 300,000,000
Weighted average interest rate with interest rate swap impact (as a percent)	2.15%
Unsecured credit agreement, extension option period (in years)	1 year
Unsecured term loans | $200.0 Million Unsecured Term Loan
Debt Instrument
Basis spread on variable rate (as a percent)	1.65%
Weighted average interest rate with interest rate swap impact (as a percent)	2.87%
Debt instrument, face amount	$ 200,000,000
Unsecured senior notes
Debt Instrument
Outstanding amount	950,000,000		$ 950,000,000
Unsecured senior notes | $300.0 Million Unsecured Senior Notes due 2021
Debt Instrument
Debt instrument, face amount	$ 300,000,000
Debt instrument, stated interest rate (as a percent)	3.38%
Debt instrument, percentage of principal amount received (as a percent)	99.21%
Debt instrument, effective interest rate (as a percent)	3.50%
Unsecured senior notes | $300.0 Million Unsecured Senior Notes due 2023
Debt Instrument
Debt instrument, face amount	$ 300,000,000
Debt instrument, stated interest rate (as a percent)	3.70%
Debt instrument, percentage of principal amount received (as a percent)	99.19%
Debt instrument, effective interest rate (as a percent)	3.80%
Unsecured senior notes | $350.0 Million Unsecured Senior Notes due 2026
Debt Instrument
Debt instrument, face amount	$ 350,000,000
Debt instrument, stated interest rate (as a percent)	3.50%
Debt instrument, percentage of principal amount received (as a percent)	99.72%
Debt instrument, effective interest rate (as a percent)	3.53%
Mortgages
Debt Instrument
Weighted average interest rate with interest rate swap impact (as a percent)	5.41%
Weighted average interest rate (as a percent)	5.01%
Minimum | Unsecured term loans | $300.0 Million Unsecured Term Loan
Debt Instrument
Basis spread on variable rate (as a percent)	0.90%
Minimum | Unsecured term loans | $200.0 Million Unsecured Term Loan
Debt Instrument
Basis spread on variable rate (as a percent)	1.50%
Minimum | Mortgages
Debt Instrument
Debt instrument, effective interest rate (as a percent)	2.45%
Maximum | Unsecured term loans | $300.0 Million Unsecured Term Loan
Debt Instrument
Basis spread on variable rate (as a percent)	1.80%
Maximum | Unsecured term loans | $200.0 Million Unsecured Term Loan
Debt Instrument
Basis spread on variable rate (as a percent)	2.45%
Maximum | Mortgages
Debt Instrument
Debt instrument, effective interest rate (as a percent)	6.39%
Unsecured revolving credit facility
Debt Instrument
Line of credit facility, borrowing capacity		$ 850,000,000
Basis spread on variable rate (as a percent)	1.05%
Line of credit facility, commitment fee (as a percent)	0.20%
Unsecured revolving credit facility | Minimum
Debt Instrument
Basis spread on variable rate (as a percent)		0.878%
Line of credit facility, commitment fee (as a percent)		0.13%
Unsecured revolving credit facility | Maximum
Debt Instrument
Basis spread on variable rate (as a percent)		1.55%
Line of credit facility, commitment fee (as a percent)		0.30%

XML

Derivative Financial Instruments and Hedging Activities - Table of Derivative Financial Instruments (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2017 USD ($) derivative	Mar. 31, 2016 USD ($)
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Cash flow hedge ineffectiveness recorded in earnings	$ 6
Cash flow hedge gain (loss) expected to be reclassified during the next 12 months	(700)
Derivative
Gain (loss) on change in fair value of derivative financial instruments, net	839	$ (2,792)
Fair value interest rate derivatives	1,800
Aggregate termination value of derivative obligations had provisions been breached	$ 1,800
Cash Flow Hedging | Designated as Hedging Instrument | Interest rate swaps
Derivative
Number of instruments (in derivatives) | derivative	5
Notional amount	$ 190,396

XML

Derivative Financial Instruments and Hedging Activities - Derivative Instruments Fair Value Table (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Derivatives, Fair Value
Asset Derivatives	$ 1,034		$ 541
Liability Derivatives	1,653		1,920
Designated as Hedging Instrument | Cash Flow Hedging | Interest rate swaps
Derivatives, Fair Value
Gain (Loss) Recognized in OCI on Derivative (Effective Portion)	(164)	$ 0
Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion)	(76)	0
Gain (Loss) Recognized in Income on Derivative (Ineffective Portion and Amount Excluded from Effectiveness Testing)	(6)	$ 0
Designated as Hedging Instrument | Cash Flow Hedging | Interest rate swaps | Receivables and other assets
Derivatives, Fair Value
Asset Derivatives	1,034		0
Designated as Hedging Instrument | Cash Flow Hedging | Interest rate swaps | Derivative financial instruments
Derivatives, Fair Value
Liability Derivatives	1,653		0
Not Designated as Hedging Instrument | Cash Flow Hedging | Interest rate swaps | Receivables and other assets
Derivatives, Fair Value
Asset Derivatives	0		541
Not Designated as Hedging Instrument | Cash Flow Hedging | Interest rate swaps | Derivative financial instruments
Derivatives, Fair Value
Liability Derivatives	$ 0		$ 1,920

XML

Derivative Financial Instruments and Hedging Activities - Derivative Offsetting (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Offsetting of Derivative Assets
Asset Derivatives	$ 1,034	$ 541
Gross Amounts in the Consolidated Balance Sheets	0	0
Net Amounts of Assets Presented in the Consolidated Balance Sheets	1,034	541
Financial Instruments	0	0
Cash Collateral Received	0	0
Net Amount	1,034	541
Offsetting of Derivative Liabilities
Liability Derivatives	1,653	1,920
Gross Amounts in the Consolidated Balance Sheets	0	0
Net Amounts of Liabilities Presented in the Consolidated Balance Sheets	1,653	1,920
Financial Instruments	0	0
Cash Collateral Received	0	0
Derivative Liability, Fair Value, Amount Not Offset Against Collateral	$ 1,653	$ 1,920

XML

Stockholders' Equity and Partners' Capital - Textuals (Details)		1 Months Ended		3 Months Ended
	Apr. 26, 2017 $ / shares	Apr. 26, 2017 USD ($) $ / shares shares	Jan. 31, 2016 USD ($)	Mar. 31, 2017 USD ($) $ / shares shares	Mar. 31, 2016 USD ($) $ / shares shares
Common Stock Offerings
Issuance of common stock					$ 91,269,000
Common Stock Dividends
Dividends declared (in usd per share) | $ / shares				$ 0.300	$ 0.295
Restricted Common Stock
Incentive Plan
Number of forfeited units (in units) | shares				2,524	3,244
Nonvested awards, total compensation cost not yet recognized				$ 11,100,000
Period for recognition (in years)				2 years 1 month 6 days
Restricted Common Stock | General and Administrative Expense
Incentive Plan
Compensation expense				$ 2,500,000	$ 1,800,000
2006 Incentive Plan
Incentive Plan
Number of shares authorized (in shares) | shares				5,000,000
Number of shares available for grant (in shares) | shares				1,710,501
Subsequent Event
Common Stock Offerings
Issuance of common stock, net (in shares) | shares		1,998,000
Issuance of common stock		$ 62,300,000
Shares issued (in dollars per share) | $ / shares	$ 31.20	$ 31.20
Common Stock Dividends
Dividends declared (in usd per share) | $ / shares	$ 0.30
ATM
Common Stock Offerings
Remaining amount of shares available for issuance				$ 177,100,000
ATM | Maximum
Common Stock Offerings
Maximum amount of common stock authorized			$ 300,000,000
Healthcare Trust of America Holdings, LP (HTALP)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend distribution ratio				1
Common Unit Offerings
Issuance of limited partner units in connection with an acquisition (in units) | shares				20,687
Issuance of partnership units in connection with an acquisition				$ 600,000
Common Stock Dividends
Dividends declared (in usd per share) | $ / shares				$ 0.300	$ 0.295

XML

Stockholders' Equity and Partners' Capital - Restricted Common Stock Activity (Details) - Restricted Common Stock - $ / shares	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Restricted Common Stock
Balance as of beginning of period (shares)	640,870	487,850
Granted (shares)	215,333	194,151
Vested (shares)	(229,621)	(162,140)
Forfeited (shares)	(2,524)	(3,244)
Balance as of end of period (shares)	624,058	516,617
Weighted Average Grant Date Fair Value
Balance as of beginning of period (usd per share)	$ 27.36	$ 23.13
Granted (usd per share)	29.31	27.17
Vested (usd per share)	24.88	22.65
Forfeited (usd per share)	29.96	24.23
Balance as of end of period (usd per share)	$ 28.94	$ 24.79

XML

Fair Value of Financial Instruments - Assets and Liabilities at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Assets:
Derivative financial instruments, asset	$ 1,034	$ 541
Liabilities:
Derivative financial instrument, liability	1,653	1,920
Fair Value, Measurements, Recurring
Assets:
Derivative financial instruments, asset	1,034	541
Liabilities:
Derivative financial instrument, liability	1,653	1,920
Fair Value, Measurements, Recurring | Level 1
Assets:
Derivative financial instruments, asset	0	0
Liabilities:
Derivative financial instrument, liability	0	0
Fair Value, Measurements, Recurring | Level 2
Assets:
Derivative financial instruments, asset	1,034	541
Liabilities:
Derivative financial instrument, liability	1,653	1,920
Fair Value, Measurements, Recurring | Level 3
Assets:
Derivative financial instruments, asset	0	0
Liabilities:
Derivative financial instrument, liability	$ 0	$ 0

XML

Fair Value of Financial Instruments - Assets on Nonrecurring Basis (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Mar. 31, 2017
Fair Value, Assets and Liabilities Measured on Nonrecurring Basis [Line Items]
Assets: MOB	$ 8,191,000	$ 0
Medical Office Buildings, Building A
Fair Value, Assets and Liabilities Measured on Nonrecurring Basis [Line Items]
Impairment charges on MOB	1,300,000
Medical Office Buildings, Building B
Fair Value, Assets and Liabilities Measured on Nonrecurring Basis [Line Items]
Impairment charges on MOB	1,800,000
Level 1
Fair Value, Assets and Liabilities Measured on Nonrecurring Basis [Line Items]
Assets: MOB	0
Level 2
Fair Value, Assets and Liabilities Measured on Nonrecurring Basis [Line Items]
Assets: MOB	8,191,000
Level 3
Fair Value, Assets and Liabilities Measured on Nonrecurring Basis [Line Items]
Assets: MOB	$ 0

XML

Fair Value of Financial Instruments - Textuals (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Fair Value Disclosures [Abstract]
Debt, fair value	$ 1,831,700	$ 1,784,000
Debt, carrying value	$ 1,811,208	$ 1,768,905

XML

Per Share Data of HTA (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		3 Months Ended
		Mar. 31, 2017	Mar. 31, 2016
Numerator:
Net income		$ 14,000	$ 10,036
Net income attributable to noncontrolling interests	[1]	(455)	(176)
Net income attributable to common stockholders/unitholders		$ 13,545	$ 9,860
Denominator:
Weighted average units outstanding - basic (in shares)		141,780	129,336
Weighted average number of shares/units outstanding — diluted (in shares)		146,117	131,240
Earnings per common share - basic
Net income attributable to common stockholders (in usd per share)		$ 0.10	$ 0.08
Earnings per common share - diluted
Net income attributable to common stockholders (in usd per share)		$ 0.09	$ 0.08
HTA, Inc.
Numerator:
Net income		$ 14,000	$ 10,036
Net income attributable to noncontrolling interests		(455)	(176)
Net income attributable to common stockholders/unitholders		$ 13,545	$ 9,860
Denominator:
Weighted average units outstanding - basic (in shares)		141,780	129,336
Dilutive shares (in shares)		4,337	1,904
Weighted average number of shares/units outstanding — diluted (in shares)		146,117	131,240
Earnings per common share - basic
Net income attributable to common stockholders (in usd per share)		$ 0.10	$ 0.08
Earnings per common share - diluted
Net income attributable to common stockholders (in usd per share)		$ 0.09	$ 0.08

[1] Includes amounts attributable to redeemable noncontrolling interests.

XML

Per Unit Data of HTALP (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		3 Months Ended
		Mar. 31, 2017	Mar. 31, 2016
Numerator:
Net income		$ 14,000	$ 10,036
Net income attributable to noncontrolling interests	[1]	(455)	(176)
Net income attributable to common stockholders/unitholders		$ 13,545	$ 9,860
Denominator:
Weighted average units outstanding - basic (in shares)		141,780	129,336
Weighted average number of shares/units outstanding — diluted (in shares)		146,117	131,240
Earnings per common unit - basic:
Net income attributable to common unitholders (in usd per share)		$ 0.10	$ 0.08
Earnings per common unit - diluted:
Net income attributable to common unitholders (in usd per share)		$ 0.09	$ 0.08
Healthcare Trust of America Holdings, LP (HTALP)
Numerator:
Net income		$ 14,000	$ 10,036
Net income attributable to noncontrolling interests		(30)	(31)
Net income attributable to common stockholders/unitholders		$ 13,970	$ 10,005
Denominator:
Weighted average units outstanding - basic (in shares)		146,117	131,242
Dilutive units (in shares)		0	0
Weighted average number of shares/units outstanding — diluted (in shares)		146,117	131,242
Earnings per common unit - basic:
Net income attributable to common unitholders (in usd per share)		$ 0.10	$ 0.08
Earnings per common unit - diluted:
Net income attributable to common unitholders (in usd per share)		$ 0.10	$ 0.08

[1] Includes amounts attributable to redeemable noncontrolling interests.

XML

Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Supplemental Disclosure of Cash Flow Information:
Interest paid	$ 19,186	$ 13,062
Income taxes paid	60	88
Supplemental Disclosure of Noncash Investing and Financing Activities:
Accrued capital expenditures	5,696	5,688
Dividend distributions declared, but not paid	44,489	38,784
Issuance of operating partnership units in connection with an acquisition	610	0
Note receivable retired in connection with an acquisition	$ 2,494	$ 0